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 ABSTRACT 
Haemorrhage remains a leading cause of death in civilian and military environments.  Recent 
research into emergency treatments for severe haemorrhaging injuries has resulted in 
production of a number of advanced haemostatic products.  In certain scenarios, 
concomitant release of toxic materials may exacerbate trauma and ultimately reduce 
survival from such injuries.  In particular, systemic absorption of the nerve agent VX (S-[2-
(diisopropylamino)ethyl]-O-ethyl methylphosphonothioate) via wounds may rapidly cause 
muscle paralysis and death.  This research explored the hypothesis that a haemostatic 
product could perform an additional function as a wound decontaminant.   
The objectives of this project were to: (i) demonstrate that haemostatic products retain 
efficacy in the presence of VX using in vitro thrombelastography (TEG); (ii) identify candidate 
products which have demonstrable ability to sequester VX from damaged and undamaged 
skin using an established in vitro percutaneous penetration model and; (iii) assess the most 
effective candidate product in vivo (anaesthetised swine) when applied to a non-
haemorrhaging skin wound contaminated with a 5xLD50 dose of 
14C-VX.  Finally, to further 
investigate the mechanism of toxicity of VX and identify potential therapeutic targets, a 
preliminary genomic analysis of exposed animal blood samples was conducted.   
Firstly, four products (WoundStatTM (WS), ProQRTM (PQR), FastActTM and VitagelTM), from an 
initial list of seven, improved coagulation kinetics of swine whole blood samples compared 
to control samples in vitro and retained this property in the presence of VX.  Secondly, four 
products (QuikClotTM (QC), CeloxTM, WS and PQR) and a novel decontaminant liquid (TOP) 
reduced penetration of 14C-VX across isolated pig skin in vitro over a 24 hour period.  
 Furthermore, WS, QC and PQR also significantly reduced penetration of 14C-VX across 
superficially damaged pig skin, to a similar extent as the current “benchmark” military 
decontaminant Fuller’s Earth.  Thirdly, when assessed in vivo WS was capable of significantly 
preventing death from intoxication, prolonging survival time and reducing the severity of 
signs of intoxication in the absence of additional medical intervention.  However, 
decontamination did not significantly improve whole blood acetylcholinesterase (AChE) 
activity, supporting the view that AChE activity is not a useful prognostic indicator and that 
mechanisms of toxicity other than AChE inhibition may exist for VX.  Finally, preliminary 
genomic analysis identified significant changes in regulation of genes involved in 
inflammatory processes, liver damage and oxidative stress. 
In summary, this project has successfully demonstrated that haemostatic products, based on 
an adsorptive mechanism of action, offer a highly effective means of countering the rapidly 
fatal effects of the chemical warfare agent VX present in wounded skin tissue.  Further 
development of the concept of a haemostatic decontaminant has life-saving implications. 
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CHAPTER 1.  Introduction 
Haemorrhage remains a leading cause of death following trauma in both civilian and military 
environments1,2.  In addition to the damage caused by the injury, further complications may 
manifest as a result of blood loss sustained in the interval between injury and treatment 
(either by first responders or at a medical centre) which can often exacerbate severe 
trauma3,4.  Rapid response to haemorrhage is therefore an important factor influencing 
survival and recovery.  In the last decade, this requirement was particularly recognised by 
the international military community5.  As a result, a number of products have been 
developed in response to the identification of the requirement for rapid pre-hospital 
treatment of haemorrhage. 
In certain scenarios the presence of environmental contaminants due to accidental or 
deliberate release, in addition to trauma and haemorrhage, may be a further complication to 
consider.  Contaminants may: 1) aggravate the initial injury; 2) cause secondary injuries; 3) 
cause toxicity following systemic absorption, or; 4) affect coagulation and haemostasis.  
These issues could seriously affect acute and chronic outcomes. 
The priority for treatment of severe haemorrhage following trauma is to achieve 
haemostasis and the benefit of locally applied haemostatic products is clear.  However, in a 
situation as described above, a haemostatic product which could also provide some 
decontamination action would be necessary. 
The purpose of the work presented in this thesis was to identify a commercially available 
haemostatic product intended for local application at the site of a haemorrhaging wound, 
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with the potential to prevent fatal blood loss and fatal poisoning with the organophosphate 
compound S-[2-(diisopropylamino)ethyl]-O-ethyl methylphosphonothioate (VX). 
In support of this objective, identification of such a product should follow a structured, step-
wise research programme.  In vitro assays may be used to screen a selection of candidate 
products, prior to evaluation in in vivo models.  These screens should assess suitability as a 
haemostat and as a decontaminant.  Haemostat performance can be assessed by an in vitro 
coagulation assay.  Decontaminant performance can be assessed using in vitro models of 
contaminant penetration through excised skin samples.  These in vitro assays can use either 
animal or human tissue: human is the gold standard tissue source, however this is subject to 
variable availability.  In vitro assays may also allow manipulation of variables, such as dose, 
exposure time or decontamination time, without compromising sample sizes.  Contaminant 
penetration through damaged skin can also be evaluated in vitro, which is of particular 
importance for the ultimate target described above.  These in vitro screens allow elimination 
of unsuitable products so that only promising candidates are taken forward for evaluation in 
in vivo models, thus reducing the numbers of animal experiments required.  The in vivo 
models can assess whether the effects in vitro can be reproduced in vivo, first with regards 
to decontaminating a contaminated skin surface wound, then by preventing death from 
toxicity and blood loss in a haemorrhaging wound. 
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Part 1:  Haemostatic products 
1.1  Strategies for testing efficacy of advanced, local haemostatic products 
The developments made in the field of “advanced haemostat” research include bandages; 
granular or powder absorptive packing materials or dressings; liquid sealants and “glues”.  
Systemically administered and active treatments such as clotting factors have also been 
examined.  Mechanisms of action vary between wound sealing, compression, passive 
absorption and concentration of clotting factors, and fibrin or thrombin activation5.   
Clearly, it is important that haemostatic products have demonstrable efficacy prior to clinical 
use.  A range of experimental techniques have been developed for this purpose, based on 
reproducible moderate to severe haemorrhaging injuries in vivo.  However, there is an 
increasing emphasis on the need to replace animal studies with suitable in vitro alternatives.   
Until recently, reports of test haemostatic products were usually anecdotal and reported 
variable effect5.  Reporting and evaluation of local haemostatic product performance in 
human trauma is limited to case reports from civilian and combat settings6,7.  These reports 
span product use and/or outcomes in certain disease states and coagulopathies etc.; on a 
desperate-use basis for surgery or trauma patients where standard-of-care has been 
unsuccessful; and in a military setting.  However, frequency of reporting, and in turn the 
reliability of case reports, may be particularly problematic in far-forward medical care 
settings.  Surveys of local haemostat use on the battlefield or in far-forward medical 
attendance have been attempted, but without much success6.  Efficacy and mechanism of 
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action of local haemostats can therefore be evaluated in more detail by in vivo studies using 
appropriate animal models of haemorrhage or trauma, or in vitro using blood samples. 
 
 
1.1.1  In vivo models: model selection and study design 
Primary targets for battlefield-intended haemostat development are injuries that may be 
treated without (or with minimal) medical background or training and the wounded area 
should be easily accessible to first responders7.  A number of models have been developed 
over the last 15 years to represent clinically relevant injuries for both civilian and military 
trauma.  In general, the pig has been more commonly used due to its larger blood volume 
and similarity with human anatomy and physiology.  The successful demonstration of the 
haemostatic ability of a product using one model only demonstrates the effectiveness for 
that type of injury, at that level of severity and within the experimental boundaries put in 
place by the researchers5.  Thus it is not possible to assess products by a single standardised 
haemorrhage model: models should be designed to mimic and reflect the likely conditions 
for the products intended deployment. 
Recent development has resulted in a generally accepted battery of models including 
aortotomy, venous, lethal extremity, complex and lethal groin injuries and liver injuries in 
swine.  The liver is the most commonly injured solid organ, and 50-90% mortality rates have 
been recorded for Grade V liver injury in humans7–12.  The current standard of care is 
abdominal packing which requires re-operation for removal and is associated with serious 
complications.  On the battlefield, certain areas of the body at the edges of personal body 
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armour were identified as frequent sites of injury, such as the neck, peritoneum and groin13.  
These are awkward sites to treat by tourniquets and compression dressings.  The complex 
groin injury model was developed in response to the growing concern for haemorrhage 
control of injuries like these13,14.  The merits of the model are that the injury involves 
damage to multiple tissues and vasculature, including complete transection of the femoral 
artery and vein.  Ultimately this is an accepted, well defined, clinically relevant model of 
severe haemorrhage from accessible major, yet awkward to treat areas of a large animal. 
Wound induction by arteriotomy does produce a near transection injury and (otherwise 
lethal) high pressure arterial haemorrhage that many modern local haemostats are 
theoretically designed for.  The severity of the femoral arteriotomy model was 
demonstrated by the 100% lethality rate resulting from treatment with the gauze Army Field 
Bandage alone15,16.  Modifications and individualised study designs can produce models with 
additional aggravation of skin, muscle and bone damage. 
Battlefield injuries to the extremities present major compressible bleeding sites, and severe 
haemorrhage that is prospectively salvageable with effective control.  In humans the aorta 
itself would not be a compressible injury site, but the swine aorta is suggested to be similar 
to the size of a human femoral artery17,18.  Additionally, the performance of haemostats 
applied through a pool of blood, against high pressure, high volume (and high rate) spurting 
blood can be assessed. 
Penetrating or impact injury to the abdomen is likely to cause trauma in multiple organs5.  
The presence of major blood vessels and multiple organs with diverse roles in close 
proximity to each other exacerbates the risk of major consequences from this type of 
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trauma.  The high volume of blood received by the liver and kidneys especially is a major 
point of concern for haemorrhage from these sites. 
The model designs can be manipulated to include complications of coagulopathy, 
hypothermia or metabolic acidosis which may accompany and exacerbate severe trauma; or 
prolonged observation periods to mimic delays between the injury and clinical treatment19.  
Physiological and post-mortem monitoring can also provide useful limits for inclusion of 
appropriate data and demonstration of uniformity of injury induction10,11. 
The primary endpoints which are monitored in the majority of these models include blood 
loss, haemorrhage control and survival, amongst others.  However, few studies analyse 
survival over a period of days to weeks.  Other endpoints such as pathology or resuscitation 
requirement are included less frequently. 
In vivo models have also demonstrated the practical variations of dressing application which 
may influence performance.  Granular haemostats are generally poured onto or into the 
wound, or sometimes poured onto gauze for application, whereas the rigidity of HemCon 
has been noted to restrict the ability of the dressing to conform to complex wounds.  
Evaluation of HemCon has sometimes required the dressing to be cut in half or pre-moulded 
to improve flexibility and enhance contact with the defect15,16.  Exothermic reactions 
following application of QuikClot to wounds has been documented to the extent that during 
some experiments, a roll of gauze has been placed over QuikClot to protect against potential 
thermal injuries to the surgeons3,8,15,16. 
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1.1.2  In vitro methods for in vivo monitoring and as alternatives to in vivo 
studies 
For intra-operative monitoring of in vivo studies, assays invariably include prothrombin time 
(PT), activated partial prothromboplastin time (aPTT), fibrinogen concentrations ([fib]), and 
usually platelet counts and complete blood cell counts (CBC).  However, local haemostat 
development may continue to progress away from in vivo studies by using in vitro tools.  
Relevant in vitro assays can identify and demonstrate haemostatic properties of substances, 
characterise mechanisms of action and screen candidate compounds, aside from in vivo 
studies.  The main advantage of these studies is that human blood or plasma can be used as 
a model.  However the appropriate choice of an in vitro method is essential.  Investigating 
specific portions of the coagulation process involves manipulation of blood samples20.  
Methods which can evaluate treatment-effects in whole blood samples may be much more 
helpful for gross evaluation of haemostatic efficacy.  The increasing inclusion of 
thrombelastographic measures for evaluation of haemostats is a step towards addressing 
this issue. 
 
Thrombelastography 
Thrombelastography is a technique which monitors and quantifies the coagulation 
characteristics and kinetics of whole blood.  Thrombelastography (TEG) measures clotting 
time, clot formation time and maximum clot firmness.  Empirically, the equipment consists 
of a pin attached to a torsion wire and a receiver: the pin is inserted into a cup containing a 
blood sample and either the cup or the sensor is rotated through 45° in each direction.  
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When the blood coagulates, the movement of the pin becomes “coupled” to the movement 
of the blood in the cup, thus the mechanical strength of the clot is transferred to the pin.  
The detected movement of the pin is reflective of coagulation progress, and ultimately the 
coagulation strength of the blood in the cup. 
The components of the TEG trace can be divided into: 
 reaction time: similar to whole blood clotting time, expressed in minutes or a trace 
distance for calculation (according to tracing speed); 
 coagulation time (or rate of coagulation); 
 rate of clot formation; 
 maximum clot elastic shear modulus (i.e. maximum clot strength); 
 fibrinolysis. 
Thrombelastography has been primarily used so far for patients as a point-of-care diagnostic 
tool, for example to diagnose coagulopathy, assess coagulation status or detect 
abnormalities in surgical or trauma patients21.  Recently, the technique has become 
increasingly utilised to assess components of products or compounds with hypothesised pro-
coagulatory characteristics22–25. 
A further advantage of thrombelastography for advanced local haemostat development is 
the provision of data on the strength and sustainability of clots.  Clot strength data could be 
reflective of patient survival and in turn recovery, and also may be representative of 
haemostat performance in cases of delayed medical attention, such as prolonged evacuation 
from a battlefield. 
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Clearly the selection of the correct model, method and observations is a delicate balance 
between acquiring as much data as possible and keeping the investigation relevant to the 
intended setting.  In vivo models have to be carefully selected and procedures amended to 
reflect the intended deployment of the product, and the haemostat can only be verified to 
be as successful within the limits of the experimental design5.  In vitro assays, whether alone 
or alongside an animal model, have numerous advantages.  Blood or plasma samples can be 
obtained for, or modified to mimic, certain disease states, coagulopathies or situations, 
whilst minimising or even eliminating the use of animal subjects.  In vitro analyses enable 
evaluation of haemostatic action on - or interaction with – blood, platelets, plasma and 
coagulation pathways, and a method of screening compounds for potential haemostatic 
action.  Most importantly of all, in vitro analyses provide a means to evaluate the haemostat 
in its intended target: human blood.  Standardisation of study designs, the definitions and 
methods of quantifying primary endpoints should be a priority to promote reliable 
comparison of haemostatic performance between studies. 
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Part 2:  Decontamination of VX 
1.2.1  Toxicity of the organophosphate compound S-[2-
(diisopropylamino)ethyl]-O-ethyl methylphosphonothioate (VX) 
Organophosphate compounds have been used in some parts of the world as pesticides for 
many years.  The primary mechanism of action of these chemicals is to inhibit 
acetylcholinesterase.  However, some organophosphates, such as S-[2-
(diisopropylamino)ethyl]-O-ethyl methylphosphonothioate (VX; Figure 1.1) have sufficient 
known toxicity to designate them as chemical warfare agents, namely nerve agents26,27.  
These particular compounds irreversibly inhibit acetylcholinesterase to an extent to which 
the ensuing accumulation of the neurotransmitter acetylcholine at synapses results in 
symptoms known as “cholinergic crisis”.  These symptoms include miosis, increased 
secretions (including salivation, bronchorrhoea, lacrimation), fasciculations, tremors, 
convulsions and eventually muscle paralysis and apnoea.  Following exposure to a sufficient 
dose, death can occur within minutes or hours28,29. 
 
  
 - 12 - 
 
 
Figure 1.1:  Structure of the organophosphate nerve agent, S-[2-(diisopropylamino)ethyl]-O-
ethyl methylphosphonothioate (VX).  
SCH2CH2NP
O
OC2H5
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CH(CH3)2
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Mechanism of organophosphate toxicity 
Organophosphates (OPs) may exert inhibitory mechanisms on various esterases, although 
acetylcholinesterase inhibition is considered to be the primary target resulting in toxicity.  
Acetylcholinesterase hydrolyses acetylcholine in the synaptic cleft, parasympathetic effector 
organ, or neuromuscular junction.  The ester moiety of acetylcholine binds to the serine 
residue in the active site of acetylcholinesterase30.  Cleavage of the enzyme-substrate 
complex yields choline and acetylated enzyme; hydrolysis of the acetylated intermediate 
completes recovery of the enzyme with intact hydroxylated serine site.  Organophosphates 
phosphorylate or phosphonylate the serine hydroxyl group in the active site of the enzyme; 
the phosphonylation mechanism is more common for nerve agents.  Cleavage of the OP 
compound yields a phosphorylated or phosphonylated serine residue rather than an 
acetylated serine residue.  The rate of hydrolysis of the phosphorylated enzyme-complex is 
much slower than that of the acetylated enzyme-complex: thus the active site is obstructed 
and regeneration of enzyme (and hence subsequent catabolism of acetylcholine) is 
effectively inhibited.  The resultant accumulation of acetylcholine results in depolarisation 
blockade and excessive stimulation of cholinergic receptors thus abnormally prolonging 
cholinergic effects31.  The resultant signs of intoxication may be termed “cholinergic crisis”. 
The specificity for the acetylcholinesterase enzyme, the affinity of the compound for the 
active site and the rate at which acetylcholinesterase may be phosphorylated varies 
between organophosphorous compounds, which partly accounts for variations in toxicity 
(particularly acute toxicity) between them32,33.  The structure of the compound contributes 
to this variation32–34.  For example, the rate of inhibition is influenced by the whole 
molecular structure, whereas the rate of dephosphorylation (and thus reactivation) is 
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determined by the structure of the group which remains complexed to the enzyme.  
Deacetylation is relatively quick (µs) compared to dephosphorylation (hours-days) and 
spontaneous reactivation by dephosphorylation is generally faster the smaller the alkyl 
groups which remain complexed to the enzyme. 
 
Aging 
“Aging” is a term given to describe the processes which further alter the phosphorylated 
enzyme and yield an intermediate so modified that reactivation may be completely 
prevented.  The dialkyl phosphorylated enzyme-complex is dealkylated either by: 1) 
hydrolysis of the P-O bond, or; 2) hydrolysis of the O-C bond, yielding an alkylated enzyme-
complex with increased stability.  The stability of the aged enzyme increases the resistance 
to reactivation34.  The rate at which “aging” occurs also depends on the structure of the 
inhibited enzyme.  Differences in the aging half-life for compounds exist between 
species34,35.  A rapid aging rate means that recovery, without (medical) intervention, would 
be dependent on synthesis of new enzyme.  However, a slower aging half-life doesn’t 
necessarily translate to reduced acute toxicity, as acute toxicity is attributed to accumulation 
of acetylcholine at synapses, not aging of acetylcholinesterase33.  The rates of 
acetylcholinesterase inhibition, aging and (spontaneous) reactivation for different 
organophosphate nerve agents are reported to be the source of variation in susceptibility to 
re-activation of acetylcholinesterase by oximes33,34,36.  
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Clinical signs of organophosphate intoxication 
Following inhalation of nerve agents, signs of intoxication can become apparent within 
minutes of exposure.  In comparison, the rate of absorption is slower following dermal 
exposure, which may delay onset and prolong effects of exposure37.  Suspected exposure to 
organophosphates may be confirmed or diagnosed by measurement of acetylcholinesterase 
activity of blood.  Clinical signs of intoxication may largely be attributed to the effect of 
accumulation of acetylcholine at muscarinic and nicotinic receptors at the central nervous 
system, nicotinic receptors at autonomic ganglia and the neuromuscular junction, and 
muscarinic receptors at parasympathetic effector organs28.  Muscarinic signs arise from 
increased activity of acetylcholine of the parasympathetic system and include 
hypersecretory effects such as salivation, lacrimation, bronchorrhoea, rhinorrhea or 
perspiration and miosis28,32.  Muscarinic effects on the GI tract and bladder include nausea 
and vomiting, cramps, and faecal and urinary incontinence28,32.  Other muscarinic effects on 
the respiratory and cardiovascular systems include bronchospasms, bronchoconstriction, 
dyspnoea, bradycardia and reduced blood pressure28,32,37, whilst nicotinic effects on the 
parasympathetic and sympathetic nerves of the cardiovascular system can cause tachycardia 
and increased blood pressure: the clinical effects on the cardiovascular system depend on 
the predominance of either muscarinic or nicotinic effects.  Excessive stimulation of nicotinic 
receptors at the neuromuscular junction may include muscle fasciculations and cramps, 
muscle weakness (a contributor to respiratory depression), increased motor activity such as 
restlessness, tremors or convulsions and flaccid or rigid paralysis28,32,38.  Accumulation of 
acetylcholine at cholinergic receptors in the brain may result in headache, confusion or 
reduced concentration, lethargy, drowsiness and fatigue, and ultimately unresponsive 
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reflexes, coma, tremors, convulsions, dyspnoea, and ultimately apnoea.  Following a 
sufficient dose, death may be caused by respiratory paralysis resulting from central effects 
(depression of respiratory centres) or accumulation of acetylcholine at the neuromuscular 
junction. 
 
Cases of nerve agent exposure, particularly VX 
There are case reports of a very small number of accidental or deliberate exposures to 
VX27,39,40.  Reports of deliberate VX exposure in humans included two murders and one 
recovery in Japan27.  A structurally and toxicologically similar organophosphorous nerve 
agent, sarin, was released in a residential area of Matsumoto, Japan in June 1994, resulting 
in 7 deaths, 58 hospital admissions41 and intoxication of approximately 600 civilians and 
responders.  Almost a year later, in March 1995, sarin was released on five cars of the Tokyo 
subway network, resulting in 11 deaths and “emergency evaluation” of more than 5000 
people26.  Detection of sarin breakdown products in soil samples from bomb craters 
effectively confirmed the use of sarin against civilians in Iraq in 198842,43.  Prior to these 
incidents, human exposures to nerve agents had mainly been confined to military personnel, 
either accidentally or experimentally, and in relatively low numbers41,44. 
 
Treatment of organophosphorous nerve agent poisoning 
Clinical assessments of the VX-recovery patient and Matsumoto patients identified an 
organophosphate cause27,45.  Organophosphate exposures commonly arise from agricultural 
exposures, and treatment of the patients was based on that of poisoning from liquid 
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agricultural organophosphate chemicals45.  Without the knowledge that the exposure had 
been to gaseous organophosphate, patients were treated and transported without 
decontamination, and protective equipment was not utilised by responders45. 
Treatment of nerve agent poisoning is based on antagonism of excessive cholinergic 
stimulation with atropine, regeneration of inhibited enzyme by a class of compounds termed 
“oximes”, and treatment of the clinical signs: including muscle relaxants and anti-
convulsants including diazepam and ventilatory support41.   
However, as medical treatment of nerve agent poisoning outside a clinical setting must 
involve combination therapies, pharmacological research into novel therapies generally use 
well characterised models which are relatively high through-put, in order to assess the 
efficacy of various drugs alone and in combination.  For example, novel therapies for 
inclusion in auto-injectors are frequently assessed in guinea pig models46–49.  Recent 
developments have included the demonstration of the efficacy of a novel oxime therapy, 
mononitrosoacetone, which crosses the blood brain barrier with relative ease compared 
with previous oxime therapies, affording effective reactivation of AChE in the CNS and 
peripheral tissues50.  Recently, increasing attention has been drawn to pre-treatments and 
bio-scavengers.  The efficacy of pre-treatment with human butyrylcholinesterase51, 
paraoxonase 152 in response to nerve agent exposures, in particular VX, has recently been 
demonstrated in guinea pigs and cynomolgus monkeys51.  Human butyrylcholinesterase has 
also been shown to be an effective post-exposure treatment in guinea pigs, even with a 
delay of 2 hours between exposure and treatment53.  Inclusion of telemetry devices for 
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continuous monitoring in some models has provided useful data pertaining to the 
physiological effects of VX exposure at sub- and supra-lethal dose levels37. 
In vitro methods are of course invaluable for determination of comparative pharmacological 
activity, and dose response effects of treatments.  However, appropriate in vivo models are 
essential for validation of in vitro pharmacological data and potential species differences in 
therapeutic response and, thus, efficacy54. 
 
Toxicokinetics of nerve agents, particularly VX 
Absorption of nerve agents usually occurs via inhalation or percutaneous routes.  The 
distribution and responses to exposure can be affected by the route of absorption.  The 
inhalation route is generally considered to be the primary hazard of other nerve agents such 
as soman, as VX is relatively non-volatile.  The vapour pressure of soman has been calculated 
as 36.4-53.4 Pa (2092-3016 mg m-3)55; in comparison, the vapour pressure of VX has been 
calculated as 0.06-0.12 Pa or 7.38-12.6 mg m-3 between 20 and 25°C56.  Thus for VX, 
assessment for systemic exposure via dermal absorption has been given the most attention. 
Toxicokinetic studies have detected that following percutaneous exposure, VX is primarily 
detected, and is persistent in, the blood and liver57,58.  This persistence is also in contrast to 
other nerve agents, which are rapidly mobilised from blood in vivo57,59.  Differences in 
distribution between species are also apparent, for example, persistence of VX in the blood 
of marmosets is longer than that of guinea pigs.  Both models are used for medical 
countermeasure research, so differences in toxicokinetics are clearly an important factor to 
consider for such studies59. 
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Metabolism of VX is generally by hydrolysis, but VX differs from other organophosphate 
nerve agents in that oxidation at nitrogen or sulphur is also possible60–62.  Spontaneous 
hydrolysis of nerve agents is generally slower than enzymatically catalysed hydrolysis63,64.  
Some of the metabolites of VX also possess acetylcholinesterase-inhibitory activity, such as 
ethyl methylphosphonic acid (EMPA)59,62,65.  Further hydrolysis reactions generate the 
relatively less toxic alkyl phosphonic acid (MPA)62,65.  Other metabolites, 2-
(diisopropylamino)ethanethiol (DAET) and a methylation product, 2-(diisopropylaminoethyl) 
methylsulphide (DAEMS), have been detected following in vivo exposures66.  Recently 
generation of a third hydrolysis product, S-[2(diisopropylamino)ethyl] 
methylphosphonothioic acid (EA-2192), and a methylation product (DAET) have been 
confirmed in vivo67–69. 
 
Mechanisms of nerve agent toxicity other than acetylcholinesterase inhibition 
Recently, attention has been increasingly drawn to mechanisms of organophosphate toxicity 
other than AChE inhibition70.  Supersensitivity to various organophosphate compounds 
including VX has been demonstrated in AChE-knockout mice71,72.  Also, there has been no 
consistent, robust correlation between lethal dose calculations for VX and levels of AChE 
activity70. 
Previous studies of GD or VX exposures in vivo have also reported various changes in 
biochemistry, including the thyroid hormone T473, Ca2+, mild hyperkalaemia and 
hyperphosphataemia and hyperglycaemia74.  Observations of sub-maximal AChE inhibition 
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following in vivo exposure to VX may also suggest the VX-resistance of some blood 
cholinesterase74. 
The general conclusions made from these findings are that mechanisms of organophosphate 
toxicity apart from AChE inhibition are of less primary concern, from the perspective of 
clinical treatment of poisoning.  However, they may be of particular interest in relation to 
chronic low-dose exposures, such as those which may be experienced by individuals who 
regularly work with organophosphorous pesticides. 
 
Part 3:  Exposure to VX via the skin and the relevance for decontamination 
1.3.1  Structure and function of the skin 
Skin is regularly exposed to chemicals and frequently serves as a route of entry of (or 
exposure to) substances, whether deliberate or accidental.  The skin serves as a physical, 
mechanical, biological and chemical barrier to exogenous substances, with the ultimate aim 
of preventing damage, whether local or systemic.  Clearly a disease or trauma (physical or 
chemical) which disrupts the organisation of the skin structure may have implications for the 
barrier function of the organ.   
Factors affecting or influencing the penetration of substances across the skin (and any 
resulting toxicity, whether direct or indirect) may be exogenous or endogenous75.  The skin 
consists of the epidermis externally and the dermis beneath (Figure 1.2).   
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Figure 1.2:  Schematic representation of the structure of human skin. 
The dermis and epidermis are separated by a basement membrane.  Hair follicles and sweat 
glands span the epidermal layers whilst blood vessels terminate in the dermis.  Blood supply 
to the epidermis is afforded by capillaries embedded in the basement membrane.  Nerve 
endings (e.g. the pacinican corpuscle on this diagram) are also located in the dermis.  The 
hypodermis is populated by fibroblasts, macrophages and adipocytes and has functions 
related to physical padding, lipid metabolism and insulation. 
Image reproduced and adapted from training pages at Surveillance Epidemiology and End 
Results (U.S. National Cancer Institute).  Image is available from  
http://training.seer.cancer.gov/melanoma/anatomy/   
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The basement membrane separates the two structures.  Hair follicles, sebaceous glands and 
eccrine glands are embedded in the dermis and span the epidermis.  Blood supply to the 
epidermis is served by capillaries embedded in the basement membrane.  The dermis makes 
up approximately 90% of the total “skin” thickness and has an important structural 
supportive function.  Beneath the dermis, adipocytes perform functions relating to physical 
padding, lipid metabolism and insulation.  Collagen and elastin in the dermis provide 
elasticity. 
The cellular structure of the epidermis mainly consists of keratinocytes, although with 
variable morphology76–79.  These cells are tightly attached to each other by desmosomes, 
and attached to the basement membrane by hemidesmosomes. 
The stratum basale is the deepest section of the epidermis: the keratinocytes here are the 
feeder cells for the upper layers of the epidermis as this is the only layer where 
keratinocytes divide.  A keratinocyte’s progression from the basal layer outward to the outer 
layers of the epidermis is accompanied by differentiation and accumulation of keratin 
within76–79.  Cells of the Stratum spinosum layer begin to produce keratin, which begins to 
crystallise into granules within the cytoplasm in the stratum granulosum above76–79.  
Filaggrin has an important role involved in serine protease cascades contributing to 
maintenance of epidermal hydration and homeostasis80.  This is a multiple layered section 
where the cells become compressed, increase in volume and begin to lose metabolic 
functions, organelles begin to degrade, and a protein layer develops beneath the cell 
membrane76–79,81,82.  In certain areas of the body, a further layer of highly keratinous cells is 
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present: the Stratum lucidum.  This is present in particularly thick skin such as the bottom of 
the feet or tip of the nose.   
Ultimately, the differentiation processes which occur as a basal cell migrates from the 
stratum basale outwards builds the outermost layer of epidermal corneocytes: the stratum 
corneum76–79,81.  At this level, the cells are flattened and arranged in multiple layers, the 
thickness of which varies with anatomical site81.  Gradually the outermost corneocytes are 
shed from the outermost surface (over approximately 2 weeks), whilst being replaced as the 
process continues beneath (also an approximately 2 week process). 
The stratum corneum is regarded as the functional barrier to contact with exogenous 
substances83, but absorption of substances across the skin is affected by the physicochemical 
properties of the substance and the physiological state of the skin at the time of contact or 
exposure. 
The “normal” lipid content of the intercellular space of the stratum corneum provides a 
hydrophobic environment which discourages transepidermal water loss.  If the stratum 
corneum is removed, the higher water content in the intercellular spaces of the epidermis 
below provides an aqueous environment for hyrdrophilic compounds to diffuse into; the 
rete ridges provide a large surface area and sufficient vasculature for subsequent diffusion 
into the systemic circulation. 
The extent of uptake of a substance following contact with the skin is influenced by (and 
may be proportional to) the substance concentration, the length of contact (time), the size 
of the area of skin exposed and the anatomical site of contact, the environmental conditions 
surrounding the point of contact, and the physicochemical properties of the substance such 
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as its molecular weight, lipophilicity, volatility, and the rate of diffusion through the stratum 
corneum75,84–86.  Deposition and distribution of a compound in the skin relative to systemic 
absorption can be quantified by the octanol/water partitioning coefficient (KOW), which 
measures the solubility of a substance.  Partitioning of the substance from its vehicle into 
the skin will also be affected by its affinity for the vehicle: i.e. the extent to which a 
substance is retained in the skin relative to systemic absorption and distribution is a balance 
of the partitioning coefficients between the substance and its vehicle and the substance and 
the skin.  The rate of diffusion is inversely related to the molecular weight or volume of the 
substance83.  The skin is generally more permeable to hydrophobic substances of low 
molecular weight than hydrophilic or high molecular weight substances83,87–90.  For 
substances of low molecular weight, hydrophobicity may be the limiting factor in 
penetration. 
 
1.3.2  Toxicity of VX following percutaneous exposure, and treatment and 
decontamination thereof 
The toxicity of nerve agents clearly preclude their evaluation in human volunteer studies.  
Data pertaining to exposures in humans are limited to early reports (circa 1950s to 1970s) of 
human exposure studies and case reports of poisoning26,41,44,91–94 .  Data obtained from case 
studies of organophosphate poisoning can provide useful supporting information.  With 
particular regard to VX, whilst limited inhalation data are available, assessment of 
penetration via the percutaneous route has been given the most attention.   
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Much attention has been given to the use of relevant models for assessment and validation 
of percutaneous penetration and distribution of different compounds.  Factors including 
type, age, sex, thickness and anatomical region of the skin; solvents or vehicles, partition co-
efficient, liphophilicity, hydrophobicity, volatility, and molecular size and weight of the 
compound all affect the percutaneous penetration of substances75,95,96.  Thus there is not a 
“one size fits all” model for assessment of percutaneous penetration of compounds: data 
must be obtained using the most appropriate model(s) for extrapolation and prediction of 
effects in humans97.   
Similarities between pig and human skin include the dermal and epidermal thickness (1-
3mm), density of hair growth, and tissue elasticity98.  Despite some differences in 
vasculature and the presence of apocrine glands rather than eccrine glands, pig skin has 
generally become an accepted model for assessment of percutaneous penetration of 
exogenous substances97–99.  However, due to anatomical regional differences in skin 
structure and permeability, equivalent anatomical regions may not necessarily be most 
comparable between models90,96,97.  A number of studies of percutaneous penetration of VX 
provide comparable data between pig and human skin, both in vitro and in vivo.  There are 
comparable in vitro data between human and pig skin for assessment of percutaneous 
penetration of certain compounds.  In particular, the skin of the pig ear has been repeatedly 
used as a suitable model for VX penetration in comparison to human forearm skin58,74,100–102.   
The percutaneous LD50 of VX is similar between humans and pigs (86 µg/kg and 60µg/kg 
respectively).  The percutaneous LD50 of guinea pigs is also not dissimilar to that of humans 
or pigs (80µg/kg)38, however, differences in the distribution of esterase enzymes in the blood 
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between humans, pigs and rodents, generally favour the use of pigs in studies of nerve agent 
toxicity and decontamination, rather than medical countermeasures34,35,54,103,104.  
Decontamination methods and barrier creams have also been assessed in the pig model, 
both in vitro and in vivo100,105–110.  
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Part 4:  Summary 
1.4.1  Strategies for identification and evaluation of a haemostatic 
decontaminant 
The primary aim of the work presented in this thesis was to identify a haemostatic product 
with the ability to decontaminate a wound contaminated with VX in vivo.  
Thrombelastography, an in vitro coagulation assay was used to test the pro-coagulatory 
performance of a range of commercially available haemostatic products (Chapter 3).  Next, 
the ability of these haemostats to reduce or prevent VX penetration across intact and 
damaged skin was assessed using an in vitro diffusion cell system (Chapter 4).  Following 
elimination of ineffective products, one candidate was selected for advanced analysis of VX-
decontamination efficacy in an in vivo damaged skin model (Chapter 5). 
1.4.2  Analysis of gene expression following exposure to VX via damaged skin 
The intention of the preceding studies was to identify a haemostatic decontaminant product 
to facilitate haemostasis during the interval between injury and medical treatment, which 
could be prolonged to up to 72 hours in a battlefield environment17.  In a case such as this, 
information on toxic effects other than AChE inhibition would be pertinent.  In order to 
gather information which may be useful to identify targets or effects of VX toxicity other 
than AChE inhibition, gene expression during VX exposure was therefore analysed (Chapter 6). 
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CHAPTER 2.  Materials and Methods 
Throughout the methods described in this chapter, the storage and use of CW agents was in 
full compliance with the Chemical Weapons Convention (1986) and animal experiments 
were conducted in accordance with the Home Office Animals (Scientific Procedures) Act, 
1986. 
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2.1  In vitro coagulation assay: thrombelastography studies of coagulation in 
swine whole blood and the effect there-upon of haemostatic products 
 
2.1.1  Materials 
Seven local haemostatic products were included in the study: CeloxTM (CX, Medtrade 
Products Ltd., Crewe, UK); QuikClot® Advanced Clotting Sponge PlusTM (QC ACS+, Z-Medica 
Corporation, Wallingford, CT, USA); HemConTM (HC, HemCon Medical Technologies Inc, 
Portland, OR, USA); ProQRTM (PQR, Biolife, Sarasota, FL, USA); WoundStatTM (WS, 
TraumaCure, Bethesda, MD, USA); FastActTM (FA, Wortham Laboratories Inc., Chattanooga, 
Tennessee, USA); VitagelTM (Orthovita, Malvern, PA, USA).  S-[2-(diisopropylamino)ethyl]-O-
ethyl methylphosphonothioate (VX) was purchased from the Defence Science and 
Technology Laboratory (Dstl, Porton Down, UK) and was reported to be >98% pure by 
nuclear magnetic resonance (NMR) spectroscopy.  Aviation turpentine fuel (AVTUR; referred 
to as JP8) was kindly supplied by Qinetiq (Boscombe Down, UK).  Calcium chloride (0.2M) 
and polyethylene thrombelastography cups were purchased from Medicell, London, UK. 
 
2.1.2  Methods 
Blood sampling was carried out according to an existing Home Office license.  Six female 
large white pigs (Sus scrofa) were housed individually for the period of the study (31 days).  
Blood samples (7.5ml) were taken daily from each animal, following sedation with 
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midazolam (Hypnoval®, Roche, Hertfordshire, UK) and anaesthesia (3-5% isoflurane in O2 8 L 
min-1).  Blood was collected in trisodium citrated collection tubes (3.2% citrate; Teklab, 
County Durham, UK) which were placed on a roller for at least 30 minutes (and not more 
than 90 minutes) before thrombelastography analysis. 
The thrombelastography equipment was prepared by adding 20µl 0.2M CaCl2 (Medicell, 
London, UK) to polyethylene cups (Medicell, London, UK) and loading them on to the TEG® 
5000 Thrombelastograph® Haemostasis Analyzer (TEG; Haemoscope Corporation, Niles, IL, 
USA).  Eight TEG® channels were available and the study was designed such that four test 
conditions were conducted in duplicate: 1) control; 2) haemostat only; 3) contaminant only 
(VX or JP8); 4) haemostat and contaminant.  These conditions are described below.  For the 
contaminated conditions, 4mls of whole blood were taken from the original collection vial 
into a fresh plastic vial, and neat VX or neat JP8 was added to a final concentration of 0.5µl 
ml-1 (condition 3; 2µl contaminant to 4mls blood).  A sample of the contaminated blood was 
then removed and added to a separate plastic vial containing pre-weighed test haemostat at 
the same ratio as the haemostat control (1 ml:4.5mg; condition 4).  To mirror treatment of 
the contaminated samples in the non-contaminated conditions, whole blood was transferred 
to plastic vials (condition 1), then a sample of that blood was added to another vial 
containing pre-weighed test haemostats at a ratio of 1 ml:4.5 mg (condition 2).  Samples 
were mixed and applied in 360µl aliquots to the pre-loaded TEG cups. 
The time to initial fibrin formation (R; minutes); the time to reach a pre-defined clot strength 
(K; minutes); the trace angle (indicative of the initial rate of clot formation) and; the 
maximum clot strength attained (maximum amplitude of pin displacement; mm) were 
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analysed.  Analysis continued for 30 minutes or until the sample trace reached maximum 
amplitude, whichever was earliest. 
Statistical analysis 
Statistical analyses were conducted using GraphPad Prism 5.04 (GraphPad Software, Inc.).  
The data were compared by Kruskal-Wallis tests with Dunn’s post-test.  Mann-Whitney U-
tests were used to compare haemostat performance between contaminated and non-
contaminated samples. 
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2.2  In vitro percutaneous absorption assay to assess the effect of haemostat 
or decontaminant application on 14C-VX penetration in isolated porcine skin. 
2.2.1  Materials 
Seven local haemostatic products were included in the study as test decontaminants: these 
are listed in section 2.1.1.  Additionally, a novel mixture of tetraglyme, oxime (2-PAM) and 
polyethyleneimine (TOP; kindly provided by Dr Richard Gordon, Walter Reid Army Institute 
of Research, MD, USA) and the currently used decontaminants Fuller’s Earth (FE; Sigma 
Chemical Co., Dorset, UK), Reactive Skin Decontaminant Lotion® (RSDL; E-Z-EM Inc., Canada) 
and M291 (current US Army decontaminant, kindly supplied by Dr Ed Clarkson, US Army 
Medical Research Institute of Chemical Defense, Maryland, USA) were included as positive 
controls.  VX (S-[2-(diisopropylamino)ethyl]-O-ethyl methylphosphonothioate), and the 
radiolabelled analogue (14C-VX; Figure 2.1) were custom synthesised by TNO Defense, 
Security and Safety (Rijswijk, Netherlands).  The radiolabelled analogue was mixed with 5g of 
undiluted agent to provide a stock solution with a nominal activity of ~ 1mCi g-1 and stored 
for up to two months at 4°C.  Aliquots of each stock solution were diluted with unlabelled 
CW agent immediately prior to each experiment to provide a working solution with a 
nominal activity of ~0.5 µCi µl-1.  Ultima-Gold Liquid Scintillation Cocktail (LSC) was supplied 
by Perkin-Elmer and Sigma.   
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Figure 2.1:  Structure of radiolabelled (14C) analogue of VX (14C-VX) utilised for in vitro and in 
vivo experiments. 
The asterisk indicates the location of the 14C-label. 
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2.2.2  Methods 
1.  Intact skin model 
Full thickness skin was collected immediately post mortem from male and female pigs (Sus 
scrofa, large white strain, six males, six females, weight range 20 - 30 kg).  Thus any cleaning 
methods used by external suppliers that may have damaged the skin were avoided.  Skin 
samples were stored flat between aluminium foil sheets at -20°C until required.  The skin 
was close clipped and dermatomed (Humeca Model D42, Eurosurgical Ltd, Guildford, UK) to 
a depth of 500 µm and cut into square sections (approximately 3 x 3 cm) in preparation for 
mounting into diffusion cells (Figure 2.2).  The study was designed such that 6 replicate 
conditions for up to 5 decontaminants could be examined using a single skin source (Table 
2.1) to eliminate inter-individual variation. 
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Figure 2.2:  The production of intact ex vivo skin sections for in vitro percutaneous 
penetration studies. 
Full thickness swine abdominal flank skin was obtained, in-house, immediately post-mortem, 
stored between aluminium foil sheets and frozen (-20°C) until used.  Intact skin sections 
were produced by dermatoming the defrosted full thickness skin to a (nominal) depth of 
500µm.  The resulting strips of partial-thickness skin were then sub-divided into sections 
(approximately 3 x 3 cm) which were mounted into diffusion cells.   
Full thickness swine 
abdominal flank skin
Dermatome, removing upper 
500µm surface
500µm thick skin sections
Sub-divide sections (~3cm2) and 
mount into diffusion cells
500 µm
~3 cm ~3 cm
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Cells Treatment 
1-6 Control: VX only 
7-12 VX plus test decontaminant 1 
13-18 VX plus test decontaminant 2 
19-24 VX plus test decontaminant 3 
25-30 VX plus test decontaminant 4 
31-36 VX plus test decontaminant 5 
 
Table 2.1:  Plan of replicated conditions used for the simultaneous assessment of “test 
decontaminant” performance in isolated porcine skin from a single source.  
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The prepared skin sections were placed flat between the glass donor and receptor chambers 
(PermeGear, Chicago, IL., USA) and held in place with a clamp.  The surface area of the skin 
available for exposure within the donor chamber was 1.77cm2.  The receptor chamber was 
filled with 50% (v/v) ethanol in deionised water solution1  as the receptor fluid (RF), so that 
the meniscus in the sampling arm was level with the skin surface.  Each cell was placed in a 
PerspexTM holding apparatus, which comprised a magnetic stirrer to mix the receptor fluid in 
each individual cell via a TeflonTM-coated iron bar placed within the receptor chamber.  The 
receptor chambers were heated by means of surrounding water supplied by a manifold and 
a circulating water heater and pump (Model GD120, Grant Instruments, Cambridge, UK).  
This enabled the skin temperature to be maintained at ~32°C (measured with infrared 
thermography; FLIR Model P640 camera, Cambridge, UK).  Skin integrity was assessed by 
measuring the resistivity across the skin surface111, then assembled cells were left to 
equilibrate for ~16-24 hours. 
For the experiment, 10µl 14C-VX was applied to each skin section (5.7mg cm-2).  Test 
decontaminants (200mg or 200µl for liquids and gels) were added 30 seconds after dosing.  
Each cell condition was replicated 6 times.  Samples of the receptor fluid (250µl) were 
withdrawn periodically and transferred straight into LSC fluid (5mls) for counting.  The 
receptor fluid volume was replenished at each sample timepoint.  Samples were collected at 
baseline, hourly for the first 6 hours in control cells and three hourly for all cells, for up to 24 
                                                     
1 Ethanol water solution was used as the receptor fluid as opposed to isotonic saline, which is 
more physiologically relevant and usually used for in vitro percutaneous penetration 
experiments.  A lipophilic receptor fluid assists removal of VX from lower skin layers, and so 
this deviation is intended to improve dose recovery and avoid underestimation of VX 
penetration rates101. 
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hours.  The amount of 14C-VX in each sample was calculated with reference to a series of 
simultaneously prepared reference samples of known concentration. 
 
2.  Damaged skin model 
The experimental set-up for the damaged skin model was virtually identical to the intact skin 
model, except for removal of the top 100µm layer from the skin by dermatome (Figure 2.3).  
The 400µm layer below was then removed and mounted into the diffusion cells, and the 
experiment conducted as described above. 
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Figure 2.3:  The production of damaged ex vivo skin sections for in vitro percutaneous 
penetration studies. 
Full thickness swine abdominal flank skin was obtained, in-house, immediately post-mortem, 
stored between aluminium foil sheets and frozen (-20°C) until used.  Superficially damaged 
skin sections were produced by initially removing the upper 100 µm layer from the original 
full thickness skin (by dermatome), then removing the underlying layer to a (nominal) depth 
of 400 µm.  The resulting strips of partial-thickness skin were then sub-divided into sections 
(approximately 3 x 3 cm) which were mounted into diffusion cells.    
Dermatome full thickness skin to 
remove upper 100µm surface.
Full thickness swine 
abdominal flank skin
Dermatome original flank skin to 
remove upper 400µm surface
400µm superficially damaged 
skin sections
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~3 cm
400 µm
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3.  Quantification of radiolabel penetration and recovery 
After 24 hours exposure, the diffusion cells were dismantled; the dosing chamber was 
removed and swabbed; the decontaminant (where applied) was collected and the skin 
section was placed into a glass scintillation vial.  The skin sections were incubated in 20mls 
Soluene-350 until homogenised.  The collected decontaminant and swabs were incubated in 
100% IPA to extract any residual 14C-VX: combined these extracts made up the “not 
penetrated” fraction.  Samples of each extract (250µl) were diluted in 5mls LSC and counted 
in triplicate by a scintillation counter (Perkin Elmer).  The mass of 14C-VX in each 
compartment was calculated with reference to a series of simultaneously prepared 
reference samples (of skin, swabs and decontaminant) of known concentration. 
 
4.  Statistical analysis 
Statistical analyses were conducted using GraphPad Prism 5.04 (GraphPad Software, Inc.).  
Experimental conditions were compared to control conditions using one-way ANOVA with 
Bonferroni post-test. 
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2.3  Decontamination of damaged ear skin of swine in vivo 
2.3.1  Materials 
Chemicals and reagents were obtained from Sigma unless otherwise stated.  Test product 
(WoundStat™) was purchased from TraumaCure, Inc. (Bethesda, MD).  The chemical warfare 
(CW) agent VX (S-[2-(diisopropylamino)ethyl]-O-ethyl methylphosphonothioate) and the 
corresponding 14C-radiolabelled analogue (shown in Figure 2.1) were custom synthesised by 
TNO Defense, Security and Safety (Rijswijk, Netherlands).  Both were reported to be >98% 
pure on synthesis.  Following delivery, the radiolabelled CW agent was mixed with 
unlabelled agent to provide a working solution with a nominal activity of ~4 mCi g-1 and 
stored for up to three months at 4°C.  Pharmaceuticals (Alfaxan® and Dolethal®) were 
obtained from Vétoquinol, Buckingham, UK).  Ultima-Gold Liquid Scintillation Cocktail (LSC) 
and Soluene-350 were obtained from Sigma and Perkin Elmer (Buckinghamshire, UK). 
 
2.3.2  Methods 
The study was conducted in two cohorts.  Radiometric analysis and gene expression analysis 
were conducted on cohort 2 animals only (Table 2.2).  The animals in each cohort were 
divided into a positive control group and an experimental group.  One group of seven 
animals served as a negative control group for both cohorts. 
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Table 2.2:  Description of the experimental groups included for analysis of decontamination 
of 14C-VX applied to damaged ear skin of swine. 
  
Group Label Number Description 
Negative 
control 
Control 7 Undamaged skin, saline application to ear 
Positive 
control 
DXD_1 6 Damaged skin, radiolabelled VX application to ear, 
no decontamination, (cohort 1/2) DXD_2 6 
Experimental 
DD_1 6 
Damaged skin, radiolabelled VX application to ear, 
WoundStat application to ear 30s later, (cohort 1/2) DD_2 6 
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1.  Animals, preparation and surgery 
Female pigs (Sus scrofa, Yorkshire landrace cross, weight range 15-25kg) were habituated for 
a minimum of 7 days with food and water ad libitum.  On the day of each experiment (and 
following an overnight fast) animals were placed into a weighing crate and sedated with a 
small dose of midazolam (4-8mls, 2mgml-1: 8-16mg, dependant on animal size and activity; 
Hypnoval, Roche).  Anaesthesia was induced in the weighing crate with 2-3% isoflurane in air 
with oxygen (6L min-1) and nitrous oxide (2L min-1) delivered via a facemask.  For surgery, the 
animal was placed on a surgical trolley in dorsal recumbency and intubated to maintain the 
airway and administer inhalation anaesthesia (0.5-2% isoflurane in air with oxygen) 
throughout surgery.  Surgery involved isolation and cannulation of the internal carotid artery 
and internal jugular vein (occasionally external jugular vein) to gain intravascular access, 
measure arterial pressure and administer intravenous anaesthesia using alfaxalone 
(Alfaxan®, Vétoquinol, Buckingham, UK) for the remainder of the study (rate between 12-
28ml hr-1, dependent on individual animal response). 
Pulse rate, ECG, arterial blood pressure, breathing rate, CO2 output, % SpO2 were monitored 
throughout the experiment (Propaq Encore® monitor, Welch Allyn, Bucks, UK).  Core body 
temperature was monitored using rectal probes, and maintained where necessary with a 
heated blanket or blankets.  After a 30 minute stabilisation period, the animal was 
transferred to a trolley in ventral recumbency using a sling.  The animal was moved to the 
fume cupboard and remained there throughout the study. All dosing and decontamination 
procedures took place within the fume cupboard. 
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Blood samples were taken just prior to commencement of Alfaxan® administration, then 
periodically throughout the experiment.  Blood samples were collected in sodium citrated 
vials for radiometric and thrombelastographic analysis, and sodium EDTA vials (Teklab, 
County Durham, UK) for measurement of haematocrit and whole blood cholinesterase 
activity. 
 
2.  Wound 
During the 30 minutes stabilisation period and 30 minutes pre-dosage baseline period a 
small area (~3cm2 maximum) superficial wound was produced on the back surface of the ear 
using a dermatome to a depth of 100µm.  This produced a small region of damage with 
localised punctate bleeding.  The end of a 20ml plastic syringe barrel was secured to the ear 
surface around the wound with Vetbond to form a dosing chamber.  The seal was checked 
using saline, which was also used to wipe or swab the wound to prevent any blood 
solidifying and creating a barrier to absorption.  The ear was maintained as flat and as 
immobile as possible with minimal occlusion using cotton-wool covered cardboard as a flat 
platform scaffold underneath the ear.  Autoclave tape was used to connect the dosing 
chamber to the cardboard, then the cardboard scaffold was clamped to the trolley arms.   
 
3.  Dosage/Exposure 
Following the 30 minute pre-dosage baseline period, a 5x LD50 (300µg kg
-1) dose of neat, 
radiolabelled VX (14C-VX; TNO, NL and Dstl, Wiltshire, UK) was applied to the wound site.  In 
the decontamination group (DD, n=12), 2g of test haemostatic decontaminant 
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(WoundStat™, TraumaCure, Bethesda, USA) was poured into the dosing chamber 30 seconds 
after dosing, and compressed lightly using a syringe plunger.  The wound and dosing site 
were not manipulated or occluded in any other way in the positive control group (DXD, 
n=12).  Negative control animals (n=7) were given an equivalent volume dose of sterile 
isotonic saline onto undamaged skin. 
Physiological parameters and signs of intoxication were monitored throughout the 
experiment by Propaq Encore® monitor (Welch Allyn, Buckinghamshire, UK).  Death within 
the 6 hour study period was confirmed following 15 minutes of apnoea.  At the end of the 
experiment (time of death or 6 hours for those animals which survived the entire study 
period) all animals were euthanised using an overdose of pentobarbital (Dolethal®, 
Vétoquinol, Buckingham, UK). 
Blood was removed as thoroughly as possible using a medical suction pump and disposable 
liners prior to post mortem examinations.  Sections of brain, heart, lung, liver, kidney, 
pancreas, spleen and diaphragm were removed post mortem and stored for further analysis 
(radiometry, cholinesterase activity, RNA expression). 
 
4.  Analysis of acetylcholinesterase activity 
Cholinesterase activity was assayed in whole blood samples.  Whole blood samples were 
stored at -20°C for at least half an hour to lyse the blood cells.  Cholinesterase activity was 
measured using a modified Ellman assay34,54,112,113; (0.25mM 5,5-dithiobis-(2 nitrobenzoic) 
acid (DTNB); 0.45mM acetylthiocholine iodide substrate; 1.0M pH 8 phosphate buffer) and 
carried out at 30°C 412nm using a spectrophotometer.  
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5.  Toxicokinetic analysis 
After termination of the experiment, the area of exposed skin was excised and incubated in 
Soluene-350 (Perkin Elmer, Bucks, UK).  A Geiger-Muller tube was used to direct excision of 
contaminated areas in the vicinity of the exposure site.  These were collected into separate 
scintillation vials and treated equivalently.  The decontaminant was collected and incubated 
in Ultima Gold liquid scintillation cocktail (LSC, Perkin Elmer and Sigma).  The dose chambers 
were also incubated in LSC and swabs were incubated in 100% isopropanol.  Samples of each 
extract (250µl) were diluted in 5mls LSC and counted in triplicate by a scintillation counter 
(Perkin Elmer).  Radiolabel extracted from the dosing chamber, decontaminant and swabs 
made up the “not penetrated” fraction. 
For analysis of radiolabel distribution in internal organs, 100mg of frozen tissue was 
incubated in 2mls Soluene-350 at 60°C for at least 6 hours (until dissolved, with gentle 
vortexing if necessary), then once cooled, the volume made up to 20mls with LSC fluid for 
scintillation counting.  For radiometric analysis of blood samples, 0.4mls whole blood were 
incubated in 1ml of a 2:1 IPA:Soluene-350 solution at 60°C for 2 hours.  Once cooled to room 
temperature, 500µl of 30% H2O2 was added slowly (50µl at a time) and gently mixed for 
approximately 5 minutes, until any foaming ceased.  The mixture was incubated at room 
temperature for 15-30 minutes; then 60°C for 30 minutes.  LSC was added to 20mls volume 
once the mixture was cooled.  All extractions were temperature and light adapted for at 
least 1 hour prior to scintillation counting. 
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The mass of 14C-VX in each compartment was calculated with reference to a series of 
simultaneously prepared reference samples (of each organ, blood, skin, swabs and 
decontaminant) of known concentration. 
 
6.  Statistical analysis 
Statistical analyses were conducted using GraphPad Prism 5.04 (GraphPad Software, Inc.).  
Survival fractions and curve analysis were calculated using the Kaplan-Meier (log-rank) 
method, and Gehan-Brislow-Wilcoxon tests.  One-way ANOVA with post-hoc Tukey’s test 
was used to analyse animal weight and survival time.  Toxicokinetics were usually analysed 
using one-tailed unpaired t-tests with Welch correction for unequal variances; except for 
recovery data for swabs, dosing chambers and spleen which were two-tailed unpaired t-tests 
with Welch correction. 
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2.4  Analysis of gene expression changes in blood following exposure of swine 
to 14C-VX 
This study utilised whole blood samples obtained from swine exposed to a 5xLD50 dose of 
14C-VX to damaged ear skin.  A test decontaminant was also subsequently applied to 
experimental subjects.  The methods of exposure, analysis, acquisition of blood samples and 
experimental protocol are described in the previous section; the results are presented in 
Chapter 5.  An aliquot of pre-dose and final blood samples were stored in RNALater® solution 
(Ambion, CA, USA) at -20°C until required.  Methods for analysis of gene expression in these 
subjects is described below. 
 
2.4.1  Materials 
Whole blood RNA extraction was performed using RNALater® and the Ambion RiboPureTM 
Blood RNA Isolation kit (Ambion®, CA, USA).  Agilent RNA Nano 6000 chips and Porcine Gene 
Expression Microarray 4x44K slides, gaskets and reagents for labelling, amplification, 
hybridisation and washing were purchased directly from Agilent Technologies Inc. (Berkshire, 
UK).  Labelling, amplification, hybridisation and washes were conducted according to the 
Agilent Low Input Quick Amp Labelling Protocol.   
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2.4.2  Methods 
Porcine whole blood samples, obtained from a concurrent study of dermal decontamination 
of VX, were stored in RNALater® solution.  Gene expression analysis was performed on RNA 
extracted from the pre-dose and final (time of death or 360 minutes exposure) blood 
samples from the 12 animals in cohort 2: 6 decontaminated with WoundStat and 6 with no 
decontamination.  The final blood samples were obtained prior to administration of 
Dolethal®. 
 
RNA extraction 
RNA extraction from whole blood was performed using the RiboPureTM Blood kit (Ambion) 
according to the manufacturer’s instructions except with the following adjustments.  Briefly, 
cells (or whole blood) preserved in RNALater® were thawed and centrifuged at 16000 x g at 
4°C.  The pellet was re-suspended in Ambion Lysis® solution and sodium acetate by vigorous 
vortexing.  After addition of acid phenol:chloroform the samples were inverted briefly and 
incubated at room temperature for 5 minutes, then centrifuged at room temperature at 
16000 x g for 5 minutes.  One half volume of 100% ethanol was added, then the samples 
were placed at -20°C for 1 hour (up to overnight).  The subsequent purification steps were 
carried out according to the manufacturer's protocol, except for one extra wash with Wash 
2/3 buffer.  The RNA was eluted with 2 x 50µl of elution buffer.  The concentration of RNA 
was measured using Nanodrop, and the quality of the extracted RNA assessed using the 
Agilent 2100 Bioanalyzer equipment and Agilent RNA Nano 6000 chips.  The labelling, 
amplification, hybridisation and post-hybridisation wash steps were carried out according to 
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the manufacturer's instructions114.  The labelling and amplification steps were performed 
using 200ng of RNA template. 
Hybridised and washed microarray slides were scanned by an Agilent High-Resolution C 
Scanner, and data extracted using Agilent Feature Extraction software (version 11).  Data 
analysis was conducted using Agilent GeneSpring GX software (version 12). 
The pre-dose samples were used as intrinsic controls for normalisation purposes: intensity 
values of the final samples were normalised to the corresponding pre-dose samples.  
Following normalisation and filtering on flags (detected in 100% of all conditions) 10,110 
probes were included in the subsequent data analysis.  Initially, the basic interpretations 
applied were “Treatment” (decontamination, “DD”, and not-decontaminated, “DXD”) and 
“Timepoint” (pre-dose, “start”, and final, “end”).  Following analysis of the preceding in vivo 
data (Chapter 5), a third interpretation, “Outcome” (“survivor” or “death”), was 
subsequently included.  Thus paired t-tests (without any false discovery rate limits set) were 
performed between: 
 pre-dose and final blood samples in the decontaminated and not-decontaminated 
groups; 
 pre-dose and final blood samples in the survivor or death groups; 
 pre-dose and final blood samples in the survivors of the decontaminated or not-
decontaminated groups; 
 pre-dose and final blood samples in the deaths of the decontaminated or not 
decontaminated groups. 
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In the statistical analyses, a paired t-test between the pre-dose and final blood sample in the 
“survivor” group was the only comparison which returned entities (n=1730) with a 
Benjamini-Hochberg FDR correction.  For consistency, all the statistical analyses were 
performed without multiple testing or false discovery rate correction.  For t-tests between 
treatment or outcome groups, Welch’s correction for unequal variances resulted in a more 
conservative entity list, so was employed for all comparisons.  Paired t-tests were performed 
for comparisons between pre-dose and final blood samples. 
  
 - 53 - 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3.  Thrombelastographic assessment of haemostatic 
products, and blood contamination with VX. 
 
 - 54 - 
 
Chapter 3.  Thrombelastographic assessment of haemostatic products, and 
blood contamination with VX. 
 
3.1  Introduction. 
Haemostatic products intended for local application to severely haemorrhaging wounds are 
available commercially, and a variety of strategies to test their efficacy have been described.  
The advantages of using in vitro methods to assess efficacy of haemostatic products are that: 
blood samples can be used, allowing experiments to be performed in the relevant species 
and reducing animal use; potential compounds or products may be assayed for coagulation 
capabilities prior to in depth in vivo experiments, reducing animal use further; in vitro assays 
are relatively high-throughput compared to in vivo methods, meaning a number of products 
may be evaluated simultaneously; conditions may be manipulated, for example the effect of 
certain conditions, such as presence of a drug, or in this case a contaminant, on blood 
coagulation may be assayed. 
There are not many direct investigations of the effect of nerve agents on haemostasis and 
coagulation, although there are reports of the effects of organophosphate exposure on 
blood chemistry and coagulation, both experimentally and in cases of human exposure93,115–
118, however the differences in the compounds and doses examined, and the circumstances 
surrounding the human exposures, make comparison of the findings of these reports 
difficult.  This study used an in vitro assay (Thrombelastography; TEG) to examine the effect 
of chemical contaminants on blood coagulation and on the efficacy of haemostatic products.  
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The contaminants used were the nerve agent VX; (S-[2-(diisopropylamino)ethyl]-O-ethyl 
methylphosphonothioate) and aviation fuel (aviation turpentine; JP8). 
 
3.2  Materials and Methods 
The materials and methods are described in detail in Chapter 2 and are briefly outlined in 
Figure 3.1. 
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Figure 3.1:  Workflow design for the in vitro analysis of haemostatic products within and 
without the presence of contaminants (VX or JP8) using thrombelastography (TEG).  
  
Control (untreated) coagulation 
Effect of VX or JP8 on coagulation 
Effect of haemostatic product on 
coagulation 
Effect of VX or JP8 on performance 
of haemostatic products  
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3.3  Results 
1. Model validation. 
All control data (n=113) for each clotting parameter were pooled and subject to analysis 
(Shapiro-Wilk normality test) to determine the statistical distribution: R time (RT), K time 
(KT), angle (α) and maximum amplitude (MA) were not normally distributed (p<0.05).  
Therefore, subsequent analyses were based on non-parametric tests. 
There were no significant time-dependent differences in R time, K time, trace angle or 
maximum amplitude between experimental days (Figures 3.2 and 3.3) as measured with the 
Friedman repeated measures test. 
The weights of the animals were recorded every study day as an indicator of welfare, and 
increased steadily during the study period (Figure 3.4). 
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Figure 3.2: Variation in thrombelastography (TEG) clotting parameters R time (A) and K time 
(B) acquired from control (untreated) samples of normal whole blood acquired over the 31 
day study period.  
All values are average ± 95% confidence intervals (CI) of up to n=6 samples per time point.  
There was no significant, time-dependent change in either parameter (p>0.05).  
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Figure 3.3: Variation in thrombelastography (TEG) clotting parameters trace angle (A) and 
maximum amplitude (B) acquired from control (untreated) samples of normal whole blood 
acquired over the 31 day study period.   
All values are average ± 95% confidence intervals (CI) of up to n=6 samples per time point.  
There was no significant, time-dependent change in either parameter (p>0.05).  
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Figure 3.4:  Individual plots of weight increase during the study period for all 6 animals 
(labelled A-F). 
  
Study day
W
e
ig
h
t 
(k
g
)
0 10 20 30 40
0
20
40
60
80
A
B
C
D
E
F
 - 61 - 
 
2. Effects of contaminants on blood clotting. 
The addition of contaminants (VX or JP8) had no measurable effect on R time, K time, trace 
angle or maximum amplitude (Figure 3.5). 
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Figure 3.5: Effect of contamination with VX or JP8 on thrombelastography (TEG) clotting 
parameters of whole blood: clotting time (R time, A); initial clot formation time (K time, B); 
rate of clotting (trace angle, C); or clot strength (maximum amplitude, D).   
All values are average ± 95% confidence intervals (CI) of n=113 (control), n=25 (+VX) or n=15 
(+JP8) samples.  There was no significant effect of contamination on blood clotting (p>0.05).  
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3. Effects of haemostatic products on blood clotting. 
Treatment of whole blood with four haemostatic products (WoundStat™ (WS), FastAct™ 
(FA), ProQR™ (PQR) and VitaGel™ (VG)) resulted in a significant decrease (p<0.05) in clotting 
time (expressed as the R time parameter; Figure 3.6A) when compared to control 
(untreated) blood.  In contrast, three treatments (Celox™, HemCon™ and QuikClot™) did not 
significantly affect R time.  Correspondingly, there was a significant (p<0.05) reduction in K 
time (Figure 3.6B) and significant increase in trace angle (α; Figure 3.6C) for WS, FA, PQR and 
VG but no change in K time and α for CX, HC or QC (p>0.05).  Addition of haemostatic 
products to whole blood resulted in no significant change in clot strength (maximum 
amplitude; Figure 3.6D). 
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Figure 3.6:  Effect of haemostatic products on R time (A); K time (B); angle (C); and maximum 
amplitude (D).   
All values are average ± 95% confidence intervals (CI) of n=9 (CX, HC); 18 (QC, VG); 19 (PQR); 
20 (FA).  Asterisks indicate that value is significantly different to (untreated) control 
(***p<0.001; ** p<0.01; *p<0.05; Kruskal-Wallis with Dunn’s post-test).  
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4. Efficacy of haemostatic products on blood clotting in the presence of contaminants (VX 
and JP8). 
There were no significant differences in the measured parameters between haemostat plus 
contaminated blood samples and their haemostat only treated counterparts (Mann-Whitney 
U-tests; Figures 3.7-3.8). 
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Figure 3.7:  Effect of VX on the efficacy of haemostatic products, expressed as R time (A); K 
time (B); angle (C); and maximum amplitude (D).   
All values are average ± 95% confidence intervals (CI) of up to n=6 measurements for the 
haemostat + contaminant condition, and up to n=20 (as Figure 3.6) for the haemostat alone 
condition.  Efficacy of each haemostatic product was not significantly affected in the 
presence of VX (Mann-Whitney U-test; p>0.05; compared groups indicated by bars).  
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Figure 3.8:  Effect of JP8 on the efficacy of haemostatic products expressed as R time (A); K 
time (B); angle (C); and maximum amplitude (D).   
All values are average ± 95% confidence intervals (CI) of up to n=4 measurements for the 
haemostat + contaminant condition, and up to n=20 (as Figure 3.6) for the haemostat alone 
condition.  Efficacy of each haemostatic product was not significantly affected in the 
presence of JP8 (Mann-Whitney U-test; p>0.05; compared groups indicated by bars).  
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3.4  Discussion 
This in vitro study of coagulation has successfully demonstrated the feasibility of acquiring 
serial, daily blood samples from a small number of animals in order to assess seven 
haemostatic products by thrombelastography (TEG) and the influence of two contaminants 
(VX and JP8).  The coagulation parameters of untreated (control) blood measured over a one 
month study period were shown to be reproducible and followed a non-Gaussian 
distribution.  Four haemostatic products (WoundStatTM, ProQRTM, FastActTM and VitagelTM) 
had a pro-coagulative effect on the parameters recorded in this study compared to control 
(untreated) samples, which were not affected by contamination of blood with VX or JP8.  
Three haemostats (Celox™, HemCon™ and QuikClot® Advanced Clotting Sponge Plus™) had 
no measurable effect on the coagulation parameters.  Moreover, it was shown that the two 
contaminants did not adversely affect normal coagulation kinetics or the performance of any 
of the seven commercially-available haemostatic products tested.  The use of TEG 
substantially reduced the number of animals that would be required to perform a similarly 
comprehensive study in vivo and so represents a significant contribution to the “three 
Rs”119,120. 
Human blood would be the “gold-standard” for the in vitro assessment of haemostatic 
products.  However, human blood was unavailable for this study.  Haemostatic products 
have been evaluated extensively in numerous pig models5, and two previous studies have 
provided some limited comparative data between in vivo and in vitro measurements of 
haemostatic products using TEG24,121.  Therefore, pig blood was chosen for this current in 
vitro study.  There are no previous studies reporting differences in coagulation between 
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human and pig blood.  However, data collated from untreated (control) blood in this study 
compare favourably with published human reference range values (Figure 3.9)122.  Clearly, 
gathering evidence to further define reference ranges of coagulation parameters for 
relevant animal models would assist future comparisons between animal and human data. 
There are several potential disadvantages of using TEG to evaluate the performance of 
haemostatic products.  Specifically, the in vitro (TEG) model may not account for 
haemostasis caused by the “tamponade” effect or blood vessel sealing 24,121.  Indeed, three 
products (QC, HC and CX) did not demonstrate any pro-coagulatory effect when evaluated 
by TEG (Figure 3.6) despite being reportedly efficacious in vivo3,4,8,9,14,17.  Thus, it could be 
reasonably deduced that the disparity in performance of haemostatic products between the 
two experimental models is due to the absence of physical factors (e.g. tamponade or 
wound sealing) in the in vitro (TEG) model.  Therefore, the use of TEG may actually be 
advantageous for identifying inherent pro-coagulatory properties of haemostatic products 
such as passive absorption of plasma or stimulation of the coagulation pathway. 
In this in vitro study, the addition of QC to whole blood did not enhance clotting kinetics.  
This was surprising, since the proposed mechanism of QC was via passive absorption of 
plasma with concomitant concentration of clotting factors123–125.  In contrast, WS and PQR 
which are reported to partly act via the same mechanism of passive absorption were very 
effective121.  This difference suggests that the in vivo clotting mechanism for QC may be 
more due to the tamponade effect than absorption of blood plasma.  
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Figure 3.9: Reference range blood coagulation values (mean ± 95% confidence interval) from 
118 healthy adult human volunteers122, and corresponding pig values derived from this 
current study.   
The parameters R time (A), K time (B), angle (C) and maximum amplitude (D) are in close 
agreement with the human reference range. 
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Stimulation of coagulatory pathways is the proposed mechanism of action for VG and FA 
3,126.  Correspondingly, TEG identified that clotting kinetics were significantly enhanced in the 
presence of both products (Figure 3.5). 
The effectiveness of these products as a function of dose was not investigated in this study: 
a set dose of 4.5 mg of test product was added to 1 ml of whole blood (4.5 mg ml-1).  In vivo 
studies of haemostatic products generally use much higher ratios of product to blood to 
more accurately model “in use” (emergency) conditions7.  Therefore, this difference in dose 
may also account for some of the disparities observed in this in vitro study compared to in 
vivo investigations.  However, the relatively low dose employed in this in vitro study was 
consistent with that from a previous study and provides a more challenging condition for the 
evaluation of haemostatic products and so would likely identify products of marginal 
efficacy.  Further investigations of the effectiveness of products as a function of dose would 
assist both pre-clinical product development and evaluation of product efficacy “in-the-
field”. 
Thrombelastography detected no significant effects of VX on coagulation parameters 
compared to untreated blood.  This is in agreement with a previous study using the nerve 
agent soman, where no major effects of coagulation were noted118.  There are no previous 
reports on the effects of JP8 on blood coagulation kinetics.  In this study, treatment of blood 
with JP8 resulted in no measureable effect. 
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The lowest intra-venous dose for which a toxic response has been observed (TDLO) in 
humans is 1.5 µg kg-1 28.  This equates to 0.1 mg for an average adult.  The dose of VX applied 
to the blood in this study (~2 mg) is equivalent to ~20 x TDLO.  This dose was intended to 
represent “worst-case scenario”.  At this relatively high dose, neither VX nor JP8 had a 
measureable effect on the clotting efficacy of the haemostatic products.  The retention of 
haemostatic capability in the presence of such a high concentration of VX (or JP8) therefore 
justified further investigation of these products as haemostatic decontaminants.  Even so, 
possible dose-response effects would be an important consideration for future 
investigations of the effects of contaminants on coagulation kinetics.In summary, the results 
of this in vitro study using TEG analysis of blood coagulation have demonstrated: 
 The feasibility of acquiring serial blood samples from a relatively small number of 
animals for analysis of blood coagulation kinetics and has provided further evidence 
in support of validating this model. 
 That thrombelastography (TEG) may be utilised for the relatively high throughput 
evaluation of haemostatic products which are not dependent on physical 
mechanisms of action such as tamponade effect or spontaneous blood vessel sealing. 
 That four products (WS, PQR, FA and VG) have demonstrable haemostatic properties 
which are retained in the presence of potentially toxic contaminants such as VX and JP8. 
Therefore, the haemostatic products were advanced for further assessment as topical skin 
decontaminants (Chapter 4) as part of the overall aims of identifying a haemostatic 
decontaminant for haemorrhaging wounds contaminated with potentially toxic chemicals. 
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This study has identified the need for further work in the following areas: 
 Direct comparison of pig and human coagulation kinetics to further contribute to in 
vitro model validation. 
 Development of a definitive reference range for pig blood coagulation kinetics. 
 Effect of haemostatic product “dose” on coagulation performance. 
 Dose-response effect of contaminants such as VX and JP8. 
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CHAPTER 4.  In vitro percutaneous absorption assay to assess the 
effect of haemostat or decontaminant application on VX penetration in 
isolated porcine skin 
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Chapter 4.  In vitro percutaneous absorption assay to assess the effect of 
haemostat or decontaminant application on VX penetration in isolated 
porcine skin 
4.1  Introduction 
The physicochemical characteristics of VX (namely lipophilicity and volatility) relative to 
other organophosphate chemical warfare agents (CWAs) means that the primary hazard 
from VX is dermal exposure to the liquid.  Swift decontamination of exposed sites is a 
priority for first responders.  In a penetrating injury or haemorrhage the integrity of the skin 
and the ability of the skin to function as a barrier to contaminants would be compromised.  A 
haemostatic decontaminant must therefore be capable of reducing or preventing 
penetration of contaminants at the injury site. 
The uppermost layer of the skin surface, the stratum corneum, is regarded as the primary 
barrier for dermal absorption83,127.  In vivo models have been used previously to study 
absorption and toxicity of nerve agents, however differences in physiology and biochemistry 
between animal models and humans must be accounted for in interpretations.  In vitro 
experiments allow preliminary investigations of decontamination properties of potential 
formulations.  These may generally be higher throughput than in vivo studies and reduce the 
numbers of animals required. 
This study used in vitro diffusion cells to assess penetration of VX across intact and damaged 
pig abdominal skin.  Test decontaminants, including “commercial off-the-shelf” (COTS) 
haemostats, novel decontaminant liquids and currently deployed decontaminant 
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formulations, were assessed on their ability to reduce penetration of VX across damaged and 
undamaged pig skin in vitro. 
 
4.2  Materials and Methods 
The materials and methods are described in detail in Chapter 2 and are briefly outlined in 
Figure 4.1.  The results presented are the averages of six replications of each condition. 
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Figure 4.1:  Workflow design for the in vitro analysis of the efficacy of haemostatic products 
(as test decontaminants) in reducing penetration of 14C-VX across intact and damaged pig 
abdominal skin, using Franz-type diffusion cells. 
  
Penetration of 14C-VX across intact skin 
Effect of test decontaminant on  
14C-VX penetration across intact skin 
Penetration of 14C-VX across damaged skin 
Effect of test decontaminant on 14C-VX 
penetration across damaged skin 
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4.3  Results 
Pooled control data (undamaged skin; n=24) were normally distributed (Shapiro-Wilk 
normality test).  Subsequent analyses were based on parametric tests. 
 
4.3.1  Effect of application of QuikClotTM, WoundStatTM, CeloxTM, ProQRTM or 
Fuller’s Earth on penetration of 14C-VX across intact pig skin over 24 hours 
1.  Quantification of 14C-VX in receptor fluid at 3 hourly intervals (µg cm-2) 
Total 14C-VX penetration at 24 hours (µg cm-2) was significantly lower for diffusion cells 
treated with QuikClotTM (QC), WoundStatTM (WS), CeloxTM (CX), ProQRTM (PQR) or Fuller’s 
Earth (FE) compared to control cells (p<0.0001; Figure 4.2).  The amount of 14C which had 
penetrated into the receptor fluid (RF) of WS or FE-treated intact skin was significantly lower 
than that of controls from 3 hours onwards (p<0.01).  Significantly lower amounts of 14C-VX 
had penetrated across PQR-treated skin compared to that of controls from 6 hours onwards 
(p<0.05), and QC or CX-treated cells had significantly lower penetrated amounts of 14C-VX 
than control cells from 9 hours onwards (p<0.01). 
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Figure 4.2:  Penetration of 14C-VX across intact pig skin over 24 hours in the first group, 
measured in the receptor fluid at 3 hour intervals and quantified as µg cm-2 (mean ± 
standard deviation; n=6).   
Total 14C-VX penetration at 24 hours (µg cm-2) was significantly lower for diffusion cells 
treated with QC, WS, CX, PQR or FE compared to controls (p<0.0001).  Bars indicate that 
amount of 14C-VX penetrated was significantly different to control: (a) from 3 hours onwards 
for WS and FE, p<0.01; (b) from 6 hours onwards for PQR, p<0.05; (c) from 9 hours onwards 
for CX and QC, p<0.01).  
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2.  Difference in quantification of 14C-VX in receptor fluid at 3 hourly intervals (µg cm-2) 
Fuller’s Earth and WoundStat had significantly lower rates of penetration of 14C-VX 
throughout the experiment compared to controls (p<0.01; Figure 4.3; Table 4.1).   
The rate of penetration of 14C-VX through QC-treated skin was significantly lower than 
controls between 3 and 6 hours exposure (p<0.05) and from 15 hours onwards (p<0.01).  
The rate of penetration of 14C-VX through PQR-treated skin was also significantly lower than 
controls between 3 and 6 hours exposure (p<0.01); but then significantly lower than controls 
from 12 hours onwards (p<0.01).  Celox-treated cells only had significantly lower penetration 
rates compared to controls between 3 and 6 hours of exposure (p<0.05). 
In control cells, the highest rate of penetration of 14C-VX was 34 ± 6.7 µg cm-2 hr-1 and was 
reached between 15 and 18 hours of exposure (Table 4.1).  
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Figure 4.3:  Rate of penetration of 14C-VX across intact pig skin in the first group, according 
to the amounts of 14C-VX quantified in the receptor fluid at three hour intervals (µg cm-2 hr-1; 
mean ± standard deviation; n=6).   
Bars indicate that rate of 14C-VX penetration was significantly different to control: (a) 
throughout the experiment for WS and FE, p<0.01; (b) from 12 hours onwards for PQR, 
p<0.01; (c) from 15 hours onwards for QC, p<0.01).  
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3.  Distribution of mass of 14C-VX quantified as “penetrated”, “remaining in skin” or “not 
penetrated” after 24 hours of exposure of intact porcine skin to 14C-VX 
The amount of 14C-VX quantified in the penetrated fraction, skin fraction and not penetrated 
(collected decontaminant and swabs) fraction of all the treated cells was significantly 
different to that in control cells (p<0.0001), relative to the total mass recovered in the 
corresponding fraction of controls and relative to the dose applied (Figure 4.4, 4.5).  The 
amount of 14C-VX quantified in the penetrated fraction and skin fraction was significantly 
higher in the control condition compared to the treated conditions (p<0.0001); 
correspondingly the amount of 14C-VX quantified in the not penetrated fraction was 
significantly lower in the control condition compared to the treated conditions (p<.0001). 
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Figure 4.4:  Recovery of 14C-VX in the first group in (A) penetrated fraction; (B) skin; (C) not 
penetrated fraction.   
Data are presented as mass (mean ± standard deviation; n=6) recovered relative to that in 
corresponding control fraction (%) following 24 hours exposure of intact skin to 14C-VX and 
treatment with test decontaminants.  Asterisks indicate significant differences 
(****p<0.0001) in recovery between control and treated cells.  
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Figure 4.5:  Recovery of 14C-VX in the first group in (A) penetrated fraction; (B) skin; (C) not 
penetrated fraction.   
Data are presented as mass (mean ± standard deviation; n=6) recovered relative to the dose 
of 14C-VX applied (%) following 24 hours exposure of intact skin to 14C-VX and treatment with 
test decontaminants.  Asterisks indicate significant differences (****p<0.0001) in recovery 
between control and treated cells.  
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4.3.2  Effect of application of HemConTM, Reactive Skin Decontamination 
Lotion®, VitagelTM, FastActTM or tetragylme-oxime-polyethyleneimine mixture 
on penetration of 14C-VX across intact pig skin over 24 hours 
1.  Quantification of 14C-VX in receptor fluid at 3 hourly intervals (µg cm-2) 
Total 14C-VX penetration at 24 hours (µg cm-2) was significantly lower for diffusion cells 
treated with TOP (p<0.001) and significantly higher in RSDL-treated cells (p<0.0001) 
compared to control cells (Figure 4.6).  Cells treated with RSDL had significantly larger 
amounts of 14C-VX penetrated than controls from 9 hours onwards (p<0.01).  Penetration of 
14C-VX in TOP-treated cells became significantly lower than controls after 12 hours exposure 
(p<0.05).  The amount of 14C-VX which had penetrated across VG or FA-treated skin was 
significantly higher than controls until 6 hours exposure (p<0.001). 
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Figure 4.6:  Penetration of 14C-VX across intact pig skin over 24 hours in the second group, 
measured in the receptor fluid at 3 hour intervals and quantified as µg cm-2 (mean ± 
standard deviation; n=6).   
Bars indicate that amount of 14C-VX penetrated was significantly different to control: (a) 
from 9 hours onwards for RSDL, p<0.01; (b) until 6 hours exposure for VG or FA, p<0.0001; 
(c) from 12 hours onwards for TOP, p<0.05).  
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2.  Difference in quantification of 14C-VX in receptor fluid at 3 hourly intervals (µg cm-2) 
The rate of penetration of 14C-VX across skin treated with TOP was significantly lower than 
that of control skin from the 6-9 hour period until 21 hours post-exposure (p<0.01; Figure 
4.7).  Cells treated with HemCon had significantly lower penetration rate than controls from 
the 15-18 hour period onwards (p<0.05).  In contrast, the 14C-VX penetration rate for RSDL-
treatment was significantly higher than control cells from the 3-6 hour period onwards 
(p<0.05).  The rate of 14C-VX penetration across cells treated with VG or FA was initially 
significantly higher than controls (p<0.0001 in the 0-3 hour time period), but there were no 
further significant differences in penetration rate between these and control cells during the 
remainder of the exposure period. 
In the control cells the maximum rate of penetration was 27 µg cm-2 hr-1 and was reached 
between 15 and 18 hours of exposure (Table 4.2). 
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Figure 4.7:  Rate of penetration of 14C-VX across intact pig skin in the second group, 
according to the amounts of 14C-VX quantified in the receptor fluid at three hour intervals 
(µg cm-2 hr-1; mean ± standard deviation; n=6).   
Bars indicate that rate of 14C-VX penetration was significantly different to control: (a) from 3-
6 hours onwards, p<0.05; (b) until 3 hours for VG or FA (p<0.0001); (c) from 15-18 hours 
onwards for HC, p<0.05; (d) from 6-9 hours onwards for TOP (p<0.01). 
 - 90 - 
 
Ti
m
e 
in
te
rv
al
 (
h
o
u
rs
 p
o
st
-e
xp
o
su
re
) 
2
1
-2
4 
Fl
u
x 
(
g 
cm
-2
 h
r-
1
) 
2
4
 ±
 1
3
 
6
.1
* 
± 
1
7
 
5
0
**
 ±
 1
5
 
1
9
 ±
 2
.6
 
1
8
 ±
 5
.8
 
2
.0
**
 ±
 1
.0
 
Ta
b
le
 4
.2
: 
 C
h
an
ge
s 
in
 r
at
e 
o
f 
p
en
et
ra
ti
o
n
 (
µ
g 
cm
-2
 h
r-
1 )
 d
u
ri
n
g 
2
4
 h
o
u
rs
 e
xp
o
su
re
 t
o
 1
4 C
-V
X
 a
n
d
 t
re
at
m
en
t 
w
it
h
 t
e
st
 d
ec
o
n
ta
m
in
an
ts
 (
m
ea
n
 ±
 
st
an
d
ar
d
 d
ev
ia
ti
o
n
).
 
A
st
er
is
ks
 in
d
ic
at
e 
si
gn
if
ic
an
t 
d
if
fe
re
n
ce
 b
et
w
ee
n
 t
re
at
m
en
t 
co
n
d
it
io
n
 a
n
d
 c
o
n
tr
o
ls
 (
*p
<0
.0
5
; *
*
p
<0
.0
1
; *
*
*p
<0
.0
0
1
; *
**
*p
<0
.0
0
0
1
).
 
1
8
-2
1 
2
6
 ±
 6
.9
 
1
2
* 
± 
4
.0
 
5
8
**
**
 ±
 1
3
 
2
3
 ±
 7
.5
 
1
9
 ±
 7
.0
 
1
.5
**
**
 ±
 0
.9
1
 
1
5
-1
8 
2
7
 ±
 5
.9
 
1
2
**
 ±
 5
.5
 
4
8
**
* 
± 
14
 
2
1
 ±
 4
.4
 
1
6
 ±
 6
.9
 
1
.6
**
**
 ±
 0
.8
 
1
2
-1
5 
2
6
 ±
 9
.8
 
1
3
 ±
 5
.5
 
5
6
**
**
 ±
 2
0
 
1
9
 ±
 4
.6
 
1
5
 ±
 1
.6
 
2
.2
**
* 
± 
1
.0
 
9
-1
2 
2
2
 ±
 4
.4
 
1
4
 ±
 7
.0
 
4
6
**
**
 ±
 1
5
 
1
7
 ±
 3
.6
 
1
4
 ±
 4
.9
 
2
.0
**
* 
± 
0
.5
 
6
-9
 
1
8
 ±
 4
.3
 
1
4
 ±
 6
.3
 
3
8
**
* 
± 
17
 
1
3
 ±
 3
.0
 
1
1
 ±
 2
.0
 
2
.0
**
 ±
 0
.5
 
3
-6
 
2
.7
 ±
 0
.7
5
 
2
.8
 ±
 1
.5
 
4
.9
* 
± 
2
.5
 
4
.1
 ±
 0
.6
 
3
.9
 ±
 0
.6
 
1
.1
 ±
 0
.3
 
0
-3
 
4
.2
 ±
 2
.0
 
5
.9
 ±
 3
.4
 
4
.9
 ±
 2
.5
 
1
9
**
**
 ±
 1
.8
 
2
8
**
**
 ±
 9
.3
 
6
.6
 ±
 0
.9
 
Tr
ea
tm
en
t 
C
o
n
tr
o
l 
H
em
C
o
n
 
R
SD
L 
V
it
ag
el
 
Fa
st
A
ct
 
TO
P
 
 - 91 - 
 
3.  Distribution of mass of 14C-VX quantified as “penetrated”, “remaining in skin” or “not 
penetrated” after 24 hours of exposure of intact porcine skin to 14C-VX 
The amount of 14C-VX quantified in the penetrated fraction of VG-treated cells was 
significantly lower than that in control cells, (p<0.001; Figure 4.8-4.9).  The penetrated 
fraction of RSDL-treated cells contained significantly higher amounts of 14C-VX than controls 
(p<0.0001; Figure 4.8-4.9). 
The amount of 14C-VX quantified in the skin (p<0.01) of all treated cells was significantly 
lower than that of controls (Figure 4.8-4.9). 
In the not penetrated fraction, cells treated with RSDL or TOP had significantly higher 
amounts of 14C-VX than controls (relative to that of the controls and relative to the dose 
applied: p<0.05; Figure 4.8-4.9). 
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Figure 4.8:  Recovery of 14C-VX in the second group in (A) penetrated fraction; (B) skin; (C) 
not penetrated fraction.   
Data are presented as mass (mean ± standard deviation; n=6) recovered relative to that in 
corresponding control fraction (%) following 24 hours exposure of intact skin to 14C-VX and 
treatment with test decontaminants.  Asterisks indicate significant differences in recovery 
between control and treated cells (*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001).  
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Figure 4.9:  Recovery of 14C-VX in the second group in (A) penetrated fraction; (B) skin; (C) 
not penetrated fraction.   
Data are presented as mass (mean ± standard deviation; n=6) recovered relative to the dose 
of 14C-VX applied (%) following 24 hours exposure of intact skin to 14C-VX and treatment with 
test decontaminants.  Asterisks indicate significant differences in recovery between control 
and treated cells (*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001).  
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4.3.3  Effect of application of VitagelTM + TOP, FastActTM + TOP, M291 or 
occlusion on penetration of 14C-VX across intact pig skin over 24 hours 
1.  Quantification of 14C-VX in receptor fluid at 3 hourly intervals (µg cm-2) 
The amount of 14C-VX which had penetrated across cells treated with VG+TOP, FA+TOP or 
M291 was significantly lower than controls after 24 hours exposure (p<0.0001; Figure 4.10).  
The amount of 14C-VX penetrating across M291-treated cells was significantly lower than 
control cells after 6 hours exposure (p<0.0001). 
Initially, cells treated with VG+TOP or FA+TOP had significantly higher amounts of 14C-VX 
penetrating than control cells until 6 hours post-exposure (p<0.05).  From then on the 
penetration of 14C-VX was lower than control cells: the difference between these treatments 
and control cells was significant after 9 hours for FA+TOP and 12 hours for VG+TOP. 
Occlusion had no significant effect on the amount of 14C-VX penetrating across intact skin 
during the experiment. 
  
 - 95 - 
 
Time (hours)
T
o
ta
l
1
4
C
-V
X
 p
e
n
e
tr
a
te
d
  
( 
g
 c
m
-2
)
0 6 12 18 24
0
200
400
600
800
1000 Control
Vitagel + TOP
FastAct + TOP
M291
Occluded
b
a
c
 
Figure 4.10:  Penetration of 14C-VX across intact pig skin over 24 hours in the first group, 
measured in the receptor fluid at 3 hour intervals and quantified as µg cm-2 (mean ± 
standard deviation; n=6).   
Total 14C-VX penetration at 24 hours (µg cm-2) was significantly lower for diffusion cells 
treated with QC, WS, CX, PQR or FE compared to controls (p<0.0001).  Bars indicate that 
amount of 14C-VX penetrated was significantly different to control: (a) from 6 hours onwards 
for M291, p<0.0001; (b) until 6 hours for VG+TOP and FA+TOP, p<0.05; (c) from 12 hours 
onwards for VG+TOP and FA+TOP).  
 - 96 - 
 
2.  Difference in quantification of 14C-VX in receptor fluid at 3 hourly intervals (µg cm-2) 
The rate of penetration of 14C-VX across skin treated with M291 was significantly lower than 
control cells from 3 hours onwards (Figure 4.11 and Table 4.3). 
During the first 3 hours of exposure, the rate of penetration of 14C-VX across skin treated 
with FA+TOP or VG+TOP was initially significantly higher than controls (p<0.0001); from then 
on the rate of penetration was significantly lower than controls (p<0.001). 
In control cells the maximum penetration rate was 41µg cm-2 hr-1 and was reached between 
9 and 12 hours exposure (Table 4.3). 
 
The rate of penetration across occluded cells was only significantly lower than that of control 
cells between 6 and 12 hours exposure.  In contrast, the rate of penetration across occluded 
cells was significantly higher than control cells between 21 and 24 hours exposure. 
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Figure 4.11:  Rate of penetration of 14C-VX across intact pig skin in the third group, according 
to the amounts of 14C-VX quantified in the receptor fluid at three hour intervals (µg cm-2 hr-1; 
mean ± standard deviation; n=6).  
Bars indicate that rate of 14C-VX penetration was significantly different to control: (a) from 3-
6 hours onwards for M291, VG+TOP and FA+TOP, p<0.05; (b) until 3 hours for VG or FA 
(p<0.0001). 
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3.  Distribution of mass of 14C-VX quantified as “penetrated”, “remaining in skin” or “not 
penetrated” after 24 hours of exposure of intact porcine skin to 14C-VX 
The amount of 14C-VX quantified in the penetrated fraction and skin of FA+TOP, VG+TOP or 
M291-treated cells was significantly lower than that in control cells, relative to that which 
was penetrated in the control condition and relative to the dose applied (p<0.0001; Figure 
4.12-4.13).  Correspondingly, significantly larger amounts of 14C-VX were quantified in the 
“not penetrated” fraction of FA+TOP, VG+TOP or M291 treated cells compared to control 
cells, when expressed relative to that which was quantified in the control “not penetrated” 
fraction or relative to the applied dose of 14C-VX (p<0.0001). 
The collected decontaminant fraction of M291-treatment contained a significantly larger 
proportion of the applied dose than that of VG+TOP or FA+TOP-treatment (p<0.001). 
There were no significant differences in amounts of 14C-VX quantified in each fraction 
between occluded and control cells (figure 4.12-4.13). 
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Figure 4.12:  Recovery of 14C-VX in the third group in (A) penetrated fraction; (B) skin; (C) not 
penetrated fraction.   
Data are presented as mass (mean ± standard deviation; n=6) recovered relative to that in 
corresponding control fraction (%) following 24 hours exposure of intact skin to 14C-VX and 
treatment with test decontaminants.  Asterisks indicate significant differences in recovery 
between control and treated cells (****p<0.0001).  
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Figure 4.13:.  Recovery of 14C-VX in the third group in (A) penetrated fraction; (B) skin; (C) 
not penetrated fraction.   
Data are presented as mass (mean ± standard deviation; n=6) recovered relative to the dose 
of 14C-VX applied (%) following 24 hours exposure of intact skin to 14C-VX and treatment with 
test decontaminants.  Asterisks indicate significant differences in recovery between control 
and treated cells (****p<0.0001).  
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4.3.4  Decontaminant efficacy 
There were significant differences in the mass of 14C-VX recovered in the decontaminant 
fraction (relative to applied dose) between RSDL and VG or FA-treated cells (p<0.01; Figure 
4.14).  The mass of 14C-VX recovered in collected M291 (relative to applied dose) was also 
significantly higher than in collected VG+TOP or FA+TOP (p<0.001; Figure 4.14). 
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Figure 4.14:  Amount of 14C-VX quantified in the decontaminant fraction of diffusion cells 
treated with test and current decontaminants, relative to the applied dose (mean ± standard 
deviation; n=6).   
Statistical analyses (1-way ANOVA with post-hoc Tukey’s test) compared treatments within 
each individual study (to account for variation between control conditions).  Bars indicate 
significant differences between treatments (within each study; **p<0.01; ***p<0.001). 
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4.3.5  Effect of application of QuikClot® ACS+, WoundStatTM, ProQRTM or 
Fuller’s EarthTM on penetration of 14C-VX across damaged pig skin over 24 
hours 
1.  Quantification of 14C-VX in receptor fluid at 3 hourly intervals (µg cm-2) 
Total 14C-VX penetration (µg cm-2) at 24 hours was significantly (p<0.001) higher in damaged 
skin (897 ± 176 µg cm-2) compared to undamaged skin (563 ± 71 µg cm-2; Figure 4.15).  All 
the treatments (QC, WS, PQR, FE) significantly reduced the amount of 14C-VX which had 
penetrated damaged skin at 24 hours (p<0.0001; Figure 4.15). 
The amount of 14C-VX penetrating across damaged skin was significantly higher than 
undamaged skin, and all the treated damaged-skin cells from 3 hours onwards (p<0.001; 
Figure 4.15). 
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Figure 4.15:  Penetration of 14C-VX across damaged pig skin over 24 hours, measured in the 
receptor fluid at 3 hour intervals and quantified as µg cm-2 (mean ± standard deviation; n=6). 
Total 14C-VX penetration at 24 hours (µg cm-2) was significantly higher through damaged skin 
than untreated skin and damaged skin treated diffusion cells treated with QC, WS, PQR or FE 
throughout the exposure period.  
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2.  Difference in quantification of 14C-VX in receptor fluid at 3 hourly intervals (µg cm-2) 
Initially, the rate of penetration across intact skin was significantly lower than damaged skin, 
until 9 hours of exposure (p<0.0001; Figure 4.16).  After 12 hours of exposure, the rate of 
penetration across intact skin was significantly higher than that of damaged skin, until 18 
hours post-exposure (p<0.01), and again between 21 and 24 hours exposure (p<0.05).  The 
rate of penetration across treated damaged skin was significantly lower than that of 
untreated damaged skin for all treatments throughout the exposure period (p<0.001). 
In damaged skin, the maximum penetration rate of 14C-VX was 72 µg cm-2 hr-1 and was 
reached between 3 and 6 hours exposure.  In contrast, the maximum 14C-VX penetration 
rate was 31µg cm-2 hr-1 and was reached between 15 and 18 hours exposure (Table 4.4). 
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Figure 4.16:  Rate of penetration of 14C-VX across damaged pig skin in the second group, 
according to the amounts of 14C-VX quantified in the receptor fluid at three hour intervals 
(µg cm-2 hr-1; mean ± standard deviation; n=6). 
Penetration rate of 14C-VX across damaged skin was significantly different to that of 
undamaged skin at all time intervals except for 9-12 hours and 18-21 hours (p<0.05).  The 
treated cells had significantly lower penetration rates than damaged skin throughout the 
study period (p<0.001). 
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3.  Distribution of mass of 14C-VX quantified as “penetrated”, “remaining in skin” or “not 
penetrated” after 24 hours of exposure of damaged porcine skin to 14C-VX 
The “penetrated” fraction from damaged skin was significantly larger than undamaged 
(p<0.001) and all treated cells (Figure 4.17- 4.18 (A); p<0.0001). 
The amount of 14C-VX quantified in undamaged skin was significantly larger than that 
quantified in damaged skin (Figure 4.17-4.18 (B); p<0.0001).  In contrast, all the treatments 
significantly reduced the amount of 14C-VX quantified in the damaged skin fraction, 
compared to the damaged skin controls (p<0.0001). 
There was no difference in amount of 14C-VX “not penetrated” between damaged and 
undamaged skin (Figure 4.17-4.18 (C)).  The not penetrated fraction was significantly larger 
for all treatments compared to damaged skin (p<0.0001). 
 
There were significant inter-treatment differences in the proportion of applied dose 
quantified in the decontaminant fractions.  The QC and FE fractions contained significantly 
less 14C-VX than WS or PQR fractions (Figure 4.19; p<0.001). 
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Figure 4.17:  Recovery of 14C-VX in the fourth group in (A) penetrated fraction; (B) skin; (C) 
not penetrated fraction.   
Data are presented as mass (mean ± standard deviation; n=6) recovered relative to that in 
corresponding control fraction (%) following 24 hours exposure of intact skin to 14C-VX and 
treatment with test decontaminants.  Asterisks indicate significant differences in recovery 
between control and treated cells (****p<0.0001).  
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Figure 4.18:  Recovery of 14C-VX in the fourth group in (A) penetrated fraction; (B) skin; (C) 
not penetrated fraction.   
Data are presented as mass (mean ± standard deviation; n=6) recovered relative to the dose 
of 14C-VX applied (%) following 24 hours exposure of intact skin to 14C-VX and treatment with 
test decontaminants.  Asterisks indicate significant differences in recovery between control 
and treated cells (****p<0.0001).  
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Figure 4.19:  Recovery of 14C-VX in the decontaminant fraction following 24 hours exposure 
on damaged skin.   
Data are presented as the mass of 14C-VX recovered relative to the applied dose (%; mean ± 
standard deviation; n=6).  Annotations indicate significant differences between treatments 
which bear the same annotation (p<0.001). 
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4.4  Discussion 
This experiment utilised in vitro diffusion cells to quantify penetration of 14C-VX through 
intact, occluded and damaged pig abdominal skin over a 24 hour period.  Penetration of 14C-
VX was significantly enhanced by removal of the top 100µm layer of skin prior to exposure.  
Along with the currently in-use military decontaminants FE and M291, five test products 
(QuikClot® ACS+TM, WoundStatTM, CeloxTM, ProQRTM and a novel decontaminant liquid (TOP)) 
were able to reduce 14C-VX penetration across undamaged skin during the 24 hour exposure 
period QuikClot® ACS+TM, WoundStatTM, ProQRTM and Fuller’s Earth also reduced 14C-VX 
penetration across damaged skin.  Occluding the skin did not significantly affect penetration 
of 14C-VX across intact pig abdominal skin. 
Treatment of undamaged skin with certain haemostats or decontaminants also resulted in 
significantly altered profiles of penetration rate across intact skin during the 24 hour 
exposure period compared to untreated control skin.  For example, WS was the only 
haemostat which significantly reduced 14C-VX penetration rate at all time-points throughout 
the 24 hour exposure period.  Fuller’s Earth was the only currently “in-use” decontaminant 
which shared this trait.  In contrast, QC, WS, PQR (and FE) all significantly reduced the rate of 
14C-VX penetration across damaged skin at all time-points during the exposure period. 
Human skin would be the “gold-standard” for the in vitro assessment of percutaneous 
penetration of VX.  However, human skin was unavailable for this study.  In vitro studies 
have provided some comparative data between pig and human abdominal skin for 
penetration of VX and nerve agent simulants 101,107,108,110.  The toxicokinetics of VX have also 
been described for the pig in vivo, following VX application to inner ear skin58,100.  Therefore, 
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pig skin was chosen for this in vitro study.  The use of pig abdominal skin allowed more 
products to be assessed simultaneously in skin from a common original source.  Whilst 
quantitative data obtained here may not be directly predictive of penetration in humans as a 
result of species or anatomical differences, this study should permit an empirical assessment 
of the basic efficacy of the products.  This also served to reduce the numbers of animals 
required to provide skin samples.  The data obtained in this study compare favourably with a 
previous in vitro study of pig abdominal skin permeability to VX, taking into account (and 
assuming a linear relationship) between the variation in doses between studies101. 
Some of the measured parameters differed significantly between the third studies and the 
others.  This may be due to differences in skin type between groups: this may have occurred 
because skin may have been sampled more distally or proximally to the abdomen midline 
between sources depending on damage.   
There are no previous studies reporting differences in permeability of undamaged and 
damaged pig skin for VX specifically.  However, varied efficacy of a selection of 
decontamination regimes in the context of VX-exposure in a full-thickness swine skin wound 
has been demonstrated in vivo105.  Various other methods, such as tape stripping, abrasion 
or needle puncture have been employed to study effects of skin surface damage or 
compromised barrier function on penetration of compounds in vitro128. 
There are potential disadvantages of using in vitro assays of penetration to predict human 
absorption or toxicity in vivo.  Isolating skin penetration experiments to an in vitro setting 
eliminates systemic circulation and distribution (and excretion), deposition in organs and 
metabolism.  However, this enables the empirical assessment of skin absorption kinetics.  
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Flow-through diffusion cells can address the issue of removal of the penetrant from the 
exposure or absorption site, but this is not always a reliable estimation129.  Owing to the 
toxicity of VX, the ability of the products to reduce, or indeed prevent, penetration of VX 
across the stratum corneum in the first instance was the main factor under investigation. 
In addition, using radiolabelled VX allows penetration of the compound to be followed at 
each sampling time-point, as well as quantification of 14C-VX in each fraction (skin, 
decontaminant, receptor fluid, swabs) at the conclusion of the experiment.  However, this 
can only be interpreted as an estimation of the progress of penetration, as radioactivity is 
measured, not specifically VX.  Due to the period of exposure, the relatively slow hydrolysis 
kinetics of VX (compared to other OP nerve agents) and the limited metabolic capacity of ex 
vivo skin, this quantified amount of 14C is assumed to be the parent compound for the 
purposes of analysis108,110,130.  However, the possibility that breakdown products may 
account for some of the quantified 14C cannot be ignored. 
Indeed, the increased penetration kinetics induced by RSDL here are in apparent contrast 
with the efficacy of RSDL already demonstrated in vivo38,105.  This apparent inconsistency 
may be partly explained by penetration of, and thus quantification of, decontamination 
products, rather than 14C-VX.  Additionally, in contrast to previous studies, RSDL was not 
removed in this experiment. 
The uncertainty of the exact molecules which are quantified in the mass balance should not 
affect the qualitative net interpretation of the results, viz toxicity in vivo, as some of the 
known metabolites and breakdown products of VX are also toxic.  Gas chromatographic and 
mass spectrometric analysis of solvent extracts from the skin (or other exposed areas) would 
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address this uncertainty and enable speciation of penetrated substances.  This would be 
particularly useful for products where the primary mechanism of action is to decontaminate 
exposed skin, rather than prevent or reduce penetration.   
The total recovery of 14C-VX from RSDL treated cells was above 100% of the applied mass: 
this is most notable in the recovery of 14C-VX from the decontaminant fraction alone (Figure 
4.14) and thus the significant difference in recovery from the decontaminant fraction 
between RSDL and VG or FA is not surprising.  The standard deviation for the 14C-VX 
quantification for the RSDL treatment condition is large and reflects large variations in the 
quantification of 14C-VX in the different fractions between the individual replicates.  Reasons 
for this variation could include a chemiluminescence effect of RSDL influencing scintillation 
counts (which could be determined with further investigation); dosing errors resulting in 
variations in the amount of 14C-VX applied to the individual skin sections or decontaminant 
standard reference samples for this condition; or sampling errors.  Consequently the 14C-VX 
quantification data for the RSDL condition are unreliable.  In the damaged skin model, the 
14C-VX extracted from WS and PQR conditions (the “not penetrated” fraction, and in 
particular the decontaminant fraction) were also calculated to be above 100% of the applied 
mass, so the significant difference between those treatments and QC and FE are also 
unsurprising (Figure 4.19).  Similarly, sampling or dosing errors (either of the reference 
decontaminant standards or the skin sections) may have contributed to this error.  A further 
possibility is that if these particular decontaminants had a quenching effect on scintillation, 
any variations in mass of the decontaminant between the reference standards and 
experimental samples may have resulted in samples being quenched to different extents.  
Insufficient mixing of the decontaminant during extraction may also have contributed to this 
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observation.  The 14C-VX quantification data for the WS and PQR decontaminant fraction (in 
the damaged skin model) are unreliable, although further experiments would be useful to 
investigate these observations further. 
The effectiveness of products as a function of dose was not investigated in this study.  A set 
dose of 200mg was added to 10µl of contaminant.  As described earlier (chapter 1 & 3), in 
vivo studies of haemostats generally use much higher ratios of product to blood in order to 
more accurately model “in use” (emergency) conditions7.  Analysis of the effects of product 
dose on decontamination ability may be useful for product development.  However, inability 
of a product to prevent or reduce VX penetration (at a given dose of product) whilst other 
products are effective at the same dose, should preclude its inclusion in further studies. 
In this in vitro experiment of percutaneous penetration, the mechanism by which these 
haemostatic products are presumed to reduce penetration of VX is by adsorption of the 
contaminant onto or into the product matrix.  Previously, the possibility that discrepancies in 
product efficacy between in vitro and in vivo models was due to dose-response effects or 
mechanism of action was put forward.  For example, it was suggested that QC may not act 
(primarily) via passive absorption to promote blood coagulation (Chapter 3).  The apparent 
contradiction of this suggestion by the results of the diffusion cell study may partly be 
explained by the higher ratio of product mass to contaminant mass (1µl VX: 9mg product for 
TEG; 1µl VX : 20mg product for diffusion cells).  Reactions with VX on the surface of the 
decontaminants may also be involved. 
The dose of VX applied (5.7mg cm-2; 10µl volume) in this study was intended to be 
representative of a “worst-case” scenario: indeed, this models a finite dose in vivo101 and 
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represents a multiple LD50 for both humans and pigs
58.  An apparent inability to reduce or 
prevent absorption of this dose would preclude inclusion of a product in further studies of 
decontamination of a multiple LD50 in vivo. 
Furthermore, the test decontaminants remained in contact with the skin for the duration of 
the experiment.  This contrast to standard “in-use” procedure enabled identification of 
products which were immediately ineffective, or products in which efficacy may be inversely 
proportional to length of exposure (Figure 4.20).  Indeed, the mass of unabsorbed 
contaminant may arguably be considered as “mass available to penetrate with prolonged 
exposure”.  Desorption kinetics for test decontaminants is also an important point for 
product development with regards to secondary exposure due to “off-gassing”.  Therefore, 
desorption kinetics along with gas chromatographic and speciation analysis studies would be 
important to assess “in-use” efficacy of test decontaminants.   
In comparison with other chemical warfare agents (such as sulphur mustard), enhanced 
penetration caused by occlusion of exposed skin is perhaps less likely for VX due to its 
relative lower volatility105,131–133.  For volatile compounds, certain vehicles may act 
occlusively by preventing evaporation132.  In this experiment, occlusion did not significantly 
enhance the penetration of 14C-VX across intact pig abdominal skin.  The novel liquid 
decontaminant mixture, TOP, significantly reduced penetration of 14C-VX.  In that case, the 
enhanced penetration kinetics observed following treatment with the other liquid products, 
VG and FA (and RSDL as described previously) may partly be explained by (a) reactions 
between VX and the vehicle, or; (b) reactions between the vehicle and the skin resulting in 
increased permeability.  
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Figure 4.20:  Short-term and long-term efficacy of test decontaminants on penetration of 
14C-VX across intact skin (n=6): (A) Study 1; (B) Study 2; (C) Study 3; and damaged skin: (D) 
Study 4. 
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In summary, the results of this in vitro diffusion cell study of 14C-VX penetration across pig 
abdominal skin demonstrated: 
 Enhanced permeability of pig skin following removal of the uppermost ~100µm layer. 
 That four haemostatic products (WS, QC, PQR, CX) and a novel liquid decontaminant 
mixture (TOP) have demonstrable efficacy in reducing penetration of VX across 
undamaged skin. 
 That three haemostatic products (WS, QC, PQR) have demonstrable efficacy in 
reducing penetration of VX across damaged skin, to a similar level as the currently 
“in-use” military decontaminant, Fuller’s Earth. 
Taken together with the favourable pro-coagulative characteristics measured by TEG 
(Chapter 3), WoundStat was advanced for further assessment in an in vivo model of 
percutaneous VX exposure in swine. 
This study has identified the need for further work in the following areas: 
 Dose-response effects of contaminant penetration at finite doses. 
 Dose-response effects of test decontaminants on penetration of contaminants. 
 More detailed characterisation of anatomical differences in penetration between 
species. 
 Reactions between contaminants and decontaminant vehicles. 
 Speciation analysis of resultant mixtures following decontamination. 
Desorption (“off-gassing”) kinetics (and speciation analysis) for test decontaminants. 
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CHAPTER 5.  Decontamination of 14C-VX applied to damaged skin in 
vivo 
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CHAPTER 5.  DECONTAMINATION OF 14C-VX APPLIED TO DAMAGED SKIN 
IN VIVO 
5.1  Introduction 
The skin is a potential route of entry for toxic organophosphate nerve agents such as VX.  
The toxicity of these compounds clearly prohibits investigations in humans.  Much of the 
data relating to toxicity, and indeed, decontamination, of nerve agents is obtained from in 
vivo models.  Swine models are frequently chosen as a closely representative model for 
extrapolation or prediction of effects in humans, following skin exposure to VX.  The efficacy 
of decontamination products or regimes, in response to VX exposure, has been 
demonstrated in swine models105,134. 
An increased hazard was demonstrated by the enhanced penetration kinetics of 14C-VX 
across damaged pig skin measured in vitro (Chapter 4), along with the efficacy of 
WoundStatTM, a haemostatic product, to counter this effect.  WoundStatTM was also one of a 
small number of haemostatic products which retained demonstrable pro-coagulative 
characteristics in the presence of VX, in vitro.  The aim of a haemostatic decontaminant 
would be to facilitate haemostasis in the presence of contaminants and prevent fatal 
toxicity.  An in vivo feasibility study of swine exposure to VX via superficially damaged skin, 
and subsequent treatment with a test decontaminant, should provide useful, empirical 
toxicokinetic data, which may be used as evidence to either support or reject further 
investigation of this product as a potential haemostatic decontaminant.  Hence, the purpose 
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of this study was to assess the efficacy of the haemostat WoundStat as a decontaminant on 
a VX-exposed, non-haemorrhaging, superficial wound in vivo. 
5.2  Materials and Methods 
The materials and methods are described in detail in Chapter 2 and are briefly outlined in 
Figure 5.1. 
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Figure 5.1:  Workflow design for the in vivo analysis of the efficacy of the haemostatic 
product WoundStat as a decontaminant.  
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5.3  Results 
5.3.1  Animal weight and dosage 
The weights of all 31 animals included in the study were normally distributed (Shapiro-Wilk 
test).  The mean body weight was 20.6 ± 1.6kg (mean ± standard deviation; range 16.6-
23.1kg) and there was no significant difference in mean body weight between groups (Figure 
5.2).  The mean mass of 14C-VX applied to the skin was 6.3 ± 0.4mg (range 5.4–7.0mg). 
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Figure 5.2:  Body weight (mean ± standard deviation) of swine included in the 14C-VX 
exposure and decontamination study, measured prior to commencement of the experiment.   
Animals were fasted overnight before the experiment and allowed access to water ad 
libitum.  Body weight did not significantly differ between the control (n=7), not-
decontaminated (DXD, n=12) and decontaminated (DD, n=12) groups (p>0.05).  
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5.3.2  Survival 
1.  Survival fractions and curve analysis 
After 360 minutes the survival fractions were 100% (6/6) in the control group; 92% (11/12) 
for the decontaminated group; and 25% (3/12) for the not-decontaminated group.  Gehan-
Brislow-Wilcoxon analysis showed that the survival curve for the not-decontaminated (DXD) 
group differed significantly from that of control group (p<0.01), and the decontaminated 
(DD) group (Figure 5.3). 
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Figure 5.3:  Survival curve for anaesthetised swine exposed to a 5xLD50 (300µg kg
-1) dose of 
neat 14C-VX via damaged ear skin (DXD; n=12); similarly exposed swine treated with a test 
decontaminant (DD; n=12); and anaesthetised control (un-exposed) animals (mean 
percentage of group survival ± 95% confidence interval).   
The survival curve for the DXD group differed significantly from the control group and the DD 
group (Gehan-Brislow-analysis; p<0.01). 
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2.  Survival time 
The mean survival times for the non-decontaminated group and decontaminated group 
were 168 ± 79 and 341 ± 41 minutes respectively (mean ± 95% CI; Figure 5.4).  The survival 
time for the not-decontaminated group was significantly lower than the control (p<0.01) and 
decontaminated (p<0.01) groups. 
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Figure 5.4:  Mean survival times for anaesthetised swine exposed to a 5xLD50 (300µg kg
-1) 
dose of neat 14C-VX via damaged ear skin (DXD; n=12); similarly exposed swine treated with 
a test decontaminant (DD; n=12); and anaesthetised control (un-exposed) animals (mean 
percentage of group survival ± 95% confidence interval).   
Asterisks indicate groups with mean survival times which are significantly different to that of 
the control group (**p<0.01).  The bar indicates a significant difference in survival time 
between treatment groups (**p<0.01). 
  
Treatment Group
S
u
rv
iv
a
l 
ti
m
e
 (
m
in
u
te
s
)
Control DXD DD
0
100
200
300
400
500 **
**
 - 131 - 
 
5.3.3  Acetylcholinesterase activity 
1.  Effect of 14C-VX  exposure on whole blood acetylcholinesterase activity 
There were no significant differences in whole blood acetylcholinesterase (AChE) activity in 
the control group at 15, 60, or 360 minutes (during the 6 hour observation period1. 
Exposure to 14C-VX resulted in a rapid, significant decrease in whole blood AChE activity, to 
below 30% of mean pre-dose activity within 15 minutes for both exposed groups (p<0.05; 
Figure 5.5).  At 15, 60 and 360 minutes post-exposure, mean whole blood AChE activity of 
the exposed animals was significantly lower than non-exposed controls2.  Whole blood AChE 
activity was not significantly different between the exposed groups at 15, 60 or 360 minutes 
post-exposure). 
  
                                                     
1
 Data for the intervening timepoints for the control group are unavailable. 
2
 NB: only 3 animals in the DXD groups survived to 360 minutes which may reduce the power 
of these interpretations. 
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Figure 5.5:  Whole blood acetylcholinesterase (AChE) activity of anaesthetised swine 
exposed to a 5xLD50 (300µg kg
-1) dose of neat 14C-VX via damaged ear skin (DXD; n=12); 
similarly exposed swine treated with a test decontaminant (DD; n=12); and anaesthetised 
control (un-exposed) animals (mean ± SEM).   
Data presented are relative to the mean activity at time of dose, or 0 minutes for controls.  
Within 15 minutes post-exposure, AChE activity decreased to below 30% of mean pre-dose 
levels (indicated by arrow; p<0.05) and remained significantly lower than that of control 
animals for the remainder of the exposure period.  
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2.  Whole blood acetylcholinesterase activity at time of death. 
For animals exposed to 14C-VX, whole blood AChE activity of the final blood sample (i.e. at 
the time of death or 360 minutes post-exposure) was significantly lower than that of control 
animals (after 360 minutes anaesthesia).  Whole blood AChE activity of the final blood 
sample was not significantly different between the decontaminated and not-
decontaminated groups (Figure 5.6). 
Furthermore, in animals which did not survive the 6 hour exposure period, the AChE activity 
at time of death did not correlate with survival time (Spearman’s rank-order correlation 
coefficient analysis; Figure 5.7). 
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Figure 5.6:  Whole blood acetylcholinesterase activity (relative to that of time zero) of the 
final blood sample obtained from anaesthetised swine exposed to a 5xLD50 (300µg kg
-1) dose 
of neat 14C-VX via damaged ear skin (DXD; n=12); similarly exposed swine treated with a test 
decontaminant (DD; n=12); and control (un-exposed) animals (mean ± SEM).   
The final blood sample was taken either at the time of death or 360 minutes post-exposure 
in surviving animals.  Asterisks indicate a significant difference between 14C-VX-exposed 
groups (DXD and DD) and control group (*p<0.05; ***p<0.001).  There was no significant 
difference between the DXD and DD groups.  
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Figure 5.7:  Individual scatter plot relating AChE activity of the final blood sample (relative to 
pre-dose activity) to survival time (up to 6 hours) of anaesthetised swine exposed to a 5xLD50 
(300µg kg-1) dose of neat 14C-VX via damaged ear skin (DXD; n=12); similarly exposed swine 
treated with a test decontaminant (DD; n=12); and control (un-exposed) animals (mean ± 
SEM).   
When surviving animals were excluded, Spearman’s rank-order correlation coefficient 
analysis showed no significant correlation between AChE activity at time of death and 
survival time.  
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5.3.4  Toxicokinetics 
Analysis of 14C-VX recovery and distribution was conducted in cohort 2 only.  Toxicokinetic 
data are presented as the percentage of applied mass which was recovered from each 
compartment (mean ± standard deviation), rather than the total mass, to account for the 
variation in mass of 14C-VX applied according to differences in animal weight.  Data were 
analysed by Mann-Whitney tests. 
 
1.  Total recovery 
Total 14C-VX recovery in the decontaminated group (55 ± 11% of the applied mass) was 
significantly higher than that of the non-decontaminated group (20 ± 4.1% of applied mass; 
p<0.01; Figure 5.8). 
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Figure 5.8:  Total post-mortem recovery (and distribution) of 14C-VX from anaesthetised 
swine exposed to a 5xLD50 (300µg kg
-1) dose of neat 14C-VX via damaged ear skin (DXD; n=6); 
and similarly exposed swine (DD; n=6) treated with a test decontaminant (percentage of 
mass applied; mean ± standard deviation).   
Total recovery of 14C-VX was significantly lower in the DXD group compared to the DD group 
(**p<0.01).  Total recovery of 14C-VX from the exposure site was not above 0.05% in either 
treatment group. 
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2.  Not penetrated 
Recovery of 14C-VX from the not penetrated fraction (decontaminant, dose chamber and 
swabs) was significantly higher in the decontaminated group (52 ± 12% of the applied mass) 
than in the non-decontaminated group (11 ± 6.2%; p<0.01; Figure 5.9). 
 
Decontaminant 
For the decontaminated group, the 14C-VX extracted from the collected WoundStat 
accounted for 47 ± 12% of the applied mass (range 34 – 66%; Figure 5.10).  Indeed, this also 
accounted for the bulk of the total 14C-VX recovery (as shown in Figure 5.8). 
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Figure 5.9:  Total post-mortem recovery of 14C-VX in the “not penetrated” fraction from 
anaesthetised swine exposed to a 5xLD50 (300µg kg
-1) dose of neat 14C-VX via damaged ear 
skin (DXD; n=6); and from similarly exposed swine treated with a test decontaminant 
(WoundStat; DD; n=6).   
The total recovery is presented relative to the applied mass (%; mean ± standard deviation).  
The amount of 14C-VX which was not penetrated was significantly higher in the 
decontaminated group (**p<0.01): the bulk of this was extracted from the decontaminant 
itself.  
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Dosing chamber and swabs 
Recovery of 14C-VX from the dosing chambers was significantly higher for the DXD group (5.1 
± 3.1% of the applied dose) compared to the DD group (0.18 ± 0.17%; p<0.01; Figure 5.11A).  
Recovery from swabs of the exposure site was 6.0 ± 4.8% in the DXD group and 4.1 ± 1.1% 
for the DD group (figure 5.10B).  The bulk of this was removed in the first swab compared to 
subsequent swabs (up to 3 per animal) and there was no significant difference in recovery of 
14C-VX from swabs between treatment groups. 
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Figure 5.10:  Total post-mortem recovery of 14C-VX from the dosing chamber (A) and swabs 
of the exposure site (B), taken from anaesthetised swine exposed to a 5xLD50 (300µg kg
-1) 
dose of neat 14C-VX via damaged ear skin (DXD; n=6); and from similarly exposed swine 
treated with a test decontaminant (DD; n=6).   
The total recovery is presented relative to the applied mass (%; mean ± standard deviation).  
A significantly larger amount of 14C-VX was extracted from the dose chambers in the not 
decontaminated group compared to the decontaminated group (**p<0.01).  Swabs of the 
exposed skin recovered similar amounts of 14C-VX in both groups.  
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3.  Exposure site 
The mean recovery of 14C-VX from the exposed skin sections, excised from non-
decontaminated animals (0.018 ± 0.0074% of the applied mass), was significantly higher 
than that from decontaminated animals (0.0011 ± 0.081 %; p<0.01; Figure 5.11). 
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Figure 5.11:  Total post-mortem recovery of 14C-VX from solubilised, exposed skin sections, 
excised from anaesthetised swine exposed to a 5xLD50 (300µg kg
-1) dose of neat 14C-VX via 
damaged ear skin (DXD; n=6); and from similarly exposed swine treated with a test 
decontaminant (DD; n=6).   
The total recovery is presented relative to the applied mass (%; mean ± standard deviation).  
Significantly less 14C-VX was recovered from the decontaminated exposure sites compared 
to the not-decontaminated sites (**p<0.01).  
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4.  Absorbed 
The total 14C-VX recovered from the sampled organs was not significantly different between 
groups (Figure 5.12).  Recovery from the liver accounted for the bulk of the absorbed 
fraction in both groups’ liver (5.1 ± 3.2% and 1.9 ± 0.64% in the DXD and DD groups 
respectively); followed by the blood (1.9 ± 1.3% and 0.79 ± 0.45% in the DXD and DD groups 
respectively).  
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Figure 5.12:  Total 14C-VX recovered from the sampled organs, post-mortem, from 
anaesthetised swine exposed to a 5xLD50 (300µg kg
-1) dose of neat 14C-VX via damaged ear 
skin (DXD; n=6); and from similarly exposed swine treated with a test decontaminant (DD; 
n=6).   
The total recovery is presented relative to the applied mass (%; mean ± standard deviation) 
and there was no significant difference in total internal recovery between groups. 
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Internal organs 
The mean mass (g) of the heart and liver of decontaminated animals was significantly lower 
than that of the not-decontaminated animals (Figure 5.13; p<0.05). 
 
For both treatment groups, the largest amount of 14C-VX recovered internally was located in 
the liver, followed by the blood, then kidney, (Figure 5.14).  The brains, hearts, lungs and 
spleens of the non-decontaminated group contained significantly higher amounts of 14C-VX 
compared to those of decontaminated animals (Figure 5.14).  Recoveries of 14C-VX from 
brain, heart, lung and spleen were significantly higher in the non-decontaminated group 
compared to the decontaminated group (p<0.05; Figure 5.14).  The concentration of 
radiolabel in the diaphragm was also significantly higher in not-decontaminated animals 
than decontaminated animals (p<0.05), whilst 14C-VX in the pancreas did not differ 
significantly between groups (Figure 5.15)1. 
                                                     
1
 As the total organ weights for pancreas and diaphragm could not be measured assuredly, 
the concentration of radiolabel (µg 14C-VX g tissue-1) in these organs was measured.   
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Figure 5.13:  Mean (± standard error) mass of organs measured post-mortem, following 6 
hours anaesthesia (control); exposure to 5xLD50 neat 
14C-VX via damaged ear skin untreated 
(DXD; survival time ranged from 29-360 minutes); and decontaminated (DD; survival time 
ranged from 137 to 360 minutes).   
Asterisks indicate a significant (p<0.05) difference in heart and liver mass between DD and 
DXD groups.  The data for the kidney is the mean mass of right and left kidneys per 
individual.  
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Figure 5.14:  Distribution of 14C-VX in specified organs, recovered (post-mortem) from 
anaesthetised swine exposed to a 5xLD50 (300µg kg
-1) dose of neat 14C-VX via damaged ear 
skin (DXD; n=6); and from similarly exposed swine treated with a test decontaminant (DD; 
n=6).   
The total recovery is presented relative to the applied mass (%; mean ± standard deviation).  
Asterisks indicate significant differences between treatment groups (*p<0.05; **p<0.01). 
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Figure 5.15:  Concentration of 14C-VX (µg g tissue-1) in pancreas (A) and diaphragm (B), 
recovered (post-mortem) from anaesthetised swine exposed to a 5xLD50 (300µg kg
-1) dose of 
neat 14C-VX via damaged ear skin (DXD; n=6); and from similarly exposed swine treated with 
a test decontaminant (DD; n=6).   
The total recovery is presented relative to the applied mass (%; mean ± standard deviation).  
Asterisks indicate significant differences between treatment groups (*p<0.05).  
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Blood 
The concentration of 14C-VX in blood became significantly different between the DXD and DD 
groups at 120 minutes post-exposure (p<0.05; Figure 5.17)1.  There was no significant 
difference between groups in concentration of 14C-VX in blood at the time of death 
(described previously, Figure 5.14).  However, the animals that died at 20, 105 (DXD) and 
135 minutes (DD) after exposure had quantitatively lower 14C-VX concentration in their final 
blood sample compared to the mean concentrations at other timepoints in their respective 
groups (Figure 5.16). 
In animals which survived to 6 hours (in either group), radiolabel concentration generally 
(but not exclusively) decreased as time progressed (Figure 5.17).  In contrast, the highest 
concentrations of radiolabel in the non-decontaminated animals which did not survive to 6 
hours were detected in the final blood samples (time of death). 
 
  
                                                     
1
 However only 2 animals in the DXD group, cohort 2, survived past 120 minutes which may 
reduce power of statistical comparisons beyond this point. 
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Figure 5.16:  Concentration (mean ± SEM) of 14C-VX in consecutive blood samples of 
anaesthetised swine exposed to a 5xLD50 (300µg kg
-1) dose of neat 14C-VX via damaged ear 
skin (DXD; n=6); and from similarly exposed swine treated with a test decontaminant (DD; 
n=6).   
Concentration became significantly different between the decontaminated (DD) and not-
decontaminated groups (DXD) at 120 minutes1.  The individual plots of concentration for 
animals which died at 20, 105 and 135 minutes are also presented: these were quantitatively 
lower than the mean concentrations of their respective groups at other time-points. 
  
                                                     
1  Only 2 animals in the DXD group survived longer than 120 minutes so statistical 
comparisons between exposed groups are not powerful beyond this time-point. 
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Figure 5.17:  Concentration (mean ± SEM) of 14C-VX in consecutive blood samples of 
individual, anaesthetised swine exposed to a 5xLD50 (300µg kg
-1) dose of neat 14C-VX via 
damaged ear skin (red connecting lines and individual plot at x=20; n=6); and from similarly 
exposed swine treated with a test decontaminant (black connecting lines; n=6).   
Generally, concentration decreased during the exposure period, particularly for animals 
which survived until 360 minutes.  In contrast, the concentration of 14C-VX  blood was 
highest at the time of death in animals which did not survive the exposure period.  
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5.3.5  Physiological recordings 
1.  Pulse rate and mean arterial pressure 
Exposure to 14C-VX without decontamination resulted in a rapid decrease in pulse rate (PR) 
and mean arterial pressure (MAP; Figure 5.18): within 15 minutes, PR and MAP of not-
decontaminated animals was significantly lower than control animals (p<0.05), and 
remained so until 120 minutes post-exposure1. 
There was also a significant, transient reduction in the pulse rate of decontaminated 
animals, compared to pre-exposure pulse rate, between 60 and 120 minutes post-exposure.  
A prolonged, late onset period of significantly decreased MAP (compared to pre-exposure 
MAP) was observed between 2 and 4 hours exposure in the decontaminated group. 
  
                                                     
1 Only three animals in the DXD group survived beyond 180 minutes exposure, which may 
reduce the power of statistical comparisons beyond this time. 
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Figure 5.18:  Pulse rate (A) and mean arterial pressure (B) for anaesthetised (control), 14C-VX 
exposed (DXD) and 14C-VX-exposed and decontaminated (DD) swine.   
Data are mean ± SEM for up to 12 animals per group, recorded over 6 hours from exposure 
at 0 minutes.  
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2.  Breathing rate, expired CO2 and saturated O2 
Exposure to 14C-VX without decontamination resulted in a rapid reduction of breathing rate: 
within 15 minutes post-exposure, breathing rate in not-decontaminated animals had 
significantly slowed compared to the pre-dose rate (Figure 5.19A; p<0.05) and remained so 
until 2 hours post-exposure.  The mean breathing rate of both groups was significantly 
slower than the pre-dose rate at 6 hours post-exposure. 
In contrast, the expired CO2 levels in exposed and non-decontaminated animals were only 
significantly higher than the pre-dose level at 60 minutes post-dose (Figure 5.19B).  For the 
three surviving animals in the DXD group, expired CO2 was significantly higher than control 
animals from 180 minutes post-exposure. 
In practice, decreasing saturated oxygen level was usually a good indicator of deterioration 
of condition; however there were no significant differences in SpO2 levels between groups 
during the 6 hours (Figure 5.20C). 
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Figure 5.19:  Respiration rate (A), expired CO2 level (B) and saturated oxygen level (SpO2; C) 
for anaesthetised (control), 14C-VX exposed (DXD) and 14C-VX-exposed and decontaminated 
(DD) swine.   
Data are mean ± SEM for up to 12 animals per group, recorded over 6 hours from exposure 
at 0 minutes.  
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3.  Haematocrit 
Exposure to 14C-VX caused without decontamination resulted in an increase in haematocrit, 
which was significantly higher than pre-exposure level at 60 and 120 minute post-exposure 
(Figure 5.20).  The haematocrit-time curves were almost parallel for the decontaminated and 
not-decontaminated group. 
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Figure 5.20:  Haematocrit values for anaesthetised (control), 14C-VX exposed (DXD) and 14C-
VX exposed and decontaminated (DD) swine.   
Data are mean ± SEM for up to 12 animals per group, recorded over 6 hours from exposure 
at 0 minutes.    
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4.  Variations 
Clear (inter-)individual variations were observed between animals within groups, which may 
complicate overall interpretations based on treatment (decontamination or no 
decontamination).  For example, in decontaminated animals, PR and MAP generally 
recovered during the remainder of the exposure period (Figure 5.18); however, in one 
decontaminated animal, a decrease in PR (from ~140 to <40bpm between 300 and 330 
minutes) and MAP (from 80 to <40mmHg after 330 minutes) was observed.  A similar profile 
was observed for one of the surviving animals from the not decontaminated group (Figure 
5.21).  These animals were both classified as displaying moderate signs of intoxication.  
Similarly, the deterioration of the condition of the decontaminated animal which did not 
survive the exposure period, more closely paralleled that of the not-decontaminated group 
(as a whole) than the decontaminated group. 
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Figure 5.21:  Pulse rate (A) and MAP (B) for two, anaesthetised 14C-VX exposed swine.   
One animal was decontaminated (VX18); the other was not (VX08).  The mean ± SEM for up 
to 7 anaesthetised (control) animals, observed over 6 hours, are also presented.  
P
u
ls
e
 r
a
te
 (
b
e
a
ts
 m
in
-1
)
0 60 120 180 240 300 360
50
100
150
200
250
VX08
Control
VX18
Time (minutes)
M
e
a
n
 a
rt
e
ri
a
l 
p
re
s
s
u
re
 (
m
m
H
g
)
0 60 120 180 240 300 360
50
100
150
200
250
VX08
Control
VX18
A
B
 - 161 - 
 
5.3.6  Signs of intoxication 
During the exposure period the signs of intoxication observed could be distinguished using 
thirty-two separate descriptions, taking into account both the type and location of the sign 
(described in Table 5.1).  To enable further analysis, a selection of the more commonly 
observed signs were organised into the following groups: 
i. Any motor effect (including fasciculations, tremors, spasms etc.); 
ii. Any secretory effect (including salivation, rhinorrhea, lacrimation; bronchorrhea); 
iii. Any regular /continuing / not sporadic abnormality observed on the ECG trace; 
iv. Mastication; 
v. Any pupil effect (miosis or mydriasis). 
These 5 groups were used to describe the severity of signs of intoxication in animals as 
follows: 
 Fatal: animals died within 360 minutes. 
 Severe: rapid onset (<30 minutes) of at least two of the groups (i-v) of signs of 
intoxication described above. 
 Moderate: onset of only 1 of the above groups (i-v) within 30 minutes OR onset of 
any of the above groups (i-v) after 30 minutes. 
 Mild: late onset (>60 minutes) of any of the groups (i-v) described above. 
The proportion of animals which were classified as moderately or fatally intoxicated was 
significantly different between the treatment groups (Table 5.2).    
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Location Description 
Face, head and neck fasciculations, tremors (including shaking or shivering-like 
movements, not twitches), side-to-side movements of the head, 
twitches or jerks, skin colour changes. 
Body and back fasciculations, tremors (including shaking or shivering-like 
movements, not twitches), twitches or jerks (including convulsions), 
skin colour changes. 
Limbs, shoulders and 
feet 
fasciculations, tremors, including shaking or shivering-like 
movements (not twitches), twitches or jerks, including convulsions, 
skin colour changes, blood pooling in the limbs or feet. 
Other signs 
Mastication, salivation, lacrimation, nasal secretions, bronchorrhea (interpreted by noisy or 
gurgling breaths when secretions themselves weren’t visible), defecation or urination, 
beading on the snout, cutis anserina and piloerection, gasping or gulping breaths, agonal 
breathing, cyanosis on the face, arrhythmia or any other unusual ECG traces, swollen snout, 
bloodshot eyes, bulging or sinking of the eyes in the sockets, movement of the eyes within 
the sockets (including rolling forward or backward, up and down, vibrating), pupil 
constriction or dilation. 
 
Table 5.1:  Descriptions of the signs of intoxication, and their localisation, observed in 
animals exposed to a 5xLD50 (300µg kg
-1) dose of neat 14C-VX via damaged ear skin (DXD; 
n=12); and in similarly exposed swine treated with a test decontaminant (DD; n=12).  
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Group Fatal** Severe Moderate* Mild 
DXD 9/12 2/12 1/12 0/12 
DD 1/12 2/12 7/12 2/12 
 
Table 5.2:  Severity of signs of intoxication in anaesthetised animals exposed to a 5xLD50 
(300µg kg-1) dose of neat 14C-VX via damaged ear skin (DXD) and a test decontaminant (DD). 
Asterisks indicate a significant difference between groups in the proportion of animals within 
the category (Fisher’s two-tailed exact test: *p<0.05; **p<0.01). 
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Onset of particular signs of intoxication 
The proportion of each treatment group which displayed any of the groups of signs 
previously described (i-v) were analysed using Fisher’s two-tailed exact test (Table 5.3).  The 
time of onset of these signs was also included in this analysis.   
There was no significant difference in occurrence or onset time of any motor or secretory 
effects or mastication between groups.  There was not a significant difference in occurrence 
of pupil effects between the groups.  However, within the animals which did display pupil 
effects, the onset of these within 30 minutes occurred in a significantly larger proportion of 
the not-decontaminated group than the decontaminated group.  Also, the onset of pupil 
effects after 30 minutes occurred in a significantly lower proportion of the not-
decontaminated group than the decontaminated group. 
Electrocardiograph irregularities were observed in a significantly larger proportion of the 
not-decontaminated group compared to the decontaminated group. 
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Sign of 
intoxication 
Treatment 
group 
Not 
observed 
Observed 
Total <30 minutes 30+ 
Alive at 
timepoint 
DXD  12 12 11 
DD  12 12 12 
Any motor 
effect 
DXD 0/12 12/12 11/12 1/11 
DD 0/12 12/12 6/12 6/12 
Any secretory 
effect 
DXD 2/12 10/12 7/10 3/10 
DD 1/12 11/12 3/11 8/11 
Mastication 
DXD 1/12 11/12 9/11 2/10 
DD 6/12 6/12 3/6 3/6 
Any pupil 
effect 
(constriction 
or dilation) 
DXD 2/12 10/12 9/10 
a
 1/9 
b
 
DD 6/12 6/12 1/6 
a
 5/6 
b
 
Any ECG effect 
or arrhythmia 
DXD 4/12 8/12 
c
 4/8 4/7 
DD 11/12 1/12 c 1/12 0/1 
 
Table 5. 3:  Observations of onset of signs of intoxication in anaesthetised animals exposed 
to a 5xLD50 (300µg kg
-1) dose of neat 14C-VX via damaged ear skin (DXD) and a test 
decontaminant (DD).   
For the onset period, the denominator takes into account both the number of animals in 
each group which displayed the given sign in the first instance and the number of animals 
which were alive in the given timeframe.  Superscript letters indicate a significant difference 
in proportions between groups bearing the same annotation: ap<0.01; bp<0.05; cp<0.01.  
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5.4  Discussion 
This study demonstrated the efficacy of swift application of a haemostatic product, 
WoundStatTM, to prevent death and reduce the severity of intoxication in swine exposed to a 
supra-lethal (5xLD50) dose of 
14C-VX via damaged ear skin.  This efficacy was evident despite 
a rapid, significant decrease in acetylcholinesterase (AChE) activity.  Application of 
WoundStatTM within 30 seconds of exposure resulted in retention of almost 50% of the 
applied dose within the decontaminant matrix, and effectively reduced deposition of 14C-VX 
in the brain, heart, lung, spleen, diaphragm and blood. 
The toxicity of VX clearly prohibits investigations in humans.  However, in vitro and in vivo 
studies have provided some comparative toxicokinetic data for VX between pig and human 
models44,58,101,105,108.  The pig ear in particular has been reported to be an appropriate model 
for human abdominal penetration of VX101.  Furthermore, swine models are also used for 
studies of haemostat treatment of severely haemorrhaging wounds5,7.  However, data 
obtained from animal models should always be interpreted within the limitations of the 
model, viz its relevance to effects in humans. 
This model was designed to be representative of a “worst-case” scenario, in all but 
haemorrhaging conditions.  Whilst dose-response effects of VX were not investigated in this 
study, the dose applied was a supra-lethal toxic challenge.  Application of neat, undiluted 
contaminant (>98% pure), rather than a less toxic simulant, allowed the clinical effects and 
outcome of exposure via damaged skin to be observed.  The pig ear has also been 
demonstrated to be more permeable to VX than pig abdomen102.  Dose-response effects of 
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the decontaminant were not investigated in the present study.  Furthermore, the 
decontaminant was left in place for the duration of the experiment, which is representative 
of “in use” procedure for an advanced haemostat, but not for a decontaminant.  Application 
of 14C-VX to damaged skin in vitro resulted in significantly enhanced penetration kinetics 
(Chapter 4).  The skin damage induced, whilst not a complex, haemorrhaging wound, may 
have created an environment favouring VX-penetration.  These elements of the study design 
provide a thorough “worst-case” scenario to assess efficacy of the test decontaminant. 
In this study the dorsal aspect of the ear (pinna) was exposed to VX.  Creating a uniform area 
of damage (that was also distal to pre-experimental superficial damage that can often be 
present on co-housed pigs) was deemed to be less complicated on the dorsal aspect of the 
pinna than the ventral aspect.  The interval between exposure and decontamination (30 
seconds) was selected to be reflective of a response time beyond which an arterial 
haemorrhaging wound may become unsalvageable. 
Interestingly, the mean survival time for animals exposed to 5xLD50 
14C-VX via damaged skin 
(without decontamination) in this study was not dissimilar to that of a previous study of an 
equivalent dose to intact ear skin in swine105.  However, three of the animals also survived 
the 5xLD50 dose of 
14C-VX in the present study, compared to none in Bjarnason et al’s study.  
The reported percutaneous LD50 for swine (specifically, ear) has differed between 50 - 80 µg 
kg-1) between previous studies of in vivo VX exposure58,102,105.  Variations in protocol, 
anaesthesia, dosing regimen or simply individual subjects may partly explain the range of 
LD50 values, and in turn may partly account for the discrepancy in survival between studies 
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using “equivalent” multiple LD50s.  Arguably, the lethality of the dose used in this study is 
supported by the death of one decontaminated animal. 
The test decontaminant was evaluated in a superficial skin wound, rather than a complex 
haemorrhaging injury.  Application of Fuller’s Earth pre-contaminated with an 80 µg kg-1 
dose of VX to a full-thickness skin wound resulted in zero fatalities within 6 hours 
exposure105.  In contrast, one animal in the decontaminated group in the present study died 
137 minutes post-exposure.  The present model is more representative of an exposure-
decontamination event; rather than a secondary exposure event due to cross-
contamination.  Furthermore, it has previously been suggested that contact with the skin is 
the limiting factor for VX-spreading100; thus spread of the agent (and, hence, the total size of 
the exposed area) may be affected to different extents between the two models. 
Autoradiography of the ear was not used to measure radiolabel spread in the present 
experiment, although a Geiger-Muller probe was used to direct excision of all contaminated 
regions in the vicinity of the exposure site for radiometric analysis.  Previously, agent spread 
over pig ear skin (measured in vivo) was shown to be approximately 5-fold lower than 
human forearm skin (measured in volunteers)44,58.  Characterisation of agent spread in 
different models would be useful for future decontamination studies, particularly to 
demonstrate whether products with different mechanisms of decontaminant action (e.g. 
absorptive material rather than barrier) have differing effects on agent spread.  The 
discrepancies between this experiment and previous swine studies (using similar or 
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equivalent doses) may partly be attributable to spread of the contaminant beyond the 
damaged skin area. 
The use of a radiolabelled contaminant does not provide a complete profile of VX-absorption 
and distribution, as radiometric analysis does not distinguish between 14C-VX and 
breakdown products or metabolites.  Furthermore, radiolabel excretion was not measured 
in this study, and it is probable that some of the un-recovered dose is contained within un-
sampled tissue.  Speciation analysis, for example GC-MS, would be essential to attempt to 
predict the hazard posed by absorbed material.   
This approach, however, does permit some interpretations of basic toxicokinetics.  The 
amount of radiolabel recovered in the skin sections in this study was noticeably lower than 
that of previous in vivo investigations of exposures to pig ear, despite a larger dose of VX 
being applied in the present study58,100.  Previous studies of VX exposure in humans and 
swine have been suggestive of the presence of a dermal reservoir of VX within the skin44,100.  
It is possible that the skin damage induced in the present model may have prevented the 
formation of a reservoir.  The longer exposure period used in the present study (6 hours 
rather than 3 hours) may also have prolonged the opportunity for excretion or deposition in 
unsampled tissues.  Indeed, blood concentration decreased with time in the surviving 
animals, which may represent mobilisation of radiolabel from the blood.  Furthermore, of 
the tissues that were sampled, the largest amount of 14C-VX was recovered from the liver.  
However, without a detailed speciation analysis, there is also no certainty about the 
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presence of structures other than 14C-VX (i.e. potential breakdown products), or their 
relative abundance and distribution, within the sampled tissues. 
The radiometric approach can also demonstrate basic decontamination efficacy.  
Approximately 47% of the applied dose was extracted from collected WoundStat alone.  
Despite this, the total 14C-VX recovery from internal organs and blood was not significantly 
different between groups; whilst recovery from brain, heart, lung, spleen and diaphragm 
(inferred by concentration) was significantly reduced by decontamination.  A possible 
explanation could be that the decontaminant may reduce the rate of penetration of 14C-VX, 
rather than preventing penetration altogether.  However, if swift decontamination reduces 
the rate of penetration to a clinically relevant extent, or prevents build-up of a reservoir, 
then this should improve prognosis.  Analyses of desorption kinetics for VX from 
decontaminant matrices, or of dose-response effects of decontaminant may provide some 
data to support or oppose this possibility.  Comparative spectrometric analysis (for example 
of extracted samples from blood or urine) would be useful to determine differences in the 
metabolic profiles (i.e. the presence or absence of structures other than 14C-VX and relative 
abundance) between decontaminated and not-decontaminated groups. 
In the present study, approximately 10% of the applied dose was recovered unabsorbed, 
extracted from the exposure chamber and swabs of the exposure site.  This is approximately 
10x higher than the unabsorbed fraction recovered following exposure to a lower dose 
(2xLD50) to intact skin
58.  The proportion of the applied dose which was absorbed in the 
present study was lower (approximately one fifth) of that which was absorbed in the 
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previous study.  The differences in total recovery between these studies may be attributed 
to variations in the doses applied or distribution of radiolabel in unsampled tissues. 
In contrast to previous in vivo studies, anaesthesia was maintained by intravenous 
alphaxalone, rather than inhaled isoflurane or halothane.  Isoflurane anaesthesia has been 
previously shown to produce up to a 15-20% reduction in acetyl cholinesterase activity74. 
A detailed analysis of prolonged alphaxalone exposure on acetylcholinesterase activity in 
swine has not been conducted.  However, althesin, a discontinued anaesthetic mixture 
containing alphaxalone, was reported to have negligible effect on cholinesterase activity135.  
A clear difference was evident between the control and VX-exposed animals; and there were 
negligible changes in acetylcholinesterase activity in control animals throughout the study 
period.  Therefore, it can be reasonably assumed that any effects on cholinesterase function 
induced by the anaesthetic regime would have had a negligible contribution to the overall 
outcome of the experiment.  Nevertheless, characterisation of anaesthetic suitability for in 
vivo nerve agent experiments is worthy of further investigation. 
It is also important to note that mild fasciculations or shivers were observed in some animals 
prior to VX-exposure, which has been reported previously following anaesthesia induction in 
swine105.  Signs of intoxication in each animal were recorded relative to any initial 
observations made prior to exposure: i.e. fasciculations and tremors etc. were recorded 
when the status of the animal worsened from that of the pre-dose period. 
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There was no detectable correlation between final acetylcholinesterase activity and survival 
time in non-surviving animals in this study.  There were also no general significant 
differences in acetylcholinesterase activity between decontaminated and not-
decontaminated animals during the exposure period (except for at the time of death).  These 
results compare favourably with previous reports that cholinesterase activity is a robust 
indicator of exposure, but not prognosis70,74.  This is particularly important following a recent 
demonstration of plasma cholinesterase rebound following VX-exposures in swine136.  This 
also suggests the requirement for further investigations and characterisations of the 
cholinesterase response in pig and human blood fractions; and the investigation of other 
possible mechanisms of VX (and indeed, organophosphate nerve agents in general) 
toxicity70–72.  Contributively or protective effects resulting from VX interaction with other 
esterases were not explored in this study.  A detailed investigation of activity of other 
esterases, including tissues other than blood, may provide useful supporting information 
relating to VX-toxicokinetics. 
In contrast to previous reports, a clear order of occurrence of signs of intoxication was not 
observed; although significant differences were identified in severity of intoxication between 
treatment groups 37,74.  This may partly be attributable to the different doses applied 
between studies.  There were, however, apparent differences in physiological parameter 
recordings between animals which died or survived, regardless of treatment group.  For 
example, the pulse rate and mean arterial pressure of two surviving individuals, one from 
each treatment group, closely paralleled each-other.  Similarly, the physiological recordings 
of the decontaminated animal which did not survive, more closely paralleled that of the not-
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decontaminated group.  This may be interpreted as further evidence that physiological 
parameters alongside signs of intoxication may be more useful as prognostic indicators. 
The predominance of different effects of VX exposure and their relative contribution to 
overall outcome (i.e. death or survival) was not clear.  Death was confirmed following a 15 
minute period of uninterrupted apnoea; but whether apnoea had resulted from central 
depression of respiratory regulation or paralysis of respiratory muscles was not clear.  The 
changes in pulse rate or blood pressure and their contribution to outcome may have causal, 
effector, synergistic or contradictory interactions.  For example, a change in pulse rate may 
be an effect of exposure, but could also be reasonably expected to affect distribution of VX.   
Core temperature was monitored but not included as an experimental endpoint.  
Temperature was artificially maintained where necessary, for monitoring of stable 
anaesthesia; furthermore, use of a rectal probe meant that a reduction in temperature often 
indicated defecation.  However, a more detailed analysis of temperature at exposure sites 
(and other anatomical locations) could provide useful information regarding temperature 
effects on penetration rates and resultant toxicity44,137. 
The present evidence cannot be used to determine whether variations in types of signs of 
intoxication observed (inter-treatment), or changes in physiological parameters observed 
during the 6 hour period (inter-individual), are due to the relative predominance of 
muscarinic or nicotinic effects of cholinesterase inhibition; non cholinesterase effects; or 
subsequent recovery following an initial period of intoxication.    
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To summarise, the results of this in vivo decontamination study demonstrated: 
 The efficacy of swift application of a haemostatic product, WoundStatTM, to reduce 
fatality and reduce the severity of signs of intoxication following exposure of swine to 
a 5xLD50 dose of 
14C-VX via damaged ear skin. 
 That WoundStatTM, applied 30 seconds after exposure of the damaged skin, was 
effective in retaining almost 50% of the applied dose. 
 That swift decontamination of the exposed area altered distribution of 14C-VX, 
specifically in the brain, heart, lung, spleen, diaphragm, and blood, although the 
mechanisms involved are not clear. 
 That acetylcholinesterase activity, following exposure to a supra-lethal dose of 14C-
VX, was not as useful for assessing prognosis as physiological monitoring. 
This study has identified the requirement for further work in the following areas: 
 In vitro comparisons of VX penetration kinetics in similarly damaged human and pig 
skin; 
 Dose-response investigations for VX application to intact and damaged pig skin, 
particularly for toxicokinetic analysis and characterisation of clinical signs of 
intoxication; 
 Effects of the dose-decontamination interval and decontaminant dose on product 
efficacy; 
 Speciation analysis of blood and tissues following in vivo experiments of VX exposure; 
 Analysis of desorption of compounds from test decontaminants; 
 Characterisation of anaesthetic suitability for in vivo nerve agent experiments.
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CHAPTER 6.  Analysis of gene expression following exposure to 14C-VX: 
effects of decontamination and outcome 
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CHAPTER 6.  ANALYSIS OF GENE EXPRESSION FOLLOWING EXPOSURE TO 
14C-VX: EFFECTS OF DECONTAMINATION AND OUTCOME 
6.1  Introduction 
The primary mechanism of toxic action of organophosphate nerve agents is inhibition of 
acetylcholinesterase.  Previous in vivo investigations have demonstrated the efficacy of 
various decontaminants to prevent death following nerve agent exposure (Chapter 5) 
105,106,134.  However, previous reports have investigated the suggestion that VX toxicity may 
not be completely explained by acetylcholinesterase inhibition71,72.  Indeed, in the preceding 
experiment, 14 animals survived 6 hours exposure to a supra-lethal (5xLD50) dose of 
14C-VX, 
with marked levels of acetylcholinesterase inhibition which were not significantly dissimilar 
to subjects which did not survive.  A microarray experiment was conducted to investigate 
changes in gene expression in whole blood samples obtained from the preceding in vivo 
decontamination study, in order to investigate processes which may have been involved in 
responses to VX-exposure. 
 
6.2  Materials and Methods 
The experimental groups, acquisition of blood samples, extraction of RNA and microarray 
hybridisation (preparation and post-hybridisation) are detailed in Chapter 2 and an 
experimental overview is summarised in Figure 6.1.   
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Figure 6.1:  Workflow design for analysis of gene expression in blood samples of swine 
exposed to a 5xLD50 dose of 
14C-VX via damaged ear skin. 
  
In vivo decontamination study 
RNA extraction from pre-dose and 
final blood samples 
Microarray hybridisation 
Analysis of gene expression 
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6.3  Results 
Normalisation and filtering on flags (detected in all conditions) resulted in 10,110 probes for 
inclusion in subsequent data analysis.  The highest number of significant changes in gene 
expression were identified when comparing the pre-dose and final blood samples of the 
decontaminated (22% of the analysed genes) or survivor (37%) groups (Table 6.1).  In 
comparison, 3% and 7% of the analysed genes were significantly changed in whole blood 
samples from non-surviving or non-decontaminated animals respectively.  Gene ontology 
analyses did not identify a shortlist of significant functional groups for any of the 
comparisons made.  Many of the features were shared between groups.  A visual 
representation of the overlap of significantly changed genes between groups is shown in 
Figure 6.2. 
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Comparison 
Down No change Up Total change 
No decontamination: 
Pre-dose vs final 
591 9455 64 655 
Decontamination: 
Pre-dose vs final 
1246 7920 944 2190 
Survivor: 
Pre-dose vs final 
2324 6417 1369 3693 
Non-survivor: 
Pre-dose vs final 
197 9853 60 257 
 
Table 6.1:  Statistical summary for number of probes showing differential expression 
(FC>1.0; p<0.05) in each comparison, between the pre-dosage and final blood sample, 
following exposure of swine to a 5x LD50 dose of 
14C-VX via damaged ear skin.   
Data were analysed by paired T-test with Welch’s correction and no false discovery rate 
limit.  
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Figure 6.2:  Venn diagram (not proportional) showing the frequency of the genes which were 
identified to be significantly (p<0.05) differently regulated (fold change >1.0) during 
exposure to 14C-VX in different conditions.   
The diagram shows the entities which are shared between groups, and entities which are 
isolated to particular groups: Survivors, Non-survivors, Decontaminated and Not 
decontaminated.  
Non-survivors
Pre-dose and final sample
↓
257 entities 
Survivors
Pre-dose and final sample
↓
3693 entities 
Decontaminated
Pre-dose and final sample
↓
2190 entities 
Not decontaminated
Pre-dose and final sample
↓
655 entities 
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6.3.1  Changes in gene expression following fatal or non-fatal exposure to 14C-
VX. 
 
Comparing expression in the final blood sample to pre-dose blood samples in the surviving 
animals identified 3693 entities (37% of those analysed) with a significant fold change 
(p<0.05; FC>1.0) following exposure to 14C-VX.  Comparing expression in the final blood 
sample to pre-dose blood samples in the animals which did not survive identified 257 
entities (3% of those analysed) with a significant fold change (p<0.05; FC>1.0) following 
exposure to 14C-VX (Figure 6.3). 
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Figure 6.3:  Volcano plot showing entities with a significant fold change (p<0.05; FC>1.0) in 
whole blood of swine which survived (A; n=7; 3693 entities) or did not survive (B; n=5; 257 
entities) exposure to a 5xLD50 dose of 
14C-VX via damaged ear skin.   
Data were analysed by paired T-tests with no false discovery rate limit.  
A
B
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Opposite regulation of genes in samples from survivors and non-survivors 
Expression of 119 genes were significantly changed during exposure in both the survivor and 
non-survivor groups.  Of these, 38 were oppositely regulated between the groups (i.e. 19 
were down-regulated in the survivor group and up-regulated in the death group; 19 were 
up-regulated in the death group and down-regulated in the survival group; Table S6.1).  
None of these significantly linked to gene ontology terms.  Three entities had significant fold 
changes above 1.5 in both survival or death groups; one with opposing regulation between 
groups (Table 6.2).  Some of the entities identified were not annotated with any Gene 
Ontology terms, whereas others were linked to up to 80 Gene Ontology terms.  Gene 
ontology analyses did not identify a shortlist of significant functional groups for any of the 
comparisons made.   
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6.3.2  Changes in gene expression in decontaminated or non decontaminated 
animals following exposure to 14C-VX. 
 
Comparing expression in the final blood sample to pre-dose blood samples in the 
decontaminated animals identified 2190 entities (22% of those analysed) with a significant 
fold change (p<0.05; FC>1.0) following exposure to 14C-VX.  Comparing expression in the final 
blood sample to pre-dose blood samples in the animals which were not decontaminated 
identified 655 entities (7% of those analysed) with a significant fold change (p<0.05; FC>1.0) 
following exposure to 14C-VX (Figure 6.4). 
 
 - 186 - 
 
Figure 6.4:  Volcano plot showing entities with a significant fold change (p<0.05; FC>1.0) in 
whole blood of swine which were decontaminated (A; n=6; 2190 entities) or not 
decontaminated (B; n=6; 655 entities) following (up to 6 hours) exposure to a 5xLD50 dose of 
14C-VX via damaged ear skin.   
Data were analysed by paired T-tests with no false discovery rate limit.  
A
B
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Differences in gene expression between decontaminated or non decontaminated animals 
Expression of 162 genes were significantly changed during exposure in both the 
decontaminated and not-decontaminated groups. 
In order to further focus the results on the most marked changes, the fold change limit was 
raised to 2.0, which identified 396 significantly differentially expressed entities (Figure 6.5).  
Of these, 3 were represented in both treatment groups (Table 6.3), and 5 were isolated to 
the “not decontaminated” group (Figure 6.5; Table 6.4).  In the “not decontaminated” group, 
no entities were identified to have a significant fold-change above 3.0 between the pre-dose 
and final blood sample. 
The most marked changes (i.e. highest fold change) were evident in the “decontaminated” 
group.  In this group, 65 entities were identified with a significant fold change between 3.0 
and 9.0 (Table S6.2).  One entity had a significant fold change above 7.0 in this group. 
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Figure 6.5:  Proportional Venn diagram showing frequency of significantly differentially 
expressed entities (FC>2.0; p<0.05) in pre-dose and “final” blood samples obtained from 
swine exposed to a 5xLD50 dose of 
14C-VX via damaged ear skin treated with a test 
decontaminant (Decontamination) or not (No decontamination).   
The entities were obtained by Volcano plot and unpaired T-test with Welch’s correction and 
no false discovery rate limit; no probes passed the Benjamini & Hochberg FDR limit).  In 
total, 396 entities were identified with significant differential expression between the pre-
dose and “final” blood samples.  Of these, 3 were identified in both treatment groups and 5 
were only identified in the not decontaminated group. 
  
No decontamination: 
Pre-dose  final
Decontamination: 
Pre-dose  final
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Probe Name 
P 
Value 
Fold 
change 
Gene Symbol Description 
A_72_P153566 0.044 2.82  
Sus scrofa mRNA, 
clone:THY010092F01, expressed in 
thymus. [AK239319] 
A_72_P330288 0.037 2.15  
Rep: Chromosome undetermined 
SCAF3439, whole genome shotgun 
sequence - Tetraodon nigroviridis 
(Green puffer), partial (6%) 
[TC538063] 
A_72_P000091 0.039 2.04 LOC100512978 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1S
AL1] [ENSSSCT00000016455] 
 
Table 6.3:  Three genes were identified which were significantly down-regulated by a fold-
change greater than 2.0, during (up to) 6 hours exposure of anaesthetised swine to a 5xLD50 
dose of 14C-VX via damaged ear skin, in blood samples of both decontaminated (n=6) and 
not-decontaminated (n=6) animals (FC>2; p<0.05).   
Data were analysed by paired T-test with Welch’s correction and no false discovery rate 
limit.  
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Probe Name 
P 
Value 
Fold 
change 
Gene Symbol Description 
A_72_P217812 0.037 2.12 ZCCHC6 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1S4J
1] [ENSSSCT00000011987] 
A_72_P165046 0.021 2.10 CD55 
Sus scrofa CD55 molecule, decay 
accelerating factor for complement 
(Cromer blood group) (CD55), mRNA 
[NM_213815] 
A_72_P413368 0.038 2.15  
Sus scrofa mRNA, 
clone:ITT010040H02, expressed in 
intestine. [AK231345] 
A_72_P374023 0.039 2.04  
Sus scrofa mRNA, 
clone:AMP010092E08, expressed in 
alveolar macrophage. [AK231094] 
A_72_P149411 0.017 2.18 ADAM8 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1SC
V2] [ENSSSCT00000011786] 
 
Table 6.4:  Five genes were identified which were significantly down-regulated by a fold-
change greater than 2.0, during (up to) 6 hours exposure of anaesthetised swine to a 5xLD50 
dose of 14C-VX via damaged ear skin (n=6).   
Four animals did not survive the 6 hour observation period: the mean survival time for these 
four animals was 103 ± 50 minutes (mean ± standard deviation; range 29 to 172 minutes).  
The remaining two animals were euthanized at 6 hours post-exposure.  Data were analysed 
by paired T-test with Welch’s correction and no false discovery rate limit.  No entities in the 
not-decontaminated group were significantly differentially expressed by a fold-change 
greater than 3.0. 
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6.3.3  Changes in gene expression with successful decontamination (survival) 
following exposure to 14C-VX 
Of the significantly differently expressed entities (p<0.05; FC>1.0), 1763 were specific to 
samples from decontaminated animals which survived (Figure 6.2).  Six of these entities 
were significantly regulated with a fold change between 5.0 and 9.0 (Table 6.5). 
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6.3.4  Changes in gene expression with un-successful decontamination 
(death) following exposure to 14C-VX 
Of the significantly differently expressed entities (p<0.05; FC>1.0), 3 were specific to the 
samples from the decontaminated animal which died (Table 6.6)1. 
 
 
 
                                                     
1 NB: Only one decontaminated animal did not survive. 
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6.3.5  Changes in gene expression with non-fatal (survival) exposure to 14C-VX 
without decontamination 
Two animals survived the exposure of damaged ear skin to 5xLD50 
14C-VX, without any 
decontamination treatment.  Of the significantly differently expressed entities (p<0.05; 
FC>1.0), 233 were specific to samples from these survivors of the not-decontaminated group 
(Figure 6.2).  Thirty six of these were differently regulated with a fold-change greater than 
1.5 (Table S6.3).  Three entities were differently regulated with a fold change greater than 
2.0 in both groups; whereas one had a fold change greater than 3.0 within the survivor 
group only (but less than 2.0 in the not-decontaminated group): this was un-annotated and 
did not map to a Gene Ontology term (Table 6.7). 
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6.3.6  Changes in gene expression with fatal exposure to 14C-VX and no 
decontamination 
Four animals which received no decontamination did not survive exposure to a 5xLD50 dose 
of 14C-VX via damaged ear skin.  Of the significantly differently expressed entities (p<0.05; 
FC>1.0), 52 were specific to samples from these non-survivors of the not-decontaminated 
group (n=4; Table S6.4).  Two entities were differently regulated with a fold-change greater 
than 1.5 (Table 6.8). 
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6.3.7  Changes in gene expression in swine blood, common to “survivor”, 
“non-survivor”, “decontaminated” and “non-decontaminated” groups 
following exposure to 5xLD50 
14C-VX via damaged ear skin 
Of the significantly differently expressed entities (p<0.05; FC>1.0), 53 were identified across 
all groups (i.e. the “survivor” group, the “death” group, the “decontaminated” group and the 
“not-decontaminated” group; Figure 6.2 and Table S6.5).  Fold change was between 1.0 and 
3.0 and only one entity had fold change greater than 1.5 in all interpretations (Table 6.9). 
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6.4  Discussion 
This extension of an in vivo study of decontamination efficacy in response to a supra-lethal 
14C-VX exposure (5xLD50) via damaged ear skin of anaesthetised swine, allowed identification 
of 4278 entities (42% of the probes included in the analysis) which were significantly 
differently expressed in the blood cells during the exposure period.  However, interpretation 
of these results viz prediction of responses in humans must be made within the limits of the 
experimental design. 
The toxicity of VX clearly precludes its use in human volunteer studies.  Toxicological data 
must, therefore, be obtained from relevant in vitro or in vivo animal models.  Swine models 
have been used previously for numerous investigations of VX-toxicity, decontamination and 
medical countermeasures.  The preceding in vivo study, in which swine were exposed to a 
supra-lethal dose of 14C-VX (Chapter 5), provided blood samples in which gene expression 
could be assessed. 
Obtaining samples from an in vivo investigation enabled analysis of gene expression in the 
blood of animals experiencing clinical signs of toxicity: thus, the results should be 
representative of the whole organism response (as represented via the blood).  The results 
may provide useful information for development of medical countermeasures for severe VX 
intoxication, particularly in terms of survival and long-term prognosis following exposure to a 
usually, and indeed, likely (i.e. without medical intervention or decontamination) fatal 
exposure to VX. 
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Gene expression analysis does not automatically infer functional protein expression.  
Furthermore quantitative confirmations of gene transcription were not validated by 
quantitative-PCR analysis.  Validation of gene expression data and proteomic analyses would 
provide a more complete reference for relationships between gene expression and protein 
expression following exposure to VX.  
In terms of quantification following the initial in vivo experiment, the mass of 14C-VX 
extracted from the blood (1.9 ± 1.3% and 0.79 ± 0.45% in the not decontaminated and 
decontaminated groups respectively; mean ± standard deviation) was second only to the 
liver.  The pre-dose blood sample for each subject could also be used as an intrinsic control.  
Analysis was performed on RNA extracted from whole blood samples.  This also brought the 
array analysis into line with the assay of AChE inhibition.  The brain, diaphragm, lungs, heart 
and liver would be of particular interest for future studies of organophosphate-induced 
changes in gene expression, as VX toxicity is frequently reported to be manifest in these 
organs. 
The observed differences in gene expression between groups cannot be exclusively 
attributed to VX–exposure and/or decontamination.  The in vivo model also included 
anaesthetic administration, and application of a >98% pure radio-labelled contaminant (i.e. 
<2% unspecified impurities).  Without a comprehensive speciation analysis of the exogenous 
compounds present in the blood, i.e. a profile of the relative concentrations of 14C-VX, 
impurities, metabolites or breakdown products, the relative influence of VX and/or other 
compounds on gene expression of the blood cannot be confirmed. Nevertheless, by 
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comparing decontaminated to non-decontaminated groups, the effects of the exposures 
was investigated. 
Genes involved in inflammatory and immune system responses were identified to be 
significantly differently regulated in all of the groups.  This may be attributed to a response 
to the skin injury which all animals had received.  However, recent microarray analyses of 
gene expression in brain tissue following soman exposure in rodents has also identified the 
involvement of inflammatory pathways138,139.  These observations could be particularly 
pertinent for studies of haemostatic decontaminant performance in a contaminated 
haemorrhaging wound. 
Information pertaining to effects of alphaxalone effects on gene expression is limited, so the 
influence of alphaxalone administration on these results cannot be confirmed.  Alphaxalone 
has been shown to have transcriptional activity at the chicken progesterone receptor and in 
cultured human neuroblastoma (SK-N-MC cells) but not at the human progesterone 
receptor140.  However, all animals were anaesthetised so any gene expression changes 
caused by the anaesthetic will be common to all groups.  The final blood sample was 
obtained prior to administration of pentobarbital, so the method of euthanasia has not 
contributed to the results presented. 
Nineteen common genes were oppositely regulated between samples from survivors (down-
regulated) and non-survivors (up-regulated).  The majority of these were un-annotated, but 
the list did include genes involved in cell signalling processes and genes specifically 
expressed in hematopoietic cells (PTPRC).  A separate common set of nineteen genes were 
also oppositely regulated between samples from survivors (up-regulated) and samples from 
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non-survivors (down-regulated).  A number of these were un-annotated, but the list did 
include genes which are involved in acute liver failure (HMGB1)141, inflammatory responses 
and wound healing (AIMP)142,143, responses to oxidative stress (SOD1), endoplasmic 
reticulum structural formation (ATL3)144, distal myopathy (including muscle weakness; 
MATR3)145, nucleic acid binding, ribosome structure and endonuclease activity (CNBP, RPL6, 
RPL7, RSP3)146.  The TTI1 gene was down-regulated in both survivor and death groups with 
one of the highest fold-changes: this gene is involved in the DNA Damage Response (DDR) 
which is initiated following DNA damage147.  Whilst liver function or damage was not directly 
under investigation, the identification of changes in HMGB1 expression in the blood cells 
could be reflective of detrimental processes taking place in the liver. 
The comparisons of genes expressed in the blood samples of survivors and non-survivors 
indicate the differential induction or suppression of responses to oxidative stress, DNA 
damage, disruption of DNA replication, stimulation of inflammatory responses or liver 
toxicity.  In addition to DNA damage, oxidative stress (OS) can also have a detrimental effect 
on cell membrane integrity via lipid peroxidation and disturbance of Ca2+ homeostasis.  
Oxidative stress has been demonstrated following organophosphate exposure93,94.  Indeed, 
mild hyperkalaemia and hyperphosphataemia has been measured in blood of swine exposed 
to a 2xLD50 dose of VX
74, which could possibly be a result of OS-induced reduced membrane 
integrity. 
A gene involved in immunoregulatory functions and the haemostasis pathway, particularly 
cell surface interactions at the vascular wall (Entrez Gene ID 100512978 sequence derived 
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from AMICA1), was one of the highest down-regulated genes in samples from both 
decontaminated and non-decontaminated groups exposed to VX148. 
Three genes which were isolated to the not-decontaminated survivor group (with the 
highest magnitude fold-change) encoded genes involved in complement cascade regulation 
(CD55)149, and zinc finger formation (ZCCHC6).  One of the genes of interest in not-
decontaminated samples (regardless of outcome) is involved in cellular interactions and 
adhesion processes, perhaps with particular relationships to immunological and 
inflammatory responses (ADAM8)150.   
The genes identified with the largest fold-change in the decontaminated samples were 
down-regulated (fold-change >6.0).  Many of these were also identified in the survivor 
interpretation.  Thus, these genes were identified in samples of surviving decontaminated 
animals.  These genes included S. scrofa lactotransferrin, S. scrofa haptoglobin, S. scrofa 
CD163 and resistin.  Resistin (RETN) is expressed in porcine leukocytes and secreted by 
adipocytes151,152.  Lactotransferrin (LF), which is an iron-binding protein expressed in 
neutrophils, has been detected in secretions including mucosal secretions, tears and saliva, 
as well as human, cattle and swine milk153–155.  Antimicrobial, antioxidant, iron absorption 
regulation and transcription activation roles for LF have also been demonstrated153–155.  
Haptoglobin (HP) is also a haem-binding protein, with suggested involvement in oxidative 
stress and responses to infection156,157.  Elevated levels of HP have been detected in sera of 
pigs in the early stages of porcine reproductive and respiratory syndrome (PRSS) infection157.  
CD163 has a role in binding specific glycoproteins of the PRRS virus (PRSSv)158–161.  An 
investigation of LF and HP, and iron and haem protein levels in blood may be an useful point 
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of investigation, as changes in permeability of blood cells have been demonstrated following 
organophosphate exposure in vitro162. 
In the samples taken from decontaminated animal which did not survive, genes of interest 
included a chemokine (CCL25) usually expressed in the porcine small intestine, which was 
up-regulated163,164; and S. scrofa phosphatidylinositol transfer protein, cytoplasmic 1 
(PITPNC1), which was down-regulated.  Similar proteins are involved in phospholipid 
trafficking.  However, in non-surviving animals, many of the changes seen are likely to be 
secondary to the detrimental effects on cell biochemistry and physiology caused by 
intoxication, rather than being a direct mechanistic effect of VX. 
The majority of the significant differential expressions identified were down-regulated.  This 
could be suggestive of an overall inhibitory effect on gene expression or transcription, but 
not entirely as only approximately 42% of the analysed genes on the array were affected in 
any way.  Additional mechanisms which may manifest as changes in gene expression may 
also be induced by processes contributing to mortality which are secondary to (i.e. resulting 
from) primary VX toxicity.  The predominant cause of death was not determined in this 
study, but death was confirmed following 15 minutes of apnoea, which may be caused by 
respiratory paralysis, either centrally or peripherally.  Gene expression changes and changes 
in transcriptional regulation have been reported due to hypoxia or asphyxia148,165–167. 
In summary, gene expression analysis identified a number of genes which were significantly 
differentially expressed in whole blood samples obtained from decontaminated or not-
decontaminated survivors or non-survivors of a supra-lethal 14C-VX exposure via damaged 
ear skin of swine.  In particular, genes of interest were identified with involvement in 
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oxidative stress, inflammatory and immunoregulatory responses, liver failure, and iron 
binding.  These processes may be important to consider in future studies of VX intoxication, 
mechanisms of action, protective measures and medical treatments. 
This experiment identified the need for further investigations of: 
 gene expression in other tissues following VX exposure. 
 characterisation of the effects of anaesthetics on gene expression. 
 inclusion of speciation analysis in in vivo exposure models to relate gene expression 
results to specific substances. 
 inclusion of specific haematology measurements in in vivo exposure models. 
 relative contributions of radiolabel and impurities to gene expression results. 
 sub-lethal VX exposures to investigate gene expression with equivalent exposure 
times. 
 microarray data, by validation of results using qPCR. 
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CHAPTER 7.  GENERAL DISCUSSION AND SUMMARY 
The aim of the work presented was to identify a product with haemostatic capability, which 
was able to prevent death following exposure of a wound contaminated with an otherwise 
lethal dose of VX (Figure 7.1).  In chapter 3, the feasibility of using thrombelastography to 
investigate inherent pro-coagulative activity of a number of commercially available 
haemostatic products was successfully demonstrated.  This was a relatively novel approach 
to investigating haemostat efficacy.  Using this in vitro technique, it was shown that a 
relatively high dose of VX had no effect on coagulation kinetics of swine blood in vitro.  
Furthermore, it was shown that VX contamination did not adversely affect the efficacy of the 
haemostats which were tested.  However, for some of the products tested, no advantage in 
coagulation kinetics was observed, despite documented in vivo evidence in the literature.  
The benefit of in vitro tests for product efficacy cannot be under-estimated, however, clearly 
physical mechanisms of action other than inherent pro-coagulation are involved for some of 
these products, which were not exploited or clearly demonstrated by the 
thrombelastographic method.  This provides supporting evidence that whilst an in vitro 
coagulation assay may be utilised for demonstrations of haemostatic efficacy, and even 
“screening” of advantageous products, efforts must be made in study designs to ensure that 
physical mechanisms of action such as compression or tamponade can be represented in 
vitro. 
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Figure 7.1:  Schematic summary of the results presented and inferences drawn from the 
studies evaluating the feasibility of applying a haemostat to a wound contaminated with VX 
in order to prevent death from blood loss or intoxication.  
Points that require further investigation are indicated by the dotted lines.  
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Further supporting evidence for the feasibility of using a haemostat as a decontaminant was 
provided by the ability of a selection of haemostats to effectively prevent, or at the very 
least reduce, penetration of VX across intact and damaged pig skin (Chapter 4).  A number of 
products compared favourably to currently “in use” decontaminants.  Including damaged 
skin in the experiments was particularly useful to assess simple mechanistic characteristics of 
these products in conditions relevant to the ultimate intended setting: a contaminated 
haemorrhaging wound.  However, the merits of products with chemical-decontamination 
mechanisms of action, rather than prevention of penetration, were perhaps not fully 
represented by this approach.  Interestingly, one novel liquid decontamination product was 
able to effectively reduce penetration.  This was particularly encouraging and merits further 
investigation of chemical-decontamination mechanisms, including speciation analysis of 
breakdown products, and the consideration of combination therapies.   
Following successful demonstrations of pro-coagulative and decontamination efficacy, one 
product, from a starting list of 7 candidates, was selected for evaluation in a superficial skin 
wound in vivo (Chapter 5).  Application of WoundStatTM was successful in reducing the 
number of fatalities, prolonging survival time and reducing the severity of signs of 
intoxication, without any additional medical treatment (other than anaesthesia).  However, 
signs of intoxication were not eliminated, and the total (estimated) internal absorption and 
extent of acetylcholinesterase inhibition were not dissimilar between decontaminated and 
non-decontaminated animals.  Acetylcholinesterase inhibition did not correlate with survival 
time and similarities were observed in physiological parameters and signs of intoxication 
between animals which did or did not survive between the treatment groups.  This evidence 
further supported the clinical need for rapid medical treatment along with effective 
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decontamination, and that acetylcholinesterase activity was not a robust indicator of 
prognosis.  The results provided further evidence for the existence of mechanisms involved 
in VX toxicity, other than acetylcholinesterase inhibition, in agreement with previous 
experimental reports in the literature.  The long-term effects and prognosis of the 
demonstrated efficacy of decontamination were not investigated.  With continuing 
improvements in decontamination methods, products and medical interventions, future 
investigations should include analysis of long term prognosis and sequelae following survival 
of severe nerve agent intoxication.  Desorption kinetics also remain to be investigated, as 
although WoundStatTM was able to retain almost 50% of the mass of 14C-VX which was 
applied, the desorption (or “off-gassing”) of VX from the decontaminant matrix could 
become a secondary hazard.  This is particularly pertinent for situations such as a battlefield 
or a mass casualty incident where evacuation to a medical centre, or receipt of treatment, 
may be delayed168,169.   
With these points in mind, changes in gene expression in the exposed animals was analysed 
(Chapter 6).  Currently, this is the only microarray investigation of gene expression changes 
in the blood of animals exposed to a supra-lethal dose of VX.  The changes in expression of 
genes involved in inflammatory responses could be attributed to the induced skin damage, 
but has also been reported following exposure of rodents to sarin or VX (without skin 
damage)138,139,170.  Genes involved in responses to oxidative stress and DNA damage were 
also identified, in accordance with reports of genotoxicity effects of organophosphate 
pesticides, along with genes involved in iron binding and liver failure.  In the context of a 
contaminated haemorrhaging wound, these findings, in particular the involvement of 
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inflammatory responses, can be a further complication to consider for successful medical 
treatment, and as a target for development of effective medical countermeasures.   
During the in vivo experimentation stage, reports of clinical safety concerns ultimately led to 
the withdrawal of WoundStatTM from use171.  Nevertheless, this work clearly demonstrated 
the proof-of-principle of a possible haemostatic decontaminant, and the resultant benefits 
of development and evaluation of standard haemostatic decontaminants cannot be under-
emphasised. 
 
Further work 
The results presented support the principle and feasibility of successful application of a 
haemostatic decontaminant, based on an adsorptive mechanism of action, to prevent death 
from intoxication following contamination of a superficial skin wound.  The efficacy of 
WoundStatTM (or a similar product) to prevent death from intoxication and blood loss in a 
severely haemorrhaging contaminated wound in vivo has yet to be established.  Validation 
and detailed investigation of the gene analysis results is also necessary.  The inclusion of 
biochemical analyses of blood during exposure to VX (in vivo) would also be useful to further 
investigate extra mechanisms of VX intoxication.  The hypothetical benefit of developing 
products with combinations of adsorptive and decontaminating mechanisms of action is also 
clearly supported.  Future investigations based on the work presented, should ultimately 
lead to enhanced decontamination products, improved medical treatments and ultimately 
life-saving results. 
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APPENDIX:  Tables Supplementary to Chapter 6 
  
 
- 2
3
2
 - 
Probe Name 
"Survivor" 
FC (up-
regulated) 
“Death” FC 
(down-
regulated) 
Gene 
Symbol 
Description 
GenBank 
Accession 
Gene Name 
A_72_P417944 1.29 1.49 HMGB1 
Sus scrofa high mobility group box 1 
(HMGB1), mRNA [NM_001004034] 
NM_00100
4034 
high mobility group box 1 
A_72_P123316 1.17 1.36 AIMP1 
Sus scrofa aminoacyl tRNA 
synthetase complex-interacting 
multifunctional protein 1 (AIMP1), 
mRNA [NM_001114283] 
NM_00111
4283 
aminoacyl tRNA synthetase 
complex-interacting 
multifunctional protein 1 
A_72_P166216 1.53 1.32  
Sus scrofa mRNA, 
clone:AMP010005H07, expressed in 
alveolar macrophage. [AK230520] 
AK230520  
A_72_P051516 1.14 1.29 
LOC1005
12835 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1SKJ
5] [ENSSSCT00000000147] 
AK234726 
eukaryotic translation 
initiation factor 3 subunit D-
like 
A_72_P043501 1.36 1.36  
Rep: CG10107 - Drosophila miranda 
(Fruit fly), partial (6%) [TC545141] 
  
Table S6.1a:  Thirty-eight genes were oppositely regulated between the “survivor” and “death” groups.  Nineteen of these were 
up-regulated in the “survivor” group and down-regulated in the “death” group. 
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Probe Name 
"Survivor" 
FC (up-
regulated) 
“Death” FC 
(down-
regulated) 
Gene 
Symbol 
Description 
GenBank 
Accession 
Gene Name 
A_72_P293799 1.24 1.17 
LOC100
520446 
PREDICTED: Sus scrofa phosphatidylinositol-
5-phosphate 4-kinase type-2 alpha-like 
(LOC100520446), mRNA [XM_003130778] 
XM_003130778 
phosphatidylinositol-
5-phosphate 4-kinase 
type-2 alpha-like 
A_72_P124171 1.21 1.25 RPL6 
Sus scrofa ribosomal protein L6 (RPL6), mRNA 
[NM_001044542] 
NM_001044542 ribosomal protein L6 
A_72_P237542 1.31 1.27 ATL3 
PREDICTED: Sus scrofa atlastin GTPase 3 
(ATL3), mRNA [XM_003122603] 
XM_003122603 atlastin GTPase 3 
A_72_P043131 1.43 1.24 MATR3 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1RGI7] 
[ENSSSCT00000015671] 
AK230971 matrin 3 
A_72_P351373 1.15 1.23  
Sus scrofa mRNA, clone:LVRM10164B01, 
expressed in liver. [AK233516] 
AK233516  
Table S6.1a (continued):  Thirty-eight genes were oppositely regulated between the “survivor” and “death” groups.  Nineteen of these 
were up-regulated in the “survivor” group and down-regulated in the “death” group. 
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Probe Name 
"Survivor" 
FC (up-
regulated) 
“Death” FC 
(down-
regulated) 
Gene 
Symbol 
Description 
GenBank 
Accession 
Gene Name 
A_72_P315983 1.11 1.20  
Sus scrofa mRNA, clone:OVRM10011C12, 
expressed in ovary. [AK234726] 
AK234726  
A_72_P301774 1.28 1.27 RPL7 
Sus scrofa ribosomal protein L7 (RPL7), 
mRNA [NM_001113217] 
NM_001113217 ribosomal protein L7 
A_72_P407373 1.17 1.13  
Sus scrofa mRNA, clone:OVRM10053F02, 
expressed in ovary. [AK235147] 
AK235147  
A_72_P296699 1.26 1.29  
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1SJA1] 
[ENSSSCT00000005809] 
AK237752  
A_72_P181041 1.51 1.16 SOD1 
Sus scrofa mRNA, clone:TES010065D08, 
expressed in testis. [AK351289] 
AK351289 
superoxide 
dismutase 1, soluble 
A_72_P041136 1.28 1.28 RPS3 
Sus scrofa ribosomal protein S3 (RPS3), 
mRNA [NM_001044601] 
NM_001044601 ribosomal protein S3 
Table S6.1a (continued):  Thirty-eight genes were oppositely regulated between the “survivor” and “death” groups.  Nineteen of these 
were up-regulated in the “survivor” group and down-regulated in the “death” group.  
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Probe Name 
"Survivor" 
FC (up-
regulated) 
“Death” FC 
(down-
regulated) 
Gene 
Symbol 
Description 
GenBank 
Accession 
Gene Name 
A_72_P381933 1.18 1.26  
Sus scrofa mRNA, clone:THY010111H04, 
expressed in thymus. [AK239542] 
AK239542  
A_72_P035951 1.19 1.15 SUCLG1 
Sus scrofa succinate-CoA ligase, alpha 
subunit (SUCLG1), nuclear gene encoding 
mitochondrial protein, mRNA [NM_214409] 
NM_214409 
succinate-CoA ligase, 
alpha subunit 
A_72_P127776 1.33 1.40 CNBP 
Sus scrofa clone 
Clu_4372.scr.msk.p1.Contig4, mRNA 
sequence. [AY609917] 
AY609917 
CCHC-type zinc 
finger, nucleic acid 
binding protein 
Table S6.1a (continued):  Thirty-eight genes were oppositely regulated between the “survivor” and “death” groups.  Nineteen of these 
were up-regulated in the “survivor” group and down-regulated in the “death” group. 
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6
 - 
Probe Name 
"Survivor" 
FC (down-
regulated) 
“Death” FC 
(up-
regulated) 
Gene 
Symbol 
Description 
GenBank 
Accession 
Gene Name 
A_72_P319703 1.43 1.17  
BP463284 full-length enriched swine cDNA 
library, adult uterus Sus scrofa cDNA clone 
UTR010061C02 5', mRNA sequence 
[BP463284] 
BP463284  
A_72_P315823 1.51 1.21  
Rep: VACUOLAR ATP SYNTHASE SUBUNIT C - 
Encephalitozoon cuniculi, partial (5%) 
[TC609086] 
  
A_72_P436894 1.18 1.16     
A_72_P041341 1.69 1.32  
Rep: Dihydroorotate dehydrogenase 1 - 
Mariprofundus ferrooxydans PV-1, partial 
(5%) [TC581282] 
  
A_72_P122626 1.39 1.19  
Rep: Ubiquitin-conjugating enzyme E2 Z - 
Rattus norvegicus (Rat), partial (5%) 
[TC574178] 
  
Table S6.1b:  Thirty-eight genes were oppositely regulated between the “survivor” and “death” groups.  Nineteen of these were down-
regulated in the “survivor” group and up-regulated in the “death” group. 
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Probe Name 
"Survivor" 
FC (down-
regulated) 
“Death” FC 
(up-
regulated) 
Gene 
Symbol 
Description 
GenBank 
Accession 
Gene Name 
A_72_P267002 1.70 1.13 C2CD2L 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1SAH4] 
[ENSSSCT00000016477] 
XM_003129928 C2CD2-like 
A_72_P287269 2.01 1.19  
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1S705] 
[ENSSSCT00000016896] 
XM_003130329  
A_72_P170936 1.42 1.29  
Rep: Uncharacterized tatC-like protein 
ymf16 - Marchantia polymorpha 
(Liverwort), partial (5%) [TC598884] 
  
A_72_P330563 1.56 1.30     
A_72_P186806 1.75 1.07 PTPRC 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1S5D7] 
[ENSSSCT00000011937] 
AK236971 
protein tyrosine 
phosphatase, 
receptor type, C 
A_72_P072301 1.76 1.27     
Table S6.1b (continued):  Thirty-eight genes were oppositely regulated between the “survivor” and “death” groups.  Nineteen of these 
were down-regulated in the “survivor” group and up-regulated in the “death” group.  
  
 
- 2
3
8
 - 
Probe Name 
"Survivor" 
FC (down-
regulated) 
“Death” FC 
(up-
regulated) 
Gene 
Symbol 
Description 
GenBank 
Accession 
GeneName 
A_72_P205202 1.33 1.47  
Sus scrofa mRNA, clone:THY010066B02, 
expressed in thymus. [AK351708] 
AK351708  
A_72_P050411 2.38 1.21  
Sus scrofa mRNA, clone:SPL010073E05, 
expressed in spleen. [AK237647] 
AK237647  
A_72_P225502 1.35 1.45  
937553 MARC 4PIG Sus scrofa cDNA 3', 
mRNA sequence [CK466354] 
CK466354  
A_72_P400518 1.34 1.24     
A_72_P346773 1.35 1.11     
A_72_P030816 1.31 1.42     
A_72_P419449 2.03 1.15  
Rep: VirB2 - Agrobacterium tumefaciens, 
partial (8%) [TC570679] 
  
A_72_P204972 1.98 1.60     
Table S6.1b (continued):  Thirty-eight genes were oppositely regulated between the “survivor” and “death” groups.  Nineteen of these 
were down-regulated in the “survivor” group and up-regulated in the “death” group. 
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Probe Name p FC Regulation 
Gene 
Symbol 
Description 
Genbank 
Accession 
Gene Name 
A_72_P219772 0.005 3.02 down 
LOC1005
13077 
PREDICTED: Sus scrofa max dimerization protein 
1-like (LOC100513077), mRNA [XM_003125065] 
XM_003125065 
max dimerization 
protein 1-like 
A_72_P050971 0.024 3.02 down CD14 
Sus scrofa CD14 molecule (CD14), mRNA 
[NM_001097445] 
NM_001097445 CD14 molecule 
A_72_P226012 0.000 3.03 down LIMK2 
PREDICTED: Sus scrofa LIM domain kinase 2, 
transcript variant 1 (LIMK2), mRNA 
[XM_001926065] 
XM_001926065 
LIM domain 
kinase 2 
A_72_P188166 0.014 3.04 down 
 
AJ950630 KN404_1 Sus scrofa cDNA clone 
C0007735b23 5', mRNA sequence [AJ950630] 
AJ950630 
 
A_72_P141156 0.022 3.04 down 
 
Sus scrofa mRNA, clone:LVRM10008D06, 
expressed in liver. [AK346027] 
AK346027 
 
A_72_P048361 0.018 3.05 down 
 
Sus scrofa mRNA, clone:OVRM10193D12, 
expressed in ovary. [AK236447] 
AK236447 
 
A_72_P320963 0.042 3.06 down 
 
Rep: contactin 1 - Mus musculus, partial (20%) 
[TC556852]   
A_72_P288384 0.022 3.09 down 
 
Sus scrofa mRNA, clone:OVRM10148D01, 
expressed in ovary. [AK236053] 
AK236053 
 
A_72_P356133 0.009 3.12 down 
    
A_72_P055401 0.003 3.17 down 
LOC1005
23979 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1RYS3] 
[ENSSSCT00000009845] 
AK344675 cyclin-G2-like 
A_72_P155761 0.014 3.18 down 
 
Rep: predicted gene, ENSMUSG00000074232 - 
Mus musculus, partial (12%) [TC625156]   
Table S6.2:  In the decontaminated group, 65 entities were identified with a significant fold change between 3.0 and 9.0.  
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Probe Name p FC Regulation 
Gene 
Symbol 
Description 
Genbank 
Accession 
Gene Name 
A_72_P136946 0.033 3.19 down 
 
rspc003_l7.y1 spc Sus scrofa cDNA 5', mRNA 
sequence [EW572445] 
EW572445 
 
A_72_P031421 0.009 3.21 down 
    
A_72_P088666 0.022 3.26 down CD14 
Sus scrofa CD14 molecule (CD14), mRNA 
[NM_001097445] 
NM_001097445 CD14 molecule 
A_72_P080016 0.018 3.27 up 
 
Rep: NADH-ubiquinone oxidoreductase chain 2 - 
Lichmera indistincta, partial (5%) [TC530628]   
A_72_P207457 0.014 3.27 down ALOX5AP 
Sus scrofa arachidonate 5-lipoxygenase-activating 
protein (ALOX5AP), mRNA [NM_001164001] 
NM_001164001 
arachidonate 5-
lipoxygenase-
activating 
protein 
A_72_P165431 0.009 3.27 down TLR4 
Sus scrofa toll-like receptor 4 (TLR4), mRNA 
[NM_001113039] 
NM_001113039 
toll-like receptor 
4 
A_72_P303724 0.009 3.28 down TLR4 
Sus scrofa toll-like receptor 4 (TLR4), mRNA 
[NM_001113039] 
NM_001113039 
toll-like receptor 
4 
A_72_P381428 0.021 3.28 down 
    
A_72_P008841 0.034 3.30 up 
 
Sus scrofa mRNA, clone:AMP010017G07, 
expressed in alveolar macrophage. [AK230622] 
AK230622 
 
A_72_P385368 0.005 3.31 down 
    
A_72_P330938 0.006 3.32 down 
 
Sus scrofa mRNA, clone:AMP010002E09, 
expressed in alveolar macrophage. [AK230491] 
AK230491 
 
A_72_P297879 0.018 3.33 down SGMS1 
Sus scrofa sphingomyelin synthase 1 (SGMS1), 
mRNA [NM_001097438] 
NM_001097438 
sphingomyelin 
synthase 1 
Table S6.2 (continued):  In the decontaminated group, 65 entities were identified with a significant fold change between 3.0 and 9.0.  
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Probe Name p FC Regulation 
Gene 
Symbol 
Description 
Genbank 
Accession 
Gene Name 
A_72_P369763 0.020 3.41 up 
 
Sus scrofa mRNA, clone:ADR010084E08, expressed 
in adrenal gland. [AK343528] 
AK343528 
 
A_72_P320648 0.010 3.44 down 
 
Sus scrofa mRNA, clone:LVR010029A05, expressed 
in liver. [AK232355] 
AK232355 
 
A_72_P146566 0.003 3.44 down 
LOC3968
67 
Sus scrofa stefin A8 (LOC396867), mRNA 
[NM_213860] 
NM_213860 stefin A8 
A_72_P085766 0.015 3.47 up 
LOC1005
21616 
Sus scrofa mRNA, clone:PBL010087G05, expressed 
in periphral blood mononuclear cell. [AK237064] 
AK237064 
interleukin-9 
receptor-like 
A_72_P076666 0.030 3.48 down 
    
A_72_P079266 0.013 3.51 down 
LOC1005
19123 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1SP55] 
[ENSSSCT00000005966] 
XM_00312205
4 
ATP-binding 
cassette sub-
family A member 
1-like 
A_72_P075026 0.009 3.51 down CHIT1 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1S7U2] 
[ENSSSCT00000016860] 
EF090909 
chitinase 1 
(chitotriosidase) 
A_72_P352528 0.006 3.52 down 
    
A_72_P237572 0.043 3.53 down 
LOC1005
20761 
PREDICTED: Sus scrofa c4b-binding protein alpha 
chain-like (LOC100520761), mRNA 
[XM_003130456] 
XM_00313045
6 
c4b-binding 
protein alpha 
chain-like 
A_72_P164781 0.005 3.54 down C5AR1 
Sus scrofa mRNA, clone:DCI010005C10, expressed 
in dendritic cells (immature). [AK344310] 
AK344310 
complement 
component 5a 
receptor 1 
Table S6.2 (continued):  In the decontaminated group, 65 entities were identified with a significant fold change between 3.0 and 9.0.  
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Probe Name p FC Regulation 
Gene 
Symbol 
Description 
Genbank 
Accession 
Gene Name 
A_72_P178346 0.018 3.56 down 
    
A_72_P289749 0.015 3.62 down 
    
A_72_P345443 0.006 3.63 down 
    
A_72_P037841 0.016 3.63 down 
 
Rep: Latency-associated nuclear antigen - Macaca 
nemestrina rhadinovirus 2, partial (5%) 
[TC544206] 
  
A_72_P266432 0.025 3.65 down 
 
Sus scrofa mRNA, clone:AMP010057A04, 
expressed in alveolar macrophages. [AK343821] 
AK343821 
 
A_72_P213242 0.017 3.75 down 
 
Sus scrofa mRNA, clone:ITT010062E10, expressed 
in small intestine. [AK345112] 
AK345112 
 
A_72_P033811 0.016 3.76 down 
 
Sus scrofa mRNA, clone:ITT010100C12, expressed 
in small intestine. [AK345293] 
AK345293 
 
A_72_P299774 0.009 3.80 down 
 
Rep: Decay-accelerating factor CD55 - Sus scrofa 
(Pig), partial (9%) [TC563365]   
A_72_P025326 0.017 3.90 down 
    
A_72_P032716 0.031 4.00 down EMR1 
Sus scrofa mRNA, clone:AMP010018D08, 
expressed in alveolar macrophage. [AK230628] 
AK230628 
egf-like module 
containing, 
mucin-like, 
hormone 
receptor-like 1 
A_72_P035486 0.011 4.13 down SGMS1 
Sus scrofa sphingomyelin synthase 1 (SGMS1), 
mRNA [NM_001097438] 
NM_001097438 
sphingomyelin 
synthase 1 
Table S6.2 (continued):  In the decontaminated group, 65 entities were identified with a significant fold change between 3.0 and 9.0.  
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Probe Name p FC Regulation 
Gene 
Symbol 
Description 
Genbank 
Accession 
Gene Name 
A_72_P368263 0.025 4.15 down 
LOC1001
56489 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1SGP9] 
[ENSSSCT00000002231] 
XM_001927895 
protein-glutamine 
gamma-
glutamyltransferase 
K-like 
A_72_P340983 0.021 4.17 down FN1 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1SS23] 
[ENSSSCT00000017611] 
AK236279 fibronectin 1 
A_72_P189121 0.021 4.20 down 
    
A_72_P262237 0.002 4.25 down 
 
Sus scrofa mRNA, clone:UTR010017A02, 
expressed in uterus. [AK239973] 
AK239973 
 
A_72_P188846 0.003 4.30 down 
 
Sus scrofa mRNA, clone:TES010027B04, 
expressed in testis. [AK351197] 
AK351197 
 
A_72_P293619 0.004 4.31 down 
 
Sus scrofa mRNA, clone:UTR010017A02, 
expressed in uterus. [AK239973] 
AK239973 
 
A_72_P055186 0.026 4.33 down CD163 
Sus scrofa mRNA, clone:SPL010088G03, 
expressed in spleen. [AK237746] 
AK237746 CD163 molecule 
A_72_P412988 0.025 4.37 down 
    
A_72_P306144 0.007 4.41 down TGFA 
Sus scrofa mRNA, clone:OVRM10010E08, 
expressed in ovary. [AK347880] 
AK347880 
transforming 
growth factor, alpha 
A_72_P130606 0.007 4.50 down 
 
Rep: Glycogenin - Bos taurus (Bovine), partial 
(16%) [TC543772] 
XM_003358602 
 
Table S6.2 (continued):  In the decontaminated group, 65 entities were identified with a significant fold change between 3.0 and 9.0.  
  
 
- 2
4
4
 - 
Probe Name p FC Regulation 
Gene 
Symbol 
Description 
Genbank 
Accession 
Gene Name 
A_72_P097366 0.005 4.54 down 
LOC1005
20641 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1SKC4] 
[ENSSSCT00000012806] 
AK236587 
glycogenin-1-
like 
A_72_P268229 0.003 4.55 down 
 
Rep: Phospholipase D/Transphosphatidylase 
precursor - Polaromonas sp. (strain JS666 / ATCC 
BAA-500), partial (11%) [TC621826] 
  
A_72_P001376 0.005 4.74 down 
LOC1005
12873 
Sus scrofa mRNA, clone:AMP010041A03, expressed 
in alveolar macrophage. [AK230779] 
AK230779 
antileukoprotei
nase-like 
A_72_P177981 0.012 4.91 down CD163 
Sus scrofa CD163 molecule (CD163), mRNA 
[NM_213976] 
NM_213976 CD163 molecule 
A_72_P160596 0.013 5.05 down CD163 Sus scrofa CD163 mRNA, complete cds. [DQ067278] DQ067278 CD163 molecule 
A_72_P177496 0.018 5.37 down RETN Sus scrofa resistin (RETN), mRNA [NM_213783] NM_213783 resistin 
A_72_P131846 0.012 5.44 down RETN Sus scrofa resistin (RETN), mRNA [NM_213783] NM_213783 resistin 
A_72_P121576 0.008 5.70 down 
    
A_72_P178006 0.008 6.22 down HP Sus scrofa haptoglobin (HP), mRNA [NM_214000] NM_214000 haptoglobin 
A_72_P004066 0.019 6.38 down 
 
Sus scrofa mRNA, clone:THY010119H01, expressed 
in thymus. [AK351987] 
AK351987 
 
A_72_P088736 0.006 8.10 down LTF 
Sus scrofa lactotransferrin (LTF), mRNA 
[NM_214362] 
NM_214362 lactotransferrin 
Table S6.2 (continued):  In the decontaminated group, 65 entities were identified with a significant fold change between 3.0 and 9.0. 
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Probe Name 
"Survivor" 
FC 
"DXD" 
FC 
Gene Symbol Description 
Genbank 
Accession 
Gene Name 
A_72_P074056 1.52 1.67   
BW979405 full-length enriched swine cDNA 
library, adult intestine Sus scrofa cDNA clone 
ITT010038B10 5', mRNA sequence [BW979405] 
BW979405   
A_72_P364398 1.54 1.61 LOC100511072 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1RMT5] 
[ENSSSCT00000015724] 
XM_003123999 
protein 
diaphanous 
homolog 1-like 
A_72_P408748 1.59 1.53         
A_72_P254562 1.64 1.71 LOC100153550 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1S8Y4] 
[ENSSSCT00000011508] 
AY609998 
exosomal core 
protein CSL4 
A_72_P258182 1.68 1.86   
susfleck_PG_18_F11 SUSFLECK Pituitary Gland Sus 
scrofa cDNA clone 18_F11, mRNA sequence 
[FD592765] 
FD592765   
A_72_P072416 1.68 1.54   
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1SD10] 
[ENSSSCT00000011405] 
AK343385   
A_72_P223132 1.69 1.61   
Sus scrofa mRNA, clone:THY010094A09, 
expressed in thymus. [AK239334] 
AK239334   
Table S6.3:  Thirty-six genes were significantly (p<0.05) differently regulated with a fold change (FC) above 1.5 in samples from non-
decontaminated (DXD) survivors.  These were all down-regulated.  
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Probe Name 
"Survivor" 
FC 
"DXD" FC 
Gene 
Symbol 
Description 
Genbank 
Accession 
Gene Name 
A_72_P163356 1.69 1.54 
LOC10051
1865 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1S3C2] 
[ENSSSCT00000015340] 
AY609632 
ras-related protein 
Rab-24-like 
A_72_P098516 1.74 1.56 
LOC10051
5356 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1ST88] 
[ENSSSCT00000005878] 
AK352242 
golgi-associated plant 
pathogenesis-related 
protein 1-like 
A_72_P363878 1.74 1.53         
A_72_P213067 1.80 1.52 BRWD3 
PREDICTED: Sus scrofa bromodomain and WD 
repeat-containing protein 3-like 
(LOC100520060), mRNA [XM_003135212] 
XM_003135212 
bromodomain and WD 
repeat domain 
containing 3 
A_72_P216567 1.82 1.60 DOK1 
Sus scrofa docking protein 1, 62kDa 
(downstream of tyrosine kinase 1) (DOK1), 
mRNA [NM_001143705] 
NM_001143705 
docking protein 1, 
62kDa (downstream of 
tyrosine kinase 1) 
A_72_P402708 1.84 1.72 
LOC10051
9082 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1RGC4] 
[ENSSSCT00000015915] 
AK237820 
interferon-induced 
transmembrane 
protein 1-like 
Table S6.3 (continued):  Thirty-six genes were significantly (p<0.05) differently regulated with a fold change (FC) above 1.5 in samples 
from non-decontaminated survivors.  These were all down-regulated.  
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Probe Name 
"Survivor" 
FC 
"DXD" 
FC 
Gene Symbol Description 
Genbank 
Accession 
Gene Name 
A_72_P085651 1.86 1.67   
Sus scrofa mRNA, clone:AMP010048B11, 
expressed in alveolar macrophage. 
[AK230816] 
AK230816   
A_72_P164771 1.86 1.55   
Rep: MGC151858 protein - Bos taurus 
(Bovine), partial (65%) [TC550554] 
XM_003129158   
A_72_P317048 1.91 1.61   
930738 MARC 4PIG Sus scrofa cDNA 5', 
mRNA sequence [CK460460] 
CK460460   
A_72_P189756 1.92 1.61   
BX920065 Sus Scrofa library (scan) Sus scrofa 
cDNA clone scan0010.l.14 5prim, mRNA 
sequence [BX920065] 
BX920065   
A_72_P180891 1.92 1.55 FGL2 
Sus scrofa fibrinogen-like 2 (FGL2), mRNA 
[NM_001005152] 
NM_001005152 fibrinogen-like 2 
A_72_P000771 1.93 1.64 BACH1 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1SHM8] 
[ENSSSCT00000013161] 
XM_003132749 
BTB and CNC 
homology 1, basic 
leucine zipper 
transcription factor 1 
Table S6.3 (continued):  Thirty-six genes were significantly (p<0.05) differently regulated with a fold change (FC) above 1.5 in samples 
from non-decontaminated survivors.  These were all down-regulated.  
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Probe Name 
"Survivor" 
FC 
"DXD" 
FC 
Gene Symbol Description 
Genbank 
Accession 
Gene Name 
A_72_P197885 1.95 1.54 DEDD 
PREDICTED: Sus scrofa death effector 
domain-containing protein-like, transcript 
variant 2 (LOC100156474), mRNA 
[XM_003125653] 
XM_003125653 
death effector domain 
containing 
A_72_P030191 1.97 1.54   
Rep: Olfactomedin-like protein 3 precursor - 
Homo sapiens (Human), complete 
[TC539943] 
    
A_72_P377998 1.97 1.57   
Sus scrofa mRNA, clone:DCI010109D09, 
expressed in dendritic cells (immature). 
[AK344690] 
AK344690   
A_72_P345513 1.98 1.57   
Rep: Brain protein I3 - Bos taurus (Bovine), 
complete [TC534832] 
XM_003354451   
A_72_P326028 2.10 1.74 LOC100516039 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1S1A0] 
[ENSSSCT00000019268] 
AK230835 
c-C motif chemokine 
23-like 
A_72_P002361 2.10 1.63   
Sus scrofa mRNA, clone:SPL010015B04, 
expressed in spleen. [AK237234] 
AK237234   
Table S6.3 (continued):  Thirty-six genes were significantly (p<0.05) differently regulated with a fold change (FC) above 1.5 in samples 
from non-decontaminated survivors.  These were all down-regulated.  
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Probe Name 
"Survivor" 
FC 
"DXD" 
FC 
Gene Symbol Description 
Genbank 
Accession 
Gene Name 
A_72_P290549 2.11 1.60 TNFAIP8L2 
Sus scrofa tumor necrosis factor, alpha-
induced protein 8-like 2 (TNFAIP8L2), mRNA 
[NM_001204370] 
NM_001204370 
tumor necrosis factor, 
alpha-induced protein 
8-like 2 
A_72_P055151 2.11 1.65   
Rep: Dof15 - Glycine max (Soybean), partial 
(7%) [TC632217] 
    
A_72_P002561 2.14 1.59   
Rep: Cellulose synthase - Synechococcus sp. 
(strain CC9605), partial (3%) [TC530941] 
XM_003354775   
A_72_P165046 2.18 2.10 CD55 
Sus scrofa CD55 molecule, decay accelerating 
factor for complement (Cromer blood group) 
(CD55), mRNA [NM_213815] 
NM_213815 
CD55 molecule, decay 
accelerating factor for 
complement (Cromer 
blood group) 
A_72_P094941 2.25 1.83         
A_72_P217812 2.27 2.12 ZCCHC6 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1S4J1] 
[ENSSSCT00000011987] 
XM_003130637 
zinc finger, CCHC 
domain containing 6 
A_72_P258487 2.35 1.69 ZNF467 
Sus scrofa mRNA, clone:OVR010064E12, 
expressed in ovary. [AK347604] 
AK347604 zinc finger protein 467 
Table S6.3 (continued):  Thirty-six genes were significantly (p<0.05) differently regulated with a fold change (FC) above 1.5 in samples 
from non-decontaminated survivors.  These were all down-regulated.  
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Probe Name 
"Survivor" 
FC 
"DXD" 
FC 
Gene Symbol Description 
Genbank 
Accession 
Gene Name 
A_72_P088056 2.65 1.78 LY96 
Sus scrofa lymphocyte antigen 96 (LY96), 
mRNA [NM_001104956] 
NM_001104956 lymphocyte antigen 96 
A_72_P136176 2.73 1.84         
A_72_P413368 2.99 2.15   
Sus scrofa mRNA, clone:ITT010040H02, 
expressed in intestine. [AK231345] 
AK231345   
A_72_P229897 3.35 1.89         
Table S6.3 (continued):  Thirty-six genes were significantly (p<0.05) differently regulated with a fold change (FC) above 1.5 in samples 
from non-decontaminated survivors.  These were all down-regulated.  
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Probe Name 
"Death" 
FC 
"DXD" 
FC 
Regulation Gene Symbol Description 
Genbank 
Accession 
Gene Name 
A_72_P115951 1.32 1.37 down 
 
Rep: Transmembrane and coiled-
coil domain-containing protein 
C6orf129 - Homo sapiens (Human), 
complete [TC558016] 
  
A_72_P274654 1.20 1.22 up 
 
Rep: Chromosome 11 SCAF14979, 
whole genome shotgun sequence - 
Tetraodon nigroviridis (Green 
puffer), partial (3%) [TC552531] 
  
A_72_P359418 1.31 1.24 down WDHD1 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1
SSP1] [ENSSSCT00000005569] 
XM_001924194 
WD repeat and 
HMG-box DNA 
binding protein 1 
A_72_P153536 1.39 1.45 down 
 
BX666888 Sus Scrofa library (scac) 
Sus scrofa cDNA clone 
scac0025.o.23 3prim, mRNA 
sequence [BX666888] 
BX666888 
 
A_72_P229677 1.26 1.35 up 
 
Rep: Isoform 3 of Q924C1  - Mus 
musculus (Mouse), partial (12%) 
[TC549174] 
  
Table S6.4:  Fifty-two genes were identified with a significant (p<0.05) differently regulated with a fold change (FC) above 1.0 in samples 
from non-decontaminated (DXD) animals which did not survive.  
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Probe Name 
"Death" 
FC 
"DXD" 
FC 
Regulation Gene Symbol Description 
Genbank 
Accession 
Gene Name 
A_72_P268254 1.25 1.22 down 
 
Sus scrofa mRNA, 
clone:AMP010021H04, expressed 
in alveolar macrophage. 
[AK230658] 
AK230658 
 
A_72_P108426 1.35 1.34 down LOC100523873 
Sus scrofa mRNA, 
clone:LVRM10157D07, expressed 
in liver. [AK233485] 
AK233485 
modulator of 
retrovirus infection 
homolog 
A_72_P237527 1.25 1.28 down LOC100511525 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1
S775] [ENSSSCT00000016580] 
AK230495 
dolichyl-
diphosphooligosacch
aride--protein 
glycosyltransferase 
subunit STT3A-like 
A_72_P281339 1.32 1.29 down 
    
A_72_P182836 1.26 1.25 up 
    
A_72_P344858 1.58 1.49 up 
 
CJ013650 full-length enriched 
swine cDNA library, adult 
mesenteric lymph node Sus scrofa 
cDNA clone MLN01B060076 5', 
mRNA sequence [CJ013650] 
CJ013650 
 
Table S6.4 (continued):  Fifty-two genes were identified with a significant (p<0.05) differently regulated with a fold change (FC) above 1.0 
in samples from non-decontaminated (DXD) animals which did not survive.  
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Probe Name 
"Death" 
FC 
"DXD" 
FC 
Regulation Gene Symbol Description 
Genbank 
Accession 
Gene Name 
A_72_P104776 1.32 1.29 down LOC100153480 
Sus scrofa mRNA, 
clone:OVRT10035E05, expressed 
in ovary. [AK348676] 
AK348676 
small nuclear 
ribonucleoprotein Sm 
D3-like 
A_72_P124386 1.54 1.55 down 
 
Sus scrofa mRNA, 
clone:LVR010018C03, expressed in 
liver. [AK232317] 
AK232317 
 
A_72_P337618 1.18 1.30 down 
 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1
SFU9] [ENSSSCT00000007202] 
EU814888 
 
A_72_P296819 1.39 1.21 down 
 
PREDICTED: Sus scrofa CD93 
molecule (CD93), mRNA 
[XM_001927042] 
XM_0019270
42  
A_72_P080576 1.52 1.46 down LOC100154056 
PREDICTED: Sus scrofa calmodulin 
(LOC100154056), mRNA 
[XM_001928187] 
XM_0019281
87 
calmodulin 
A_72_P221872 1.25 1.25 up 
    
A_72_P063496 1.34 1.38 down 
 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1
SV46] [ENSSSCT00000004033] 
AK232614 
 
Table S6.4 (continued):  Fifty-two genes were identified with a significant (p<0.05) differently regulated with a fold change (FC) above 1.0 
in samples from non-decontaminated (DXD) animals which did not survive.  
  
 
- 2
5
4
 - 
Probe Name 
"Death" 
FC 
"DXD" 
FC 
Regulation Gene Symbol Description 
Genbank 
Accession 
Gene Name 
A_72_P120391 1.30 1.29 down LOC100521387 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1
STS6] [ENSSSCT00000016272] 
AK235125 
uncharacterized 
protein C11orf73 
homolog 
A_72_P145521 1.27 1.25 down 
 
1533070 MARC 3PIG Sus scrofa 
cDNA 5', mRNA sequence 
[DY417983] 
DY417983 
 
A_72_P379698 1.27 1.24 down LOC100524500 
Non-histone chromosomal protein 
HMG-17 [Source:UniProtKB/Swiss-
Prot;Acc:P80272] 
[ENSSSCT00000003949] 
AK236192 
non-histone 
chromosomal protein 
HMG-17-like 
A_72_P206962 1.32 1.29 down ATAD2 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1
RR16] [ENSSSCT00000006566] 
AK235138 
ATPase family, AAA 
domain containing 2 
A_72_P349623 1.15 1.26 down LOC733637 
Sus scrofa myosin regulatory light 
chain 2 protein (LOC733637), 
mRNA [NM_001044572] 
NM_0010445
72 
myosin regulatory 
light chain 2 protein 
A_72_P223752 1.16 1.33 down LOC733646 
Sus scrofa lysosomal 9kDa H+ 
transporting ATPase V0 subunit e 
(LOC733646), mRNA 
[NM_001044579] 
NM_0010445
79 
lysosomal 9kDa H+ 
transporting ATPase 
V0 subunit e 
Table S6.4 (continued):  Fifty-two genes were identified with a significant (p<0.05) differently regulated with a fold change (FC) above 1.0 
in samples from non-decontaminated (DXD) animals which did not survive.  
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Probe Name 
"Death" 
FC 
"DXD" 
FC 
Regulation Gene Symbol Description 
Genbank 
Accession 
Gene Name 
A_72_P410588 1.21 1.35 up 
 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1
SE96] [ENSSSCT00000009656] 
BP438150 
 
A_72_P185306 1.48 1.42 down RPL35 
Sus scrofa ribosomal protein L35 
(RPL35), mRNA [NM_214326] 
NM_214326 
ribosomal protein 
L35 
A_72_P302514 1.22 1.25 down LOC100524500 
Non-histone chromosomal protein 
HMG-17 [Source:UniProtKB/Swiss-
Prot;Acc:P80272] 
[ENSSSCT00000003949] 
AK349259 
non-histone 
chromosomal protein 
HMG-17-like 
A_72_P049556 1.19 1.21 up 
 
Rep: Uncharacterized protein 
FAM91A1 - Homo sapiens 
(Human), partial (14%) [TC550796] 
  
A_72_P407543 1.22 1.33 down 
 
Sus scrofa mRNA, 
clone:THY010110B03, expressed in 
thymus. [AK239520] 
AK239520 
 
A_72_P202462 1.24 1.17 down 
 
Rep: tRNA pseudouridine synthase 
3 (EC 5.4.99.-) (tRNA-uridine 
isomerase 3) (tRNA 
pseudouridylate synthase 3). - Bos 
Taurus, partial (50%) [TC584687] 
  
Table S6.4 (continued):  Fifty-two genes were identified with a significant (p<0.05) differently regulated with a fold change (FC) above 1.0 
in samples from non-decontaminated (DXD) animals which did not survive.  
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Probe Name 
"Death" 
FC 
"DXD" 
FC 
Regulation Gene Symbol Description 
Genbank 
Accession 
Gene Name 
A_72_P369808 1.22 1.17 up 
 
Sus scrofa mRNA, 
clone:TCH010079F10, expressed in 
trachea. [AK238305] 
AK238305 
 
A_72_P147081 1.35 1.26 down 
 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1
RPK5] [ENSSSCT00000007401] 
AK233940 
 
A_72_P107981 1.27 1.25 down LOC100520359 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1
SJY0] [ENSSSCT00000014397] 
XM_003122715 
mediator of RNA 
polymerase II 
transcription 
subunit 19-like 
A_72_P040436 1.24 1.18 down 
 
Sus scrofa mRNA, 
clone:PBL010012G03, expressed in 
periphral blood mononuclear cell. 
[AK236819] 
AK236819 
 
A_72_P113886 1.18 1.16 down 
 
Sus scrofa mRNA, 
clone:AMP010018H04, expressed 
in alveolar macrophages. 
[AK343693] 
AK343693 
 
A_72_P227762 1.16 1.11 down UBC 
Pig poly-ubiquitin mRNA, 3' end. 
[M18159] 
M18159 ubiquitin C 
Table S6.4 (continued):  Fifty-two genes were identified with a significant (p<0.05) differently regulated with a fold change (FC) above 1.0 
in samples from non-decontaminated (DXD) animals which did not survive.  
  
 
- 2
5
7
 - 
Probe Name 
"Death" 
FC 
"DXD" 
FC 
Regulation Gene Symbol Description 
Genbank 
Accession 
Gene Name 
A_72_P122296 1.41 1.39 down 
    
A_72_P397313 1.14 1.12 up 
 
Rep: MGC137767 protein - Bos 
taurus (Bovine), partial (93%) 
[TC541708] 
  
A_72_P304269 1.23 1.19 up THOP1 
Sus scrofa thimet oligopeptidase 1 
(THOP1), mRNA [NM_214223] 
NM_214223 
thimet 
oligopeptidase 1 
A_72_P333508 1.35 1.37 down 
    
A_72_P127706 1.18 1.14 down 
 
Sus scrofa mRNA, 
clone:SPL010027C01, expressed in 
spleen. [AK237351] 
AK237351 
 
A_72_P309698 1.21 1.24 down 
 
AJ952826 KN404_1 Sus scrofa 
cDNA clone C0007738k19 3', 
mRNA sequence [AJ952826] 
AJ952826 
 
A_72_P286104 1.22 1.13 down LOC100152655 
PREDICTED: Sus scrofa lysM and 
putative peptidoglycan-binding 
domain-containing protein 4-like 
(LOC100152655), mRNA 
[XM_001928238] 
XM_001928238 
lysM and putative 
peptidoglycan-
binding domain-
containing protein 
4-like 
Table S6.4 (continued):  Fifty-two genes were identified with a significant (p<0.05) differently regulated with a fold change (FC) above 1.0 
in samples from non-decontaminated (DXD) animals which did not survive.  
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Probe Name 
"Death" 
FC 
"DXD" 
FC 
Regulation 
Gene 
Symbol 
Description 
Genbank 
Accession 
Gene Name 
A_72_P437959 1.44 1.41 down 
 
Rep: UPF0215 protein APE_0476.1 - 
Aeropyrum pernix, partial (8%) [TC616255]   
A_72_P097596 1.18 1.17 down 
 
Sus scrofa mRNA, clone:ITT010044D03, 
expressed in small intestine. [AK345045] 
AK345045 
 
A_72_P051741 1.11 1.08 down 
 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1SNN9] 
[ENSSSCT00000017690] 
AK239087 
 
A_72_P282504 1.16 1.27 down 
 
Rep: Alpha/beta hydrolase fold - 
Saccharopolyspora erythraea (strain NRRL 
23338), partial (9%) [TC552936] 
  
A_72_P257442 1.57 1.30 down 
 
Sus scrofa mRNA, clone:LVRM10063C11, 
expressed in liver. [AK232987] 
AK232987 
 
A_72_P150236 1.65 1.55 down 
 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1SCM0] 
[ENSSSCT00000002493] 
AK350727 
 
A_72_P174356 1.16 1.17 down TBP10 
26S protease regulatory subunit 8 
[Source:UniProtKB/Swiss-Prot;Acc:P62197] 
[ENSSSCT00000018819] 
AK234194 
Tat-binding 
protein 10 
Table S6.4 (continued):  Fifty-two genes were identified with a significant (p<0.05) differently regulated with a fold change (FC) above 1.0 
in samples from non-decontaminated (DXD) animals which did not survive.  
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Probe Name 
"Death" 
FC 
"DXD" 
FC 
Regulation Gene Symbol Description 
Genbank 
Accession 
Gene Name 
A_72_P420559 1.13 1.18 up LOC100517385 
PREDICTED: Sus scrofa 
hypothetical protein 
LOC100517385 (LOC100517385), 
mRNA [XM_003121502] 
XM_003121502 
hypothetical 
protein 
LOC100517385 
A_72_P233767 1.28 1.24 down 
 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1
SJP7] [ENSSSCT00000000048] 
XM_003125991 
 
Table S6.4 (continued):  Fifty-two genes were identified with a significant (p<0.05) differently regulated with a fold change (FC) above 1.0 
in samples from non-decontaminated (DXD) animals which did not survive.  
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Probe Name 
"Survivor" 
FC 
"Death" 
FC 
"DXD" 
FC 
“DD” 
FC 
Gene 
Symbol 
Description 
Genbank 
Accession 
Gene Name 
A_72_P281644 1.35 1.46 1.44 1.35 
 
Glutaredoxin-1 
[Source:UniProtKB/Swiss-
Prot;Acc:P12309] 
[ENSSSCT00000015476] 
AY550049 
 
A_72_P350248 1.40 1.14 1.21 1.36 
 
Rep: RNA-binding tegument protein - 
Cercopithecine herpesvirus 16, partial 
(15%) [TC526559] 
  
A_72_P201747 1.19 1.38 1.45 1.10 
 
Rep: COX6B - Sus scrofa (Pig), partial 
(20%) [TC541904]   
A_72_P193407 1.35 1.48 1.42 1.38 
LOC100
520751 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1SDZ8] 
[ENSSSCT00000002683] 
XM_003128681 
protein sel-1 
homolog 1-
like 
A_72_P303239 2.14 1.36 1.56 2.02 VNN1 
Sus scrofa vanin 1 (VNN1), mRNA 
[NM_214133] 
NM_214133 vanin 1 
A_72_P376378 1.26 1.41 1.33 1.31 ERP44 
Sus scrofa endoplasmic reticulum 
protein 44 (ERP44), mRNA 
[NM_001137629] 
NM_001137629 
endoplasmic 
reticulum 
protein 44 
Table S6.5a:  Of 53 genes which were identified to be significantly (p<0.05) differently regulated with a fold change (FC) above 1.0 (and 
up to 3.0) during the exposure period in all interpretations (survivors, non-survivors (death), decontaminated (DD) and not-
decontaminated (DXD)), 47 were down-regulated.  Only 1 entity had FC>1.5 in all interpretations.  
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Probe Name 
"Survivor" 
FC 
"Death" 
FC 
"DXD" 
FC 
“DD” 
FC 
Gene 
Symbol 
Description 
Genbank 
Accession 
Gene Name 
A_72_P121841 1.31 1.13 1.20 1.26 
 
Rep: Plasmid replication protein - 
Clostridium perfringens, partial (5%) 
[TC560818] 
  
A_72_P092691 1.25 1.17 1.24 1.20 
 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1SSD2] 
[ENSSSCT00000005929] 
AK235387 
 
A_72_P034906 1.25 1.20 1.24 1.21 
LOC100
518251 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1SFJ6] 
[ENSSSCT00000000604] 
XM_00312
6427 
GTPase KRas-like 
A_72_P119756 1.23 1.19 1.21 1.22 NPTN 
PREDICTED: Sus scrofa neuroplastin 
(NPTN), mRNA [XM_001928665] 
XM_00192
8665 
neuroplastin 
A_72_P262732 1.24 1.21 1.22 1.23 SLA-1 
Sus scrofa MHC class I antigen 1 (SLA-1), 
mRNA [NM_001097431] 
NM_0010
97431 
MHC class I 
antigen 1 
A_72_P209872 1.33 1.18 1.32 1.21 
LOC100
515483 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1RKI9] 
[ENSSSCT00000003279] 
AK239689 
26S proteasome 
non-ATPase 
regulatory subunit 
8-like 
A_72_P257732 1.56 1.19 1.31 1.48 
    
Table S6.5a (continued):  Of 53 genes which were identified to be significantly (p<0.05) differently regulated with a fold change (FC) 
above 1.0 (and up to 3.0) during the exposure period in all interpretations (survivors, non-survivors (death), decontaminated (DD) and 
not-decontaminated (DXD)), 47 were down-regulated.  Only 1 entity had FC>1.5 in all interpretations.  
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Probe Name 
"Survivor" 
FC 
"Death" 
FC 
"DXD" 
FC 
“DD” 
FC 
Gene 
Symbol 
Description 
Genbank 
Accession 
Gene Name 
A_72_P340103 2.18 1.47 1.82 1.88 
LOC100
525312 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1SKV5] 
[ENSSSCT00000018446] 
AK234414 importin-11-like 
A_72_P079156 1.43 1.37 1.40 1.41 
LOC100
525087 
Sus scrofa mRNA, 
clone:LVRM10066C06, expressed in 
liver. [AK233003] 
AK233003 
CCR4-NOT 
transcription 
complex subunit 
8-like 
A_72_P107181 1.74 1.51 1.46 1.84 TTI1 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1SEK2] 
[ENSSSCT00000008032] 
AK346364 
Tel2 interacting 
protein 1 homolog 
(S. pombe) 
A_72_P092501 1.87 1.33 1.48 1.78 MBP 
Sus scrofa myelin basic protein (MBP), 
mRNA [NM_001001546] 
NM_0010
01546 
myelin basic 
protein 
A_72_P016631 1.81 1.26 1.42 1.71 
LOC100
518503 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1SMC9
] [ENSSSCT00000016388] 
AK231752 
UPF0686 protein 
C11orf1 homolog 
A_72_P205857 1.16 1.42 1.38 1.15 NANS 
Sus scrofa N-acetylneuraminic acid 
synthase (NANS), mRNA 
[NM_001185139] 
NM_0011
85139 
N-
acetylneuraminic 
acid synthase 
Table S6.5a (continued):  Of 53 genes which were identified to be significantly (p<0.05) differently regulated with a fold change (FC) 
above 1.0 (and up to 3.0) during the exposure period in all interpretations (survivors, non-survivors (death), decontaminated (DD) and 
not-decontaminated (DXD)), 47 were down-regulated.  Only 1 entity had FC>1.5 in all interpretations.  
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Probe Name 
"Survivor" 
FC 
"Death" 
FC 
"DXD" 
FC 
“DD” 
FC 
Gene 
Symbol 
Description 
Genbank 
Accession 
Gene Name 
A_72_P168881 1.87 1.29 1.60 1.61 
 
Rep: AP-4 complex subunit beta-1 
(Adapter-related protein complex 4 beta 
1 subunit) (Beta subunit of AP-4) (AP-4 
adapter complex beta subunit). - Canis 
familiaris, partial (52%) [TC523497] 
  
A_72_P202087 1.79 1.31 1.48 1.66 
    
A_72_P378588 1.42 1.43 1.34 1.51 
LOC100
511905 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1SE16] 
[ENSSSCT00000007705] 
AY609592 
arylamine N-
acetyltransferase 
1-like 
A_72_P335098 1.79 1.19 1.41 1.62 
LOC100
526122 
Sus scrofa mRNA, clone:AMP010084E02, 
expressed in alveolar macrophage. 
[AK231033] 
AK231033 
ragulator 
complex protein 
LAMTOR3-like 
A_72_P304394 1.28 1.22 1.32 1.19 
 
Rep: Chromosome undetermined 
SCAF11230, whole genome shotgun 
sequence - Tetraodon nigroviridis (Green 
puffer), partial (9%) [TC525365] 
  
A_72_P241922 1.81 1.23 1.42 1.67 
 
Rep: Transforming acidic coiled-coil-
containing protein 3 (ERIC-1). - Bos 
Taurus, partial (34%) [TC535168] 
  
Table S6.5a (continued):  Of 53 genes which were identified to be significantly (p<0.05) differently regulated with a fold change (FC) 
above 1.0 (and up to 3.0) during the exposure period in all interpretations (survivors, non-survivors (death), decontaminated (DD) and 
not-decontaminated (DXD)), 47 were down-regulated.  Only 1 entity had FC>1.5 in all interpretations.  
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Probe Name 
"Survivor" 
FC 
"Death" 
FC 
"DXD" 
FC 
“DD” 
FC 
Gene 
Symbol 
Description 
Genbank 
Accession 
Gene Name 
A_72_P161631 1.39 1.14 1.25 1.30 
 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1SU5
9] [ENSSSCT00000011272] 
AK236443 
 
A_72_P223957 1.81 1.24 1.48 1.61 SULT1A1 
Sus scrofa sulfotransferase family, 
cytosolic, 1A, phenol-preferring, 
member 1 (SULT1A1), mRNA 
[NM_213765] 
NM_2137
65 
sulfotransferase 
family, cytosolic, 
1A, phenol-
preferring, 
member 1 
A_72_P105491 1.31 1.52 1.46 1.33 UBCH5B 
Sus scrofa mRNA, 
clone:SPL010093C06, expressed in 
spleen. [AK350560] 
AK350560 
E2 ubiquitin-
conjugating 
enzyme UbcH5B 
A_72_P296599 1.43 1.27 1.40 1.32 RCL1 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1SK4
6] [ENSSSCT00000005750] 
AK346045 
RNA terminal 
phosphate 
cyclase-like 1 
A_72_P415038 1.23 1.18 1.12 1.30 MORF4L1 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1RKS
0] [ENSSSCT00000001981] 
AK343838 
mortality factor 4 
like 1 
A_72_P127676 1.61 1.18 1.33 1.51 
 
Sus scrofa mRNA, 
clone:LNG010095F07, expressed in 
lung. [AK232172] 
AK232172 
 
Table S6.5a (continued):  Of 53 genes which were identified to be significantly (p<0.05) differently regulated with a fold change (FC) 
above 1.0 (and up to 3.0) during the exposure period in all interpretations (survivors, non-survivors (death), decontaminated (DD) and 
not-decontaminated (DXD)), 47 were down-regulated.  Only 1 entity had FC>1.5 in all interpretations.  
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Probe Name 
"Survivor" 
FC 
"Death" 
FC 
"DXD" 
FC 
“DD” 
FC 
Gene 
Symbol 
Description 
Genbank 
Accession 
Gene Name 
A_72_P052726 2.16 1.34 1.57 2.00 
 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1RZE
9] [ENSSSCT00000005091] 
AK230536 
 
A_72_P077771 2.39 1.47 1.87 2.04 HMGB2 
Sus scrofa high mobility group box 2 
(HMGB2), mRNA [NM_214063] 
NM_2140
63 
high mobility 
group box 2 
A_72_P076931 1.23 1.19 1.21 1.21 TPM3 
Sus scrofa tropomyosin 3 (TPM3), 
mRNA [NM_001001632] 
NM_0010
01632 
tropomyosin 3 
A_72_P116461 1.75 1.24 1.43 1.62 GGNBP2 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1S1C
1] [ENSSSCT00000019252] 
AK348998 
gametogenetin 
binding protein 2 
A_72_P431299 1.61 1.16 1.32 1.50 
LOC10052
0095 
Sus scrofa mRNA, 
clone:THY010049D07, expressed in 
thymus. [AK351624] 
AK351624 
sorting nexin-11-
like 
A_72_P322008 1.26 1.25 1.25 1.26 
 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1RUD
0] [ENSSSCT00000001457] 
AK233371 
 
Table S6.5a (continued):  Of 53 genes which were identified to be significantly (p<0.05) differently regulated with a fold change (FC) 
above 1.0 (and up to 3.0) during the exposure period in all interpretations (survivors, non-survivors (death), decontaminated (DD) and 
not-decontaminated (DXD)), 47 were down-regulated.  Only 1 entity had FC>1.5 in all interpretations.  
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Probe Name 
"Survivor" 
FC 
"Death" 
FC 
"DXD" 
FC 
“DD” 
FC 
Gene 
Symbol 
Description 
Genbank 
Accession 
Gene Name 
A_72_P330288 2.69 1.54 2.04 2.23 
 
Rep: Chromosome undetermined 
SCAF3439, whole genome shotgun 
sequence - Tetraodon nigroviridis 
(Green puffer), partial (6%) [TC538063] 
  
A_72_P097686 2.37 1.26 1.54 2.15 VNN2 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1S3Q9] 
[ENSSSCT00000004618] 
AK230630 vanin 2 
A_72_P051611 1.45 1.23 1.23 1.49 
PRPF38
B 
PREDICTED: Sus scrofa pre-mRNA-
splicing factor 38B-like (LOC100154667), 
mRNA [XM_001927806] 
XM_00192
7806 
PRP38 pre-mRNA 
processing factor 
38 (yeast) domain 
containing B 
A_72_P362328 1.42 1.32 1.38 1.37 
 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1SU59] 
[ENSSSCT00000011272] 
XM_00313
3077  
A_72_P293229 1.33 1.25 1.41 1.19 RAB11A 
Sus scrofa clone 
Clu_4682.scr.msk.p1.Contig1, mRNA 
sequence. [AY609947] 
AY609947 
RAB11A, member 
RAS oncogene 
family 
A_72_P331833 1.82 1.36 1.51 1.72 
ARHGA
P25 
Sus scrofa mRNA, clone:UTR010010D09, 
expressed in uterus. [AK239912] 
AK239912 
Rho GTPase 
activating protein 
25 
Table S6.5a (continued):  Of 53 genes which were identified to be significantly (p<0.05) differently regulated with a fold change (FC) 
above 1.0 (and up to 3.0) during the exposure period in all interpretations (survivors, non-survivors (death), decontaminated (DD) and 
not-decontaminated (DXD)), 47 were down-regulated.  Only 1 entity had FC>1.5 in all interpretations.  
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Probe Name 
"Survivor" 
FC 
"Death" 
FC 
"DXD" 
FC 
“DD” 
FC 
Gene 
Symbol 
Description 
Genbank 
Accession 
Gene Name 
A_72_P179366 1.44 1.23 1.27 1.44 
 
Rep: Pherophorin-C4 protein precursor - 
Chlamydomonas reinhardtii, partial (5%) 
[TC571577] 
  
A_72_P431724 2.12 1.20 1.34 2.09 
 
DB803791 full-length enriched swine 
cDNA library, adult skin Sus scrofa cDNA 
clone SKNB10062H08 5', mRNA 
sequence [DB803791] 
DB803791 
 
A_72_P310598 1.23 1.23 1.25 1.22 
 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1RPM5
] [ENSSSCT00000005002] 
XR_130280 
 
A_72_P003456 1.31 1.27 1.26 1.33 
LOC100
524500 
Non-histone chromosomal protein 
HMG-17 [Source:UniProtKB/Swiss-
Prot;Acc:P80272] 
[ENSSSCT00000003949] 
AK349259 
non-histone 
chromosomal 
protein HMG-17-
like 
Table S6.5a (continued):  Of 53 genes which were identified to be significantly (p<0.05) differently regulated with a fold change (FC) 
above 1.0 (and up to 3.0) during the exposure period in all interpretations (survivors, non-survivors (death), decontaminated (DD) and 
not-decontaminated (DXD)), 47 were down-regulated.  Only 1 entity had FC>1.5 in all interpretations.  
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Probe Name 
"Survivor" 
FC 
"Death" 
FC 
"DXD" 
FC 
“DD” 
FC 
Gene 
Symbol 
Description 
Genbank 
Accession 
Gene Name 
A_72_P430259 1.35 1.31 1.36 1.31 GGNBP2 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1S1C1] 
[ENSSSCT00000019252] 
AK348998 
gametogenet
in binding 
protein 2 
A_72_P063621 1.43 1.27 1.29 1.44 LOC1005
20095 
Sus scrofa mRNA, clone:THY010049D07, 
expressed in thymus. [AK351624] 
AK351624 
sorting 
nexin-11-like 
A_72_P258962 1.21 1.32 1.20 1.31 
 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1RUD0] 
[ENSSSCT00000001457] 
AK233371 
 
A_72_P034856 1.73 1.42 1.38 1.84 
 
Rep: Pherophorin-C4 protein precursor - 
Chlamydomonas reinhardtii, partial (5%) 
[TC571577] 
  
A_72_P221242 1.54 1.37 1.40 1.54 
 
Rep: Chromosome undetermined 
SCAF3439, whole genome shotgun 
sequence - Tetraodon nigroviridis (Green 
puffer), partial (6%) [TC538063] 
  
A_72_P128671 1.60 1.23 1.29 1.59 VNN2 
Uncharacterized protein 
[Source:UniProtKB/TrEMBL;Acc:F1S3Q9] 
[ENSSSCT00000004618] 
AK230630 vanin 2 
Table S6.5b:  Of fifty-three genes which were identified to be significantly (p<0.05) differently regulated with a fold change (FC) above 1.0 
(and up to 3.0) during the exposure period in all interpretations (survivors, non-survivors (death), decontaminated (DD) and not-
decontaminated (DXD)), six were up-regulated. 
